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Major depressive disorder (MDD) is one of the most common Western illnesses. The 
pathogenesis of depression consists of many factors, including heritable and environmental 
factors. These factors are associated with brain structure and function on different levels, 
including changes in neurotransmitter signaling, structure of brain regions and metabolic 
activity of the brain. However, there are still a number of unresolved issues in 
understanding the neurobiology of MDD. In this thesis, a few of these issues are addressed. 
The published literature on abnormal brain activation during emotion processing in 
MDD has revealed a myriad of findings, but it is difficult to identify a consistent pattern. In 
the first part of this thesis, the aim was to identify the most consistent abnormal brain 
activation patterns in depression. In addition, it was investigated whether these abnormal 
brain activations are specific for the depressive state or whether they are they still present 
after recovery (a trait characteristic). 
Although MDD is a heritable disease, there is no strong evidence for specific 
susceptibility genes. The use of endophenotypes in the search for the genetic basis of MDD 
could be a possible solution. Endophenotypes are neurobiological and neuropsychological 
substrates underlying a disease and are more closely related to the effects of genotypes. The 
second aim of this thesis was therefore to investigate genetic vulnerability of depression by 
using neuroimaging data as endophenotype.  
The concept of depression 
Depression is very common in the population; in the Netherlands, each year approximately 
5-7% of the population suffers from a depressive disorder (De Graaf et al., 2002; Bijl et al., 
1998; de Graaf et al., 2012) and estimations of lifetime prevalence of depression range 
between 18-40% (Bijl et al., 1998; de Graaf et al., 2012; Kruijshaar et al., 2005). 
Depression causes a high burden for the patients; it ranks on the third place of leading 
causes of burden of disease according the World Health Organization (measured in 
disability adjusted life years (DALYs, Lopez et al., 2006) and it is associated with high  
mortality rates (Cuijpers et al., 2004).  
In order to diagnose a patient as having a depressive episode, five out of nine 
possible symptoms have to be present for at least two weeks (Table 1.1). The core 
symptoms of depression are depressed or sad mood (dysphoria) and a loss of feeling 
pleasure (anhedonia). One of these core symptoms must be present according to the 
Diagnostic Statistical Manual edition four (DSM-IV). There are many possible 
combinations of these nine symptoms which will lead to the diagnosis of MDD. This makes 
MDD a heterogeneous disorder. Identification of potential endophenotypes can help the 





Table 1.1. Diagnostic criteria of a major depressive episode, reproduced verbatim from the DSM IV-TR. 
Diagnostic criteria for Major Depressive Episode 
A. Five (or more) of the following symptoms have been present during the same 2-week period and 
represent a change from previous functioning; at least one of the symptoms is either (1) depressed 
mood or (2) loss of interest or pleasure. Note: Do not include symptoms that are clearly due to a 
general medical condition, or mood-incongruent delusions or hallucinations. 
  1. depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., 
feels sad or empty) or observation made by others (e.g., appears tearful). Note: In children and 
adolescents, can be irritable mood. 
  2. markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly 
every day (as indicated by either subjective account or observation made by others) 
  3. significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body 
weight in a month), or decrease or increase in appetite nearly every day. Note: In children, consider 
failure to make expected weight gains. 
  4. insomnia or hypersomnia nearly every day 
  5. psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down) 
  6. fatigue or loss of energy nearly every day 
  7. feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly 
every day (not merely self-reproach or guilt about being sick) 
  8. diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective 
account or as observed by others) 
  9. recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific 
plan, or a suicide attempt or a specific plan for committing suicide 
B. The symptoms do not meet criteria for a Mixed Episode 
C. The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a 
medication) or a general medical condition (e.g., hypothyroidism). 
E. The symptoms are not better accounted for by Bereavement, i.e., after the loss of a loved one, the 
symptoms persist for longer than 2 months or are characterized by marked functional impairment, 
morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor 
retardation. 
 
Thus, both core symptoms involve changes in emotional experiences and assume 
that depression is primarily a disorder of mood or affect (Paykel, 2008). Depression has 
indeed been associated with a different way of processing emotional stimuli, responding to 
them and remembering them (Beck, 2008; Leppanen, 2006). Patients show increased 
attention for negative stimuli, such as sad facial expressions compared to neutral, and are 
less able to ignore negative emotional stimuli (Leppanen, 2006). Besides this increased 
attention towards negative stimuli, depression has been associated with a bias of attention 
away from positive stimuli. These biases lead to selective information processing and also 
to a bias in memory processing (Leppanen, 2006). Patients tend to remember negative 
information better than positive information. Beck (2008) proposed that these attentional 




schemas. Beck suggested that these schemas make people vulnerable to develop a 
depression and that these schemas could be activated by mild stress levels. This is the basis 
of the cognitive vulnerability theory of Beck (2008). Thus, Beck suggested that besides 
heritable factors also environmental factors are responsible for the onset of depression 
(Beck, 2008). Environmental influences affecting the onset of depression have indeed been 
estimated to be large: around 60% (Kendler et al., 1999).   
Depressive disorder has a high comorbidity with anxiety disorders (Gorman, 
1996), with comorbidity rates lying between 40 and 90% (Gorman, 1996; de Graaf et al., 
2003; Lamers et al., 2011). Therefore, it is hard to consider them separately. In addition, it 
has been proposed that depression and anxiety disorders share underlying biological 
mechanisms and genetic vulnerability (Levine et al., 2001). In this thesis, many of the 
investigated patients show comorbidity with a clinically relevant anxiety disorder. Anxiety 
disorders which are included in this thesis are generalized anxiety disorder (GAD), social 
anxiety disorder (SAD) and panic disorder (PD). The most important symptom of GAD is 
excessive general worrying. A characteristic symptom of SAD is extensive fear for social 
situations and for PD this is an excessive fear for panic attacks.    
Genetics of affective disorders 
The prevalence of depression is higher in people with first-degree relatives diagnosed with 
MDD, also shown by adoption studies (Sullivan et al., 2000). Family studies have shown 
that heritability could explain around 40% of the cause of depression (Sullivan et al., 2000). 
Knowing the susceptibility genes may have important implications for understanding and 
managing MDD for two main reasons: (i) generation of a good model of MDD etiology and 
(ii) patient stratification in the framework of personalized medicine. However, at the 
moment it is far from clear which genes cause vulnerability for affective disorders. Many 
studies have been conducted to investigate the association between specific genes and 
depression. Genes selected for these type of studies are mostly determined based on our 
knowledge of the functional properties of that gene and the biological underpinnings of 
depression.  
One of the most investigated neuromodulator systems in the etiology of MDD is 
the serotonin system (Cowen, 2008) and this is related to the fact that very commonly 
prescribed antidepressant drugs are selective serotonin reuptake inhibitors (SSRIs). This has 
led to a focus of candidate gene studies on genes influencing the serotonin system (Lau et 
al., 2010). Another neuromodulator system in the brain is the dopamine system. The 
dopamine system has attracted less attention in the research into the etiology of depression 
than the serotonin system, but there is compelling evidence for a disturbed dopamine 




reviews the current literature regarding the association between depression and genes 
influencing the dopamine system.  
Besides the monoamines, more recently peptides involved in neuroplasticity and 
cellular mechanisms became popular, for example brain-derived neurotrophic factor 
(BDNF) (Duman et al., 2006). BDNF regulates synaptic plasticity of the brain, especially in 
the hippocampus (Bath et al., 2006). BDNF levels in blood have been shown to be lower in 
depression and increase after antidepressant treatment (Brunoni et al., 2008). However, 
candidate gene association studies have shown conflicting results and a meta-analysis 
revealed no significant association between depression and the most commonly 
investigated polymorphism in this gene (val66met, Verhagen et al., 2010).  
An approach in studying genetics in a less biased way is genome wide association 
(GWA) studies. In this type of studies the whole genome is searched for a possible 
association between a gene and depression. This has led to new possible vulnerability genes 
for depression, for example the piccolo gene (PCLO, Sullivan et al., 2000), a gene coding 
for a neuron-specific neutral amino acid transporter (SLC6A15, Kohli et al., 2011)), the 
bicaudal C homologue 1 gene (BICC1, Lewis et al., 2010)), and the gene HOMER1 
(Rietschel et al., 2010).  However, no pair of these studies identified the same gene and also 
replication with the candidate gene approach appeared difficult (Major Depressive Disorder 
Working Group of the Psychiatric GWAS Consortium, 2012; Bosker et al., 2011)  
To summarize, in the last decade a large amount of research has been published on 
associations between specific genes and depression, but replication of these findings turned 
out to be difficult. This suggests that each gene only explains a small amount of variation in 
the association and many genes are ‘necessary’ for vulnerability for depression (Lau et al., 
2010).  
Besides the problem that depression is likely to be a multifactorial epigenetic 
disorder in which many genes have a small effect on vulnerability, another problem in 
genetic association studies might be a proper phenotype definition. One solution would be 
research into endophenotypes (or also called intermediate phenotypes). Research to 
endophenotypes in depression is also promising for the clinic, because endophenotypes 
could be the site of action of antidepressant medication. According to Cannon and Keller 
(2006) a good endophenotype should be heritable, be associated with the cause of the 
disorder and should vary continuously in the general population. Possible endophenotypes 
for the research to depression could be brain activation and morphology. Therefore, an 
understanding of abnormalities in brain function and structure in depression is essential for 





Neurobiology of emotional processing 
As mentioned above, affective disorders are primarily disorders of emotional processing. 
To understand the neurobiological pathology of affective disorders, it is important to 
understand the neurobiology of emotional processing. Functional magnetic resonance 
imaging (fMRI) is one of the most used methods to investigate neural mechanisms during 
emotional processing.  
There are several steps in coming from perception of emotion to an emotional 
reaction or an affective state (Phillips et al., 2003a). First, we have to perceive an emotional 
stimulus and we should identify the emotional significance. Subsequently, our body will 
give an autonomic, neuroendocrine and somatomotor response to the stimulus. Information 
from the senses is integrated with bodily reactions to generate a subjective affective state. 
Finally, the affective state and emotional behavior following the perception of a stimulus 
could be regulated and the previous two steps could be inhibited. Different brain areas are 
involved in these different steps. In a recent extensive review and meta-analysis (Lindquist 
et al., 2012), it has indeed been shown that there is not one brain regions for each specific 
emotion. Rather, a network of brain regions is involved in making sense of what we 
perceive. Many areas in the limbic and prefrontal region are involved in noticing, 
perceiving and giving meaning to sensory input to form an emotion (Lindquist et al., 2012).  
In the first step of emotional processing, the initial appraisal and identification of 
emotional significance of a stimulus, the amygdala plays a central role (Phillips et al., 
2003a). The amygdala activates in response to salient and new information (Lindquist et al., 
2012). In addition, it plays a role in directing the attention towards emotionally salient 
information and modulating vigilance (Davis et al., 2001).  
The next step, integrating our bodily reactions and generating an affective state, is 
mediated by several regions. First, the insula (especially the anterior part) is involved in 
awareness of body states, called interoception, and awareness of emotions (Lindquist et al., 
2012; Craig, 2009). Awareness of the bodily reaction to physical stimuli is important for 
emotional experience (Craig, 2009). MRI studies have indeed shown that the insula 
activates when people evaluate their feelings and become aware of them (Lindquist et al., 
2012). Second, the orbitofrontal cortex (OFC) has also been described as an area implicated 
in the production of emotional behavior and affective states (Phillips et al., 2003a). 
Specifically, it is thought that the OFC integrates external and internal sensory information 
and uses this to guide behavior (Lindquist et al., 2012). In addition, the OFC has indeed 
been linked to associative and reward learning, which is also important for emotional 
learning (Rolls, 2004). 
The anterior cingulate cortex (ACC) has a cognitive (dorsal part) and emotional 
subdivision (subgenual and pregenual part) (Bush et al., 2000). The ACC has close 




position to function as a hub between the more emotional generating areas and cortical 
controlling areas. Besides its central role in the brain, the ACC has also been associated 
with different stages of emotional processing. The ACC has been shown to be involved in 
salience detection, awareness of affective state and regulation of the emotional response 
(Lindquist et al., 2012; Bush et al., 2000; Phan et al., 2004).  
In attributing sense to the sensory cues, the medial prefrontal cortex (MPFC), 
medial temporal lobe (including the hippocampus) and the posterior cingulate cortex (PCC) 
play a role. These areas couple the sensory input to stored representations of prior 
experiences that come from the self or from observing others (Lindquist et al., 2012). The 
role of the hippocampus is primarily memory processing (Rolls, 2010), whereas the MPFC 
and PCC have previously been associated by our group with processing during self-
reflection (van der Meer et al., 2010).  
Finally, the lateral part of the PFC is divided into a ventral and a dorsal part, which 
have both been associated with regulation of emotional behavior (Lindquist et al., 2012; 
Ochsner et al., 2005). The ventral part is activated during down regulation of negative 
emotions (Johnstone et al., 2007), and also during other kinds of behavioral inhibition tasks 
(van der Meer et al., 2011; Aron et al., 2004). The dorsolateral PFC (DLPFC) is part of the 
executive attentional system and activates during explicitly attending, evaluating or 
reappraisal of emotions (Lindquist et al., 2012; Ochsner et al., 2005).  
Phillips et al. (2003a) proposed a model for emotion perception in which they 
divided the above mentioned regions roughly into two systems: a ventral and a dorsal 
system. The perception of the emotional significance and the generation of emotional 
behavior and affective state is thought to mostly result from the ventral system, which 
includes the amygdala, insula and ventral regions of ACC and PFC. The dorsal system 
consists of the hippocampus and the dorsal regions of the ACC and PFC, which is thought 
to regulate emotions and behavior (Phillips et al., 2003a). These authors propose that these 
two systems influence each other in both directions.   
Neurobiology of depression 
Functional differences 
As described in the previous paragraph, a network of limbic and prefrontal areas has been 
found to be involved in emotional processing. Depression is thought to be the result of 
complex abnormal interactions between these limbic and prefrontal cortical areas 
(Seminowicz et al., 2004).  
Two influential models have been described on the underlying neurobiological 
abnormalities in depression. Phillips et al.( 2003b) used their emotional perception model 
to hypothesize on the disturbances in depression. They suggested that the ventral system 




a bias in attention towards increased processing of negative information. The increased 
activation of the ventral system is thought to lead to an increased tendency to identify 
stimuli as negative and an increased experience of negative affect. In addition, the dorsal 
system (hippocampus, dorsal ACC and PFC) is less activated, leading to less regulation of 
the emotional behavior and the negative affective state. This combination is thought to lead 
to a decrease in mood and a depressed state.  
Some years before Phillips et al. proposed their model, Mayberg (1997) described 
a limbic-cortical dysregulation model (which was revised and extended by Seminowicz et 
al., 2004)), which has great similarities with the model of Phillips et al.. The model of 
Mayberg also suggested a hyperactive ventral compartment and a hypoactive dorsal 
compartment. In this model, the dorsal compartment consists of the DLPFC, dorsal ACC, 
hippocampus, inferior parietal cortex and striatum. This compartment in the brain was 
thought to play a role in the symptoms apathy, psychomotor slowing and impaired 
performance on executive tasks. The ventral compartment consists of the amygdala, insula, 
subgenual ACC (BA25) and brainstem and was thought to mediate the somatic symptoms 
of depression. The model of Mayberg (Seminowicz et al., 2004; Mayberg, 1997) includes 
an additional third ‘emotion-cognition integration component’, which includes the rostral 
part of the ACC (BA 24), medial PFC and OFC. This component was thought to function 
as a link between the ventral and dorsal compartments. Mayberg suggested that depression 
results from a dysfunction of the interaction between the three compartments and of the 
regions within a compartment.  
Although the models regarding abnormal activation in depression are quite clear, 
neuroimaging studies are not consistent in their findings. Differences in techniques 
(PET/fMRI) and tasks during which activity is measured might explain part of these 
differences, in addition to heterogeneity of patient samples. Combining studies in a meta-
analysis showed more activation during emotional processing in areas of the subgenual part 
of the ACC, ventral PFC, amygdala and putamen and less activation in areas of the 
pregenual ACC, orbitofrontal cortex, DLPFC and insula (Fitzgerald et al., 2008a), which is 
in line with the proposed models. However, this meta-analysis has been performed on six 
studies. Since publication of this meta-analysis, numerous studies have been conducted. 
Therefore, an update of this meta-analysis could give a lot of additional insights. We 
conducted a new meta-analysis to investigate consistencies in the literature regarding 
abnormal activity in depression and to evaluate the proposed neurobiological models. This 
meta-analysis is described in chapter 3 of this thesis.  
In addition, at the moment it is still not clear if these abnormalities in brain 
activation in depressed patients are a trait (always present independent of mood status) or 
state characteristic of depression (only present during a depressive episode). This is an 
important question in investigating brain activity as endophenotype, because an 




Evidence for abnormal brain activation as a trait characteristic comes from studies 
investigating people vulnerable for depression based on their family history or by studies 
investigating remitted patients. These studies show differences in brain activation during 
emotional processing compared to people with no personal or family history of MDD 
(Lisiecka et al., 2012; Mannie et al., 2011; Gotlib et al., 2010; Monk et al., 2008; Hooley et 
al., 2005; McCabe et al., 2012; Kanske et al., 2012; Kerestes et al., 2012; Norbury et al., 
2010; Hooley et al., 2009). In contrast, there are also studies showing effects in the brain 
specific for severely depressed patients (van Tol et al., 2011), implying that there are 
abnormal activations which are characteristic for/dependent on the depressive state.  
A drawback of these studies is that they are all cross-sectional studies and 
evidence from follow-up studies is still limited. There is some evidence from treatment 
studies, which have shown that remission following selective serotonin reuptake inhibitors 
(SSRIs) treatment was accompanied by decreased activity of the rostral ACC, insula, 
amygdala, VLPFC and hippocampal regions and this was accompanied by increased 
DLPFC, dorsal posterior cingulate gyrus and putamen activity (Fitzgerald et al., 2008a; 
Delaveau et al., 2011). This suggests a normalization of brain activity during remission, but 
a healthy control group to confirm this suggestion was not included in most of these 
studies. Another limitation of these studies is the possibility that the change in activity is 
related to medication effects and not to remission per se. We tried to overcome some of 
these shortcomings in chapter 4 of this thesis where we addressed the question of brain 
activity as state or trait marker in depression from a naturalistic point of view.  
Structural differences 
Besides functional abnormalities, also structural abnormalities have been demonstrated in 
depression. Several meta-analyses has been published which showed that the most 
consistent findings are a reduction in volume of the anterior cingulate cortex (ACC), middle 
and inferior frontal gyrus, orbitofrontal cortex, hippocampus, putamen, thalamus and 
DLPFC and DMPFC (Koolschijn et al., 2009; Bora et al., 2012; Du et al., 2012). These 
areas are in accordance with the areas thought to influence emotional processing.  
Neuroimaging genetics 
Studies have been conducted to elucidate the genetic influence on variability in brain 
activation and morphology in the healthy population. Special interest has been on brain 
areas relevant for psychiatric disorders and genes influencing the main neuromodulator 
systems in the brain: serotonin, dopamine and glutamate. For example, there is ample 
evidence for an effect of the serotonin transporter gene on amygdala activation (Munafo et 
al., 2008). Besides these neuromodulator systems, there is increasing interest for genes 




hippocampal volume (Karnik et al., 2010) and genes which have been associated with 
psychopathology from genome wide association (GWA) studies, for example the piccolo 
gene (Woudstra et al., 2012). These studies have mostly focused on the association between 
genes and possible endophenotypes in samples consisting of only healthy participants. 
Because the presence of psychopathology has an influence on the brain, it is of tremendous 
interest for evaluating our current models of endophenotypes for psychopathology to 
investigate the associations between genes and neuroimaging data in psychiatric patients in 
addition to healthy participants. 
There are two possible approaches in choosing an endophenotype: a bottom-up 
approach from gene to neurotransmitter to brain to behavior, or a top-down approach 
starting from the behavior and via cognitions to the brain and genes (Lau et al., 2010; 
Meyer-Lindenberg et al., 2006b). We chose to use a top-down approach, based on the 
assumption that a hypothesis-based, theory-driven approach limits the search area and 
maximizes the odds of finding biologically plausible correlates that can help understand 
underlying mechanisms. We have chosen genes which come to expression in brain regions 
affected in depression. Specific polymorphisms in these genes have been chosen based on 
their influence on protein expression or function. Based on the above described models for 
brain abnormalities in depression, this resulted in a gene influencing the lateral prefrontal 
cortex (Catechol-O-methyltransferase [COMT], chapter 5), a gene influencing the dorsal 
system described in the neuroanatomical models of depression (DLPFC and hippocampus, 
Disrupted-in-Schizophrenia [DISC1], chapter 6) and a gene influencing the amygdala 
(Neuropeptide Y [NPY], chapter 7). In this last chapter, we also address the question of 
gene by environment interactions on the brain. 
Aim and outline of this thesis 
To summarize, this thesis addresses several aims. The first part of this thesis considers the 
genetics of depression, in chapter 2 an extensive literature review is given on association 
studies into genes influencing dopamine metabolism and signaling to investigate if these 
genes might predispose to depression.   
Subsequently, to gain a clear insight on the association between depression and 
brain activation, we investigated consistent findings in the literature on brain activation 
during emotional processing. In chapter 3, the results of a meta-analysis are described 
which included all studies using functional MRI to investigate differences in brain 
activation in patients compared to healthy controls. We evaluated these findings in the 
context of current neurobiological models of depression. In chapter 4, the issue of state or 
trait characteristics regarding neurobiological pathology is addressed. By using longitudinal 




investigated. In addition, it was investigated if brain activation could be a predictor of 
future recovery.  
The next part of the thesis combines neuroimaging and genetic analyses in several 
studies to investigate structural and functional differences in the brain that could qualify as 
endophenotypes for depression. First, the dopamine system was studied. In chapter 5, a 
study into the influence of the gene coding for the catechol-O-methyltransferase (COMT) 
on brain activity was studied. COMT catabolizes dopamine and thereby stops dopamine 
transmission. Specifically, we investigated the influence of this gene on PFC processing 
during tasks of emotional, cognitive and memory processing. Secondly, the gene disrupted-
in-schizophrenia (DISC1) is highly expressed in the prefrontal cortex and hippocampus. 
These areas are part of the dorsal system described in the model of Phillips et al. (Phillips et 
al., 2003a; Phillips et al., 2003b) and therefore it is interesting to investigate the role of this 
gene on brain activation in depression. In chapter 6 the influence of the DISC1 gene on 
activity during tasks of planning and memory and brain structure is described. Thirdly, the 
focus was on the amygdala, another key brain structure in the study of depression. 
Neuropeptide Y (NPY) is a peptide highly expressed in the amygdala and it influences the 
stress response. In chapter 7 the interaction of the gene for NPY and stressful 
environmental exposure, in this case childhood emotional maltreatment, is investigated on 
brain activation during emotional processing. 
The empirical studies described in this thesis are part of the Netherlands Study of 
Depression and Anxiety (NESDA), which is an ongoing longitudinal multi-center cohort 
study (Penninx et al., 2008), which is described in box 1. 
Finally, in chapter 8 the findings of chapters 2-7 are integrated and discussed. 
Furthermore, suggestions for clinical implications and directions for future research on this 
topic are given.  
 
Figure 1.1: Schematic overview of studies in this thesis 






Box 1: The Netherlands Study of Depression and Anxiety   
The empirical studies described in this thesis are part of the Netherlands Study of Depression and 
Anxiety (NESDA), which is an ongoing longitudinal multi-center cohort study involving the University 
Medical Center Groningen (UMCG), Leiden University Medical Center (LUMC) and VU University 
Medical Center Amsterdam (VUMC, Penninx et al, 2008). At baseline measurement (in 2008 the 
inclusion was completed), 2981 participants were included. The aim of NESDA is to elucidate 
predictors and long-term causes and consequences of depression and anxiety. This is pursued by 
integrating biological and psychosocial research methods. 
Of all participants, 301 underwent MRI scanning during a baseline measurement. During 
scanning, tasks were performed measuring executive functioning (Tower of Londen), memory 
processing (emotional words memory task) and emotional processing (Karolinska faces task). In 
addition, a resting state scan and a structural T1*weighted image were made. After two years, the 
complete scanning procedure was repeated in 199 participants. The sample used in the NESDA-
MRI study is one of the largest described at the moment. 
 
Results of the baseline MRI measurement 
Differences in brain activity and morphology between patients and healthy controls during the 
baseline measurement have already been fully described (Demenescu et al. 2012; van Tol et al., 
2010; van Tol et al., 2011; van Tol et al., 2012). In short, these studies have shown volume 
reduction in all patient groups in the pregenual ACC (van Tol et al., 2010). During executive 
functioning, moderately to severely depressed patients showed more left DLPFC activity although 
their task performance was normal (van Tol et al., 2011). This could imply that the DLPFC functions 
less efficiently in these patients, because it has to “work harder” to obtain the same behavioural 
output. In addition, this finding could imply that this abnormal activity is a state effect, because it was 
only found in the moderately to severely depressed patients and not in the mild and remitted 
patients. During emotional memory processing, depressed patients showed a reduction in 
hippocampal activity during encoding of positive words and more activity during encoding of 
negative words in the insula, amygdala and inferior frontal gyrus (van Tol et al., 2012). In the dorsal 
ACC, there was an effect seen related to depressive state. During encoding of positive words, the 
ACC was more active only in moderately to severely depressed patients. Emotional facial 
expressions elicited hyperactivation in the right DLPFC (Brodmann areas 9/10) only during 
processing of happy expressions (Demenescu et al. 2012). To summarise, findings within the 
baseline NESDA-MRI study showed areas consistent with current neurobiological models although 
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Major depressive disorder (MDD) is a common psychiatric disorder and leading cause of 
disability worldwide. It is associated with increased mortality, especially from suicide. 
Heritability of MDD is estimated around 40%, suggesting that genotyping is a promising 
field for research into the development of MDD. According to the dopamine theory of 
affective disorders, a deficiency in dopaminergic neurotransmission may play a role in the 
major symptoms of MDD. Specific polymorphisms in genes that affect dopamine 
transmission could increase susceptibility to MDD. To determine the extent to which these 
genes influence vulnerability to MDD, we discuss genes for crucial steps in dopamine 
neurotransmission: synthesis, signalling and inactivation. The val158met polymorphism of 
the COMT gene exemplifies the lack of consensus in the literature: although it is one of the 
most reported polymorphisms that relates to MDD vulnerability, its role is not corroborated 
by meta-analysis. Gene-gene interactions and gene-environment interactions provide more 
explanatory potential than single gene associations. Two notable exceptions are the DRD4 
and DAT gene: both have variable tandem repeat polymorphisms which may have a “single 









Major depressive disorder (MDD) is a common psychiatric disorder that has been predicted 
to become the second leading cause of disability worldwide by 2020 (Murray et al., 1996). 
It is associated with increased mortality, especially from suicide (Harris et al., 1998; 
Schneider et al., 2001). In order to develop new pharmacotherapeutic strategies it is crucial 
to comprehensively understand the aetiology of MDD. Part of the phenotypic variation of 
MDD is genetic: twin studies estimate the heritability of MDD around 40% (Sullivan et al., 
2000)  or even higher (Kendler et al., 2001). Therefore, genetics are a promising field for 
research into aetiology of MDD. 
On the longer term, knowledge of genetic variance associated with MDD might 
aid treatment strategies. The concept of personalised medicine (Langreth et al., 1999), 
originally formulated for oncological drugs, recommends that people be treated with drugs 
that suit their personal genotype. This might also be of relevance in psychiatry as a poor 
treatment response often results from giving every patient the same treatment (Lin et al., 
2008). It has even been shown that patient stratification based on genetically determined 
aspects of personality could be employed to maximize the response to antidepressant 
treatment (Joyce et al., 1994). In sum, specific genotyping is important in the battle against 
MDD for two main reasons: (i) generation of a good model of MDD aetiology and (ii) 
patient stratification in the framework of personalised medicine. 
Most genetic studies in MDD have until now focused on genes regulating the 
serotonergic neuromodulatory system. A meta-analysis on genetic association studies in 
MDD (Lopez-Leon et al., 2008) showed however that of the genes involved in serotonergic 
neurotransmission only one (the serotonin transporter gene, SLC6A4) showed a significant 
association. However, this area continues to be contentious (Risch et al., 2009).  
Dopamine and the MDD phenotype  
Despite the large focus on the serotonin system, already in 1965 it was postulated that 
dopamine is involved in MDD (Schildkraut, 1965) and since then the idea that prominent 
symptoms of MDD arise at least in part from disturbances in dopamine neurotransmission 
has been reiterated in the literature many times (Dunlop et al., 2007; Brown et al., 1993; 
Diehl et al., 1992; Schildkraut, 1974; Schildkraut et al., 1967). Indeed, a considerable body 
of historical and recent evidence is consistent with this idea. First, to meet the criteria of a 
major depressive episode (MDE), at least five symptoms need to be present during the same 
two-week period. These symptoms are listed in table 1.1 (American Psychiatric 
Association, 2007). Strikingly, disturbances in processes regulated by dopamine are known 
to lead to similar symptoms. Dopamine regulates the reward system (Lippa et al., 1973; 




Wise et al., 1984), attention (Nieoullon, 2002), decision making (Assadi et al., 2009), and 
psychomotor speed (Poirier et al., 1975). Dopamine release in the ventral striatum is also 
correlated with the euphoric response to amphetamines (Drevets et al., 2001). Euphoria is 
the opposite feeling of dysphoria and dysphoria is an important symptom of a MDE. 
Therefore, dysphoria may be linked to dopamine neurotransmission. Amphetamines are 
used as pharmacological drug in the treatment of narcolepsy and obesity (Berman et al., 
2009), which underscores the role of dopamine in weight control and sleep regulation. 
Second, antidepressants that are precursors in the biosynthesis of dopamine, dopamine 
agonists and dopamine reuptake inhibitors all improve depressive symptoms (Kapur et al., 
1992). For example, the dopamine agonist pramipexole was found to have antidepressant 
effects in MDD and bipolar disorder (Corrigan et al., 2000; Goldberg et al., 2004; Zarate et 
al., 2004). Conversely, dopamine depletors and antagonists reduce motivation and mood 
and induce a depressed state (Bressan et al., 2002; Verhoeff et al., 2003). Third, dopamine 
levels are influenced by stress (Corrodi et al., 1971; Pani et al., 2000) and stress is a well 
known factor in the aetiology of MDD. Indeed, stress-induced dopamine release has been 
shown to be tightly coupled to neuroendocrine stress responses (e.g. elevated plasma 
corticosterone levels, Sullivan et al., 1998). Finally, depression also arises as secondary 
symptom of diseases which are strongly associated with dopamine depletion such as 
Parkinson’s disease (Cummings, 1992) and drug addiction (Volkow, 2004).  
Dopamine neurotransmission 
Disturbances in dopamine transmission could result from
 
either disturbed dopamine release 
from presynaptic neurons, impaired
 
signalling, or disturbed catabolism. Therefore, in order 
to shed light on the role of dopamine in MDD, we focus on proteins involved in dopamine 
metabolism and the main signalling steps; these include the dopamine receptors and 
transporters. In principle, any gene variant for a protein involved in dopamine 
neurotransmission provides a potential cause of a congenital proneness to MDD. In addition 
any one of these genes is a potential therapeutic target.  
Neurotransmission is a complex phenomenon involving the interplay of several 
processes. There are many other genes influencing dopamine neurotransmission like 
vasicular monoamine tranporter (VMAT, Erickson et al., 1992), organic cation transporters 
(OCT, Ciarimboli, 2008), but for this review we will focus on the following processes: 1). 
biosynthesis of the neurotransmitter, 2). interaction of the neurotransmitter with specific 
receptors located on postsynaptic membrames, and 3). removal of the transmitter via 
enzymatic degradation or via specialized transporter proteins on presynaptic terminal.  
The biosynthesis of dopamine (figure 2.1) depends on availability of the amino-
acid tyrosine, which is converted to dihydroxyphenylalanine (dopa) by the enzyme tyrosine 




(DDC) rapidly catalyzes formation of dopamine from dopa. DDC is also called aromatic l- 
amino acid decarboxylase (Lovenberg et al., 1962), because it also acts on other aromatic 
amino acids, such as tryptophan. In neurons that use dopamine as a neurotransmitter, no 
further enzymatic modification occurs. In some neurons, dopamine is substrate for 
dopamine-β-hydroxylase (DBH). DBH converts dopamine to norepinephrine, which in turn 
can be transformed into epinephrine by phenylethanolamine-N-methyltransferase (PNMT, 
Kopin, 1968).   
 





After release from the terminal, dopamine binds to and activates G protein-coupled 
receptors on synaptic and extrasynaptic membranes and thereby exerts its effects. There are 
five subtypes of dopamine receptors which can be divided into two groups, the dopamine 
D1-like receptors (receptors D1 and D5) and the dopamine D2-like receptors (receptors D2, 
D3 and D4). The D1 and D2 receptors were the first receptors that have been discovered 
and the later discovered dopamine receptors show high homology with D1 and D2 (Jackson 
et al., 1994). D1-like receptors activate the adenylate cyclase second messenger system, 
leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) 
concentrations. cAMP increases protein kinase A activity with resulting functional changes 
of enzymes and other proteins within the cell. The D2-like receptors, when stimulated, all 
inhibit adenylate cyclase activity (Kebabian et al., 1979; Stoof et al., 1984).  
Dopamine transporters (DAT) provide the re-uptake mechanism for terminating 
receptor stimulation by dopamine (Amara et al., 1993). DAT use energy of the 
electrochemical gradients of sodium and chloride to transport extracellular dopamine back 
into the neuron (Horn, 1990). Dopamine degradation is the other way to terminate the effect 
of dopamine. Dopamine can be degraded by two primary enzymes: catechol-O-
methyltransferase (COMT, Axelrod et al., 1958; Axelrod, 1957) and monoamine oxidase 
(MAO, Rosengren, 1960). They metabolize dopamine to physiologically inactive metabolic 
products. MAO exists as two isozymes, A and B, with different substrate and inhibitor 
specificities. Dopamine is converted to 3-methoxytyramine by COMT and MAO converts 
dopamine to 3,4-dihydroxyphenylacetic acid (DOPAC, Rosengren, 1960). Homovanillic 
acid (HVA) is the main metabolite of dopamine (Goldstein et al., 1959) and is formed 
through subsequent degradation by COMT and MAO, in either order (see figure 2.2, Anden 
et al., 1963). 
Every biochemical step in the neurotransmission and metabolism of dopamine 
corresponds to a specific enzyme, encoded for by a corresponding gene. Polymorphisms in 
these genes could have major implications for dopamine metabolism and neurotransmission 













In this review, we focus on association studies between MDD and genes involved in the 
dopamine system. Association studies have a number of important limitations. First, most 
of the described studies have a small sample size leading to lack of statistical power to 
detect a small gene effect. A second important limitation of association studies is 
population stratification. A problem of population stratification is that significant 
differences are not due to disease status, but due to population differences between the two 
samples. With regard to drawing conclusions a review has also the limitation of publication 
bias. This concerns the fact that often studies which find no associations are less likely to be 
published. An additional limitation in association studies to MDD is the heterogeneity of 
MDD. MDD as phenotype might be too broad. Differences in findings between studies 
might be due to that these studies investigate different subtypes of MDD.  
A method to overcome the first two limitations is meta-analysis. There are 
published meta-analyses on association studies between genes involved in dopamine 
processing and MDD (Lopez-Leon et al., 2008; Lopez Leon et al., 2005). These meta-
analyses have more power to detect small gene effects, but they do not extensively 
elaborate on how these genes may be involved in the susceptibility to MDD. In this review, 
we aim to give more structure to the current findings about the extent to which genes that 
code the above described steps of dopamine neurotransmission and metabolism influence 




disorder, we also discuss the involvement of genes on symptoms of MDD. These symptoms 
can also occur in other disorders, for example bipolar disorder. However, a full discussion 
of bipolar disorder is beyond the scope of our review, as we focus on MDD. The 
involvement of dopamine-related genes in bipolar disorder has already been reviewed 
elsewhere (Cousins et al., 2009). We will use MDD to refer to the diagnosis major 
depressive disorder and depression for other forms of depression, for example depression in 
patients with schizophrenia or bipolar disorder. Genes of dopamine anabolism, signalling 
and catabolism will be discussed, in that order.  
 
Table 2: Association studies in MDD of genes involved in the dopamine system. 
This table can be found at the end of this chapter.  
Tyrosine hydroxylase gene 
TH is the rate-limiting enzyme in the synthesis of dopamine (Nagatsu et al., 1964). 
Inhibition of TH with α-methylparatyrosine (AMPT) can cause depressive symptoms in 
healthy subjects (Verhoeff et al., 2003; Fujita et al., 2000; Laruelle et al., 1997; McCann et 
al., 1993; Verhoeff et al., 2001), like decreased mood (Verhoeff et al., 2003; Laruelle et al., 
1997), decreased alertness (Verhoeff et al., 2003), and changes in sleep pattern (Laruelle et 
al., 1997). However, these results were not always replicated (McCann et al., 1995; 
Salomon et al., 1997). In remitted depressed patients, experimentally administered AMPT 
can cause depressive relapse (Berman et al., 1999; Bremner et al., 2003; Lam et al., 2001; 
Miller et al., 1996). The reverse effect has also been shown: increasing TH expression has 
antidepressant effects in rats (Fu et al., 2006). 
The TH gene (OMIM accession number 191290) is localized on the short arm of 
chromosome 11 (11p15.5, Moss et al., 1986; Powell et al., 1984). A certain tetranucleotide 
repeat polymorphism (Polymeropoulos et al., 1991) is the most frequently reported 
polymorphism in relation to MDD. Most studies on this polymorphism reported five alleles, 
but Furlong et al. (1999b) reported a sixth allele in their sample but they did not elaborate 
on this finding.  
Serretti et al. (1998a) found that allele 1 of this tetranucleotide repeat 
polymorphism was less often found in their sample of MDD patients than in their control 
sample. Short after the publication of this study, a meta-analysis was performed on three 
other studies (Furlong et al., 1999b; Oruc et al., 1997; Souery et al., 1996) with a total of 
204 MDD patients and 359 comparison individuals (Furlong et al., 1999b) and this meta-
analysis did not show an association, neither did these individual studies. Although the 
sample sizes of these studies and meta-analysis are small, current evidence goes in the 
direction that this polymorphism is not likely associated with MDD. 
Ho et al. (2000) investigated the association between the tetranucleotide 




performed this analysis on the same sample as Furlong et al. (1999b) and did not find a 
relationship between these two variables and this polymorphism. A more symptomatic 
definition is to look at depression scores independent of diagnosis. It appears that allele 2 of 
this polymorphism is found to be associated with lower depression scores in a sample of 
psychiatric patients with mood disorders, the sample size is small however 
(bipolars/unipolars = 41/5, Serretti et al., 1998b). In summary, the tetranucleotide 
polymorphism is not associated with the diagnosis MDD, but there are small indications for 
a more symptomatic association between this polymorphism and depressive symptoms 
independent of diagnosis.   
Also other polymorphisms in the TH gene have been investigated in association 
with MDD. They include a TaqI restriction fragment length polymorphism (RFLP) located 
in the 5’ untranslated region (UTR), BglII and PstI RFLPs located toward the 3’ UTR of the 
gene (Furlong et al., 1999b; O'Malley et al., 1988) and a valine (val) to methionine (met) 
substitution (val81met polymorphism, rs6356) in exon 2 (Yoshida et al., 2008). These 
studies show indications for a higher risk for MDD for carriers of 2/2 genotype of the TaqI 
RFLP (Souery et al., 1996) and for carriers of the B-allele of the PstI RFLP (Furlong et al., 
1999b). The PstI RFLP is not associated with number of depressive episodes or age of 
onset (Ho et al., 2000). No associations were found between MDD and BglII (Korner et al., 
1990) or val81met (Koks et al., 2006). According to these findings, the most promising 
polymorphisms in the TH gene are PstI RFLP and TaqI RFLP. 
In summary, the tetranucleoctide repeat polymorphisms in the TH gene have been 
extensively investigated, but the results do not indicate an involvement in the development 
of MDD. The TH gene might have other variants that predispose to MDD and these could 
be more extensively investigated in the future instead of the tetranucleotide repeat 
polymorphism. Current examples are PstI RFLP in the 3’ UTR and TaqI RFLP in the 5’ 
UTR.  
Dopa decarboxylase gene  
DDC is another enzyme in the biosynthesis of dopamine, with the difference that DDC, 
unlike TH, is not rate-limiting (Opacka-Juffry et al., 1995). However, DDC can be 
regulated (Berry et al., 1996) and low levels of DDC expression or function would very 
likely reduce dopamine concentrations and have an effect on mood and motivation.  
The DDC gene (OMIM accession number 107930) is located at chromosome 
7p11-p13 (Craig et al., 1992; Scherer et al., 1992; Sumi-Ichinose et al., 1992). Børglum et 
al. (Borglum et al., 1999) described two variants in the DDC gene, a four base pair (bp) 
deletion consisting of a GAGA sequence (consisting of guanine (G) and adenine (A)) in the 
untranslated region of exon 1 and a 1-bp deletion in the DDC promoter. The latter leads to a 
drop of the binding capacity for a family of NGF1-A transcription factors and this suggests 




only two studies investigated the association between MDD and these two polymorphisms 
(Borglum et al., 1999; Jahnes et al., 2002), but surprisingly neither found a significant 
association. Probably, these polymorphisms do not have sufficient influence on dopamine 
levels, because DDC is not rate-limiting. 
There is currently no evidence to conclude that these polymorphisms in the DDC 
gene play a role in the susceptibility for MDD. The amount of data is currently limited and 
possibly other polymorphisms in this gene constitute a risk for the development of MDD.  
Dopamine receptor genes 
Alterations in receptor proteins can affect affinity for ligands, expression levels and signal 
transduction. Any of these could play a role in MDD.  
Dopamine D1 receptor gene 
Dopamine D1-like receptors activate the adenylate cyclase signalling pathway, leading to 
increased intracellular cAMP levels. The dopamine D1 receptor has the highest level of 
expression of all dopamine receptors (Missale et al., 1998). Abnormal levels of dopamine 
D1 receptor expression in the prefrontal cortex cause less performance on executive 
functioning (Takahashi et al., 2008) and working memory (Williams et al., 2006). D1 
receptors also play a role in rewarding effects of cocaine (Caine et al., 2007) and nicotine 
(David et al., 2006). Therefore, this receptor is of prime interest to explore in relation to 
MDD.   
The gene that codes for the dopamine D1 receptor (DRD1, OMIM accession 
number 126449) is located on chromosome 5q35.1 (Grandy et al., 1990; Sunahara et al., 
1990; Wilkie et al., 1993). Multiple association studies on DRD1 and bipolar disorder show 
an association (Del Zompo et al., 2007; Dmitrzak-Weglarz et al., 2006; Ni et al., 2002; 
Severino et al., 2005), but others do not (Mitchell et al., 1992; Nothen et al., 1992; Savoye 
et al., 1998). There is no evidence for associations with other disorders which involve 
alteration in dopamine functioning like schizophrenia, autism or attention deficit 
hyperactivity disorder (ADHD, Wong et al., 2000). This is not surprising, because none of 
the currently identified polymorphisms cause known functional changes in the receptor, e.g. 
in biological activity or pharmacological profile (Wong et al., 2000).  
We found only two association study on MDD and DRD1 (Koks et al., 2006; 
Garriock et al., 2006). In total they investigated eight SNPs in association with MDD. Only 
for the SNP C2102A (not listed in NCBI dbSNP database) Koks et al. (2006) found an 
association with MDD, but this association did not reach significance after correction for 
multiple comparisons. To conclude, also for MDD there are no indications for an 
association with the DRD1 gene. Hence, currently genotyped polymorphisms in the DRD1 




could be a susceptibility gene for MDD, but functional polymorphisms still need to be 
identified.  
Dopamine D2 receptor gene  
Dopamine D2 receptor is involved in reward-mediating mesocorticolimbic pathways 
(Missale et al., 1998). As for the other D2-like receptors, stimulation of dopamine D2 
receptor causes an inhibition of cAMP formation by inhibition of adenylate cyclise (Tang et 
al., 1994).  
Reward deficiency syndrome results from dysfunction or hypoexpression of 
dopamine D2 receptors (Blum et al., 1996). Reward deficiency syndrome unites addictive, 
impulsive, and compulsive behaviours as a result of dopamine receptor deficiency leading 
to reduced sensitivity to reward (Bowirrat et al., 2005). MDD is similar to reward 
deficiency syndrome with the difference that MDD patients do not extensively keep 
searching for reward but show limited efforts to pursue reward.  
Involvement of dopamine D2 receptors in MDD is supported by the finding that 
after treatment with antidepressants, D2 binding is increased in the striatum (Larisch et al., 
1997), the anterior cingulate cortex (Larisch et al., 1997) and the nucleus accumbens 
(Gershon et al., 2007). Depression also occurs in schizophrenia as a side-effect of treatment 
with typical antipsychotic drugs and the level of D2 receptor blockade correlates with 
severity of depressive symptoms (Bressan et al., 2002). This makes mutations in the D2 
encoding gene (DRD2, OMIM accession number 126450) a plausible factor in MDD 
aetiology.  
DRD2 is located on the long arm of chromosome 11 (11q22-23, Grandy et al., 
1989). A frequently investigated polymorphism in this gene is the Taq1A (rs1800497), a C 
(A2-allele) to T (A1-allele) substitution. Originally it was thought to be located in the 
noncoding region of the DRD2 gene (Grandy et al., 1989; Dubertret et al., 2004), but it 
seems to be located in the adjacent ANKK1 (ankyrin repeat and kinase domain-containing 
protein 1) gene (OMIM accession number 608774, (Neville et al., 2004). Most association 
studies still describe Taq1A as a polymorphism of the DRD2 gene (Koks et al., 2006; Chen 
et al., 2002; Elovainio et al., 2007; Light et al., 2007; Vaske et al., 2008), but Lucht & 
Rosskopf (2008) declare that caution must be held when considering linking Taq1A 
variants, DRD2 expression, and the observed phenotype in light of the complexities of this 
genetic locus.  
Despite debate about the exact locus, the A1-allele of the Taq1A polymorphism 
accounts for lower D2 receptor availability and binding potential in the brain (Jonsson et 
al., 1999; Noble et al., 1991; Pohjalainen et al., 1998), but this finding was not always 
replicated (Laruelle et al., 1998). Carriers also show reduced glucose metabolism in 




(Noble et al., 1997). As a consequence of this reduced glucose metabolism they have 
diminished activity in the brain dopaminergic reward system (Noble, 2003).  
The first study published on this polymorphism found that the A2-allele in boys 
(12 to 16 years old) was associated with higher levels of depression severity (Berman et al., 
2003). A few years later, Elovainio et al. (2007) found no main effect of this polymorphism 
on depressive symptoms in adults (mean age 31,9), but found indications that Taq1A 
moderates the effect of stressful life events (death or serious illness of spouse or children, 
divorce, and unemployment) on depressive symptoms. Carriers of the A2/A2 genotype may 
be more vulnerable to depressive symptoms after stressful live events than others. As an 
explanation for the direction of these findings, it has been suggested by Berman et al. 
(2003) that carriers of the A1 allele, because of their diminished brain dopaminergic reward 
system, have developed better coping mechanisms for experiencing negative affect to 
maintain their emotional balance during stressful events. Therefore A2/A2 carriers may be 
more vulnerable to MDD after stressful events 
In opposite direction of previous findings (Elovainio et al., 2007), Vaske et al. 
(2008) found a relationship between depressive symptoms and the A1-allele, especially in 
males. They also investigated the interaction with stressful life-events (victimization), but 
this was not present. No association between Taq1A genotype and MDD was reported in 
females (Vaske et al., 2008; Berman et al., 2003) or in studies were both sexes were 
analyzed as one group (Koks et al., 2006; Elovainio et al., 2007; Massat et al., 2002).  
To summarize, it is not quite clear in which gene the Taq1A polymorphism is 
located, but there is clear evidence for an association with dopaminergic neurotransmission. 
Despite the limited number of studies on the association of this polymorphism with MDD is 
limited, it seems that it influences the vulnerability to MDD. The evidence goes in the 
direction of the A2-allele increasing vulnerability in combination with stressful events.  
Other investigated polymorphisms in the DRD2 gene are 141C Ins/Del 
(rs1799732), ser311cys (rs1801028) and C957T (rs6277). None of these SNPs show an 
association with MDD (Koks et al., 2006; Cusin et al., 2002; Furlong et al., 1998; Huuhka 
et al., 2008; Manki et al., 1996). However, within a group of MDD patients, carriers of the 
T/T genotype of the C957T SNP had more depressive symptoms than carriers of the other 
genotypes (Huuhka et al., 2008). These subjects also respond less favorable to 
antidepressant treatment. PET and SPECT studies often measure binding potential, which is 
a compound measure proportional to free receptors and affinity. A PET study showed that 
the T allele of the polymorphism C957T causes lower binding potential of the D2 receptor 
for dopamine (Hirvonen et al., 2004). Lower binding potential could be caused by fewer 
receptors, lower affinity or more dopamine in the synaptic cleft. This supports the idea of 
an association between the T/T genotype and depressive symptoms. Rs1799732 is also not 
associated with MDD, but within MDD patients it is associated with psychosis in MDD 




differently distributed between MDD patients and controls, but within MDD the C957T 
SNP is associated with severity of depression and rs1799732 with psychotic symptoms.  
To conclude, there are indications that DRD2 plays a role in the susceptibility to 
MDD. Multiple polymorphisms of this gene have been investigated and for every 
polymorphism there is only a limited amount of studies. Based on current evidence, the 
polymorphisms with most influence on the susceptibility to MDD are Taq1A and C957T. It 
is most likely that these polymorphisms influence individual symptoms within MDD rather 
than the syndrome of MDD, possibly in combination with stress. 
Dopamine D3 receptor gene 
Dopamine D3 receptors, like D2 receptors, inhibit cAMP formation by inhibition of 
adenylate cyclase activity. The dopamine D3 receptor is densely expressed in the limbic 
areas and the islands of Calleja (Missale et al., 1998). Ropinirole and pramipexole are D2-
like receptor agonists with high affinity for the D3 receptor. They were developed as 
possible drugs for Parkinson’s disease, but they also appeared to have intrinsic 
antidepressant properties (Gershon et al., 2007). Multiple chronic antidepressant treatments 
selectively increase D3 receptor expression in the nucleus accumbens (Lammers et al., 
2000). Elevated dopamine stimulation of this receptor was postulated to participate in the 
antidepressant activity (Lammers et al., 2000). 
Most of the known variation in the gene coding for dopamine D3 receptor (DRD3, 
OMIM accession number 126451), which is located on chromosome 3q13.3 (Le Coniat et 
al., 1991), comes from a SNP whereby an A base is substituted for a G base (rs6280), and 
this results in a substitution of serine to glycine at position 9 (ser9gly) in the extracellular 
N-terminal part of the receptor protein. The N-terminal part of the receptor may affect the 
protein insertion into the membrane (Rietschel et al., 1993). Homozygotes for the gly-allele 
have a D3 receptor with a higher affinity for dopamine (Lundstrom et al., 1996). DRD3 is 
not only a postsynaptic receptor, but also an autoreceptor (Sokoloff et al., 1990). 
Autoreceptors are located at the presynaptic neuron and activation of autoreceptors results 
in decreased dopamine release.  
Most studies did not find an association between the Ser9Gly polymorphism and 
MDD (Koks et al., 2006; Garriock et al., 2006; Massat et al., 2002; Manki et al., 1996), 
depression scores in a community sample (Henderson et al., 2000) nor with depressive 
symptoms in psychiatric patients (Serretti et al., 1999a). One study found that the gly-allele 
is associated with increased risk for MDD (Dikeos et al., 1999). Strikingly, this study had 
the smallest sample size of all studies (36 MDD patients and 38 controls). In a meta-
analysis (Lopez-Leon et al., 2008) on most of the association studies (Koks et al., 2006; 
Garriock et al., 2006; Manki et al., 1996; Dikeos et al., 1999) the total number of MDD 
patients (n=541) and healthy controls (n=606) was not large enough to detect an 




say that most evidence points in the direction of no association between the ser9gly 
polymorphism and MDD. This could be explained by that this polymorphism perhaps not 
only causes elevated affinity for the receptors, but also for the autoreceptors and these 
mechanisms will compensate each other and therefore would not cause a susceptibility.  
There is an association study on two other SNPs in the DRD3 gene (rs1800828 
and rs1800827), but they did not find an association for either of these SNPs (Koks et al., 
2006).  
To date, the most investigated polymorphism in the DRD3 gene is the ser9gly and 
the currently published studies do not support a role for this polymorphism in the 
susceptibility to MDD.  
Dopamine D4 receptor gene 
The dopamine D4 receptor has the same effect on adenylate cyclase as other D2-like 
receptors, but the mRNA distribution profile differs from other dopamine receptors in 
having elevated expression levels in prefrontal cortex and amygdala (Matsumoto et al., 
1995; van Tol et al., 1991). These areas are known to be involved in the psychopathology 
of MDD (Fitzgerald et al., 2008a; Davidson et al., 2002; Drevets, 2000), therefore the 
dopamine D4 receptor gene (DRD4) is a good candidate to mediate the pathology of MDD.  
Dopamine D4 receptor gene  (DRD4, OMIM accession number 126452) is located 
at the tip of the short arm of chromosome 11 (11p15.5, van Tol et al., 1991; Gelernter et al., 
1992; Petronis et al., 1993). Most of the known diversity in the DRD4 gene is the result of a 
48-bp variable number tandem repeat (VNTR) in exon 3 of the gene, which encodes the 
third cytoplasmic loop of the receptor (van Tol et al., 1992). Van Tol et al. (1992)  
identified five alleles of this VNTR (2, 3, 4, 5 and 7-repeat units). These variants have 
different pharmacological properties with respect to clozapine and spiperone binding and 
may underlie individual differences in susceptibility to neuropsychiatric disease and in 
responsiveness to antipsychotic medication. To date, nine repeat alleles have been 
identified (2 to 10 repeat alleles, Asghari et al., 1994; Lichter et al., 1993). The 2-, 4- and 7-
repeat alleles are the most common globally, but the frequency varies widely depending on 
ethnicity (Chang et al., 1996). A direct comparison between DRD4.2, DRD4.4 and DRD4.7 
receptor isoforms indicated that the dopamine DRD4.7 receptor has a two-fold lower 
potency for coupling dopamine receptors to adenylate cyclase as compared to DRD4.4 and 
DRD4.2 receptors (Asghari et al., 1995; Oak et al., 2000). Therefore, the D4 receptor 
isoform coded by DRD4.7 is less potent to inhibit cAMP after binding of dopamine. The 7-
repeat allele is also found to cause noise in brain activation in the dorsolateral prefrontal 
cortex during a working memory task (Herrmann et al., 2007). It is plausible that a 
suboptimal functionality of DRD4, caused by the 7-repeat allele, would lead to an increased 




Most studies on the association between 48-bp VNTR and MDD did not find an 
association (Oruc et al., 1997; Garriock et al., 2006; Frisch et al., 1999; Serretti et al., 
1999b) or depression severity (Serretti et al., 2002) except for one (Manki et al., 1996). 
Manki et al. (1996) found that carriers of the 5-repeat allele had a higher risk for MDD and 
that the 4-repeat allele was a protective factor. This is not in correspondence with the 
expectation that the 7-repeat allele would constitute a risk factor. It must be added that the 
sample of Manki et al. (1996) consisted of Japanese subjects and that Asians have a very 
low incidence of the 7-repeat allele (Chang et al., 1996).  
In contrast to the findings of individual studies, a meta-analysis on these studies 
showed that carriers of the 2-repeat allele have a higher risk for MDD (Lopez Leon et al., 
2005). According to Reist et al. (2007) a frequently overlooked but important characteristic 
of these VNTR alleles is that the DRD4.2 protein appears to have a functional ability to 
reduce cAMP that is intermediate between the DRD4.4 and the DRD4.7 protein, and 
therefore also has a diminished potency to inhibit cAMP compared to the DRD4.4 protein. 
This could explain the unexpected association between MDD and the 2-repeat allele.  
In addition to an association with MDD vulnerability, the 48-bp VNTR is also 
involved in patient stratification aimed at optimal treatment outcome. Genotypes of this 
polymorphism are differently distributed between patients who respond to antidepressant 
treatment and patients who do not respond (Garriock et al., 2006).  
There is only one study that looked at SNPs in the DRD4 gene and there was no 
association between these SNPs and MDD (Koks et al., 2006). 
To conclude, the most investigated polymorphism in the DRD4 gene is the 48-bp 
VNTR and to date this is also the only polymorphism in this gene that shows an association 
with MDD.  The 2-, 4-, and 7-repeat alleles are the most common alleles, whereby the 2-
repeat allele is associated with a higher risk for MDD. The 4-repeat allele is the most 
common allele in the population world-wide (Chang et al., 1996) and is shown to be a 
protective factor against MDD in the Japanese population (Manki et al., 1996). It is a good 
possibility that this allele is a protective factor for MDD in the whole population.  
Dopamine D5 receptor gene 
The intracellular effect of activation of dopamine D5 receptors is the same as for the 
dopamine D1 receptor, activating adenylate cyclase. Its affinity for dopamine is 10-fold 
higher than that of the dopamine D1 receptor (Sunahara et al., 1991): but dopamine D5 
receptor expression has a more restricted topology in the brain (Missale et al., 1998). Based 
on literature there are not a lot of reasons to assume that the DRD5 gene will be associated 
with MDD. There are no cues that this gene is associated with other neuropsychiatric 
diseases, like schizophrenia and bipolar disorder, and there are no known therapeutic drugs 




The dopamine D5 receptor gene (DRD5, OMIM accession number 126453) is 
located on chromosome 4p16.1-15.3 (Grandy et al., 1992; Sherrington et al., 1993). The 
DRD5 gene is the least investigated dopamine receptor gene in relation to MDD, to our 
knowledge only one study (Koks et al., 2006) investigated the role of the DRD5 gene as a 
risk for MDD. It investigated one polymorphism in this gene (rs1967551 in the 3’UTR) and 
did not find an association. More research is needed in order to formulate a good hypothesis 
on the association of the DRD5 gene with MDD.  
Dopamine transporter gene 
DAT mediates re-uptake of released dopamine back up into presynaptic terminals and 
thereby terminates the receptor activating effect of dopamine. Patients with a MDE have 
reduced DAT binding potential compared to healthy people (Meyer et al., 2001). An 
explanatory model for this observation is that DAT is compensatorily down-regulated 
secondary to lower dopamine concentration, thus increasing synaptic neurotransmission 
(Gordon et al., 1996; Ikawa et al., 1994; Kilbourn et al., 1992). Quite the opposite, MDD 
can also be associated with higher DAT density (Amsterdam et al., 2007; Laasonen-Balk et 
al., 1999), which results in a more effective re-uptake of dopamine into the presynaptic 
neurons. This leads to a lower concentration of dopamine in the synaptic cleft and a 
consequent reduction in dopaminergic neurotransmission. DAT is the primary target for 
psychostimulant amphetamines and for cocaine. Either way, it is clear that abnormalities in 
DAT expression feature in MDD, and they may play a pivotal causal role.  
The gene coding for DAT is the solute carrier family 6, member 3 gene (SLC6A3, 
OMIM accession number 126455). The gene is mapped to chromosome 5p15.3. The gene 
is most often called DAT1 to increase clarity about its function. The most described 
polymorphism is a 40-bp VNTR polymorphism in the 3’ UTR in exon 15. It gives rise to 
seven known alleles, ranging from 3 to 11 tandem repeats, with 9 or 10 tandem repeats 
occurring most frequently (Vandenbergh et al., 1992). Although the alleles are in the 
untranslated region, they do have functional consequences. Strikingly, the 9-repeat allele in 
particular is associated with decreased levels of DAT expression (Mill et al., 2002). 
Heterozygote carriers of the 9-repeat/10-repeat genotype have lower (Heinz et al., 2000), 
higher (Jacobsen et al., 2000; van Dyck et al., 2005), or similar (Martinez et al., 2001) 
binding potential of DAT compared to carriers of the homozygote 10-repeat genotype. The 
inconsistent relationship between DAT binding potential and the heterozygous genotype 
could arise due to SNPs within the VNTR alleles (Miller et al., 2002). On the basis of this 
finding, individuals defined as ‘homozygous’ on the basis of the number of repeats in the 
40-bp VNTR may actually have two distinctly different alleles based on SNPs.  
In individual studies comparing MDD patients and healthy controls, there is no 
association between MDD and this VNTR (Manki et al., 1996; Frisch et al., 1999), but a 




repeat genotype compared to the 10-repeat/10-repeat genotype (Lopez-Leon et al., 2008). 
No difference is found between MDD patients and healthy controls for distributions of the 
9-repeat/9-repeat genotype and 10-repeat/10-repeat genotype or the 9-repeat allele and 10-
repeat allele. Surprisingly, only the heterozygote genotype predisposes to MDD.   
The finding of increased risk for MDD for carriers of the 9-repeat/10-repeat 
genotype is not consistent with the finding of Mill et al. (2002) showing decreased DAT 
expression associated with the 9-repeat allele, since higher DAT expression and therefore 
less dopamine activity in depressed patients is most plausible. The findings according the 
consequences on binding potential of different genotypes of this VNTR are inconsistent. If 
the 9-repeat/10-repeat genotype is a risk for MDD, it is expected that this genotype would 
cause higher DAT binding potential compared to 10-repeat/10-repeat genotype, 
corresponding to the findings of Jacobsen et al. (2000) and Van Dyck et al. (2005) and not 
lower DAT binding as Heinz et al. (2000) found. In summary, the 9-repeat/10-repeat 
predisposes to MDD and this genotype is likely to cause higher DAT binding potential.  
Within MDD patients differences have been observed between different 
genotypes. For example, atypical depression may be associated with the 10/10 genotype 
(Hahn et al., 2008). In addition to an association with MDD vulnerability, the 40-bp VNTR 
has also been associated with differences between MDD patients in treatment outcome. 
Kirchheiner et al. ( 2007) observed differences in treatment outcome between patients with 
different genotypes of this polymorphism.  
A different kind of approach to the involvement of genetics in the development of 
MDD is polymorphisms in interaction with environmental factors. The SNP rs40184 is 
located in intron 14, by definition an untranslated part of DNA, and consists of a C and a T-
allele. It is unclear whether this SNP has direct functional significance, but it is located 
within the 3' UTR of the DAT1 gene and alleles of this SNP frequently occur jointly with 
alleles of the 40-bp VNTR (rs40184 and the 40-bp VNTR have a high linkage 
disequilibrium (Haeffel et al., 2008). Haeffel et al. (2008) found that male adolescents with 
the T/T genotype were more depressed in response to perceived maternal rejection.  
Recently, two other SNPs have been identified for association with MDD and 
treatment response: rs8179029 and rs2550936 (Dong et al., 2009). 
To conclude, the 9-repeat/10-repeat genotype may enhance risk for MDD, 
probably by causing higher DAT binding potentials thereby reducing dopamine levels in 
the synaptic cleft. SNPs in this gene may be promising for future research, especially in 






Dopamine--hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine 
(Kopin, 1968). According to the catecholamine theory of affective disorders, low levels of 
dopamine and norepinephrine both can cause MDD. DBH influences the levels of both 
these neurotransmitters, but in opposite ways. Low levels of DBH expression or activity 
would cause low levels of norepinephrine while high levels of DBH would cause low levels 
of dopamine. Focussing on the dopamine theory of MDD, we would expect that high levels 
of DBH are associated with MDD.  
DBH activity can be measured in human plasma (Weinshilboum et al., 1971) and 
the biochemical properties of plasma DBH are similar to DBH in the nervous system 
(Weinshilboum, 1978). The assumption is that due to exocytocic release of DBH during 
sympathetic neurotransmission, the enzyme is released into the blood circulation and thus 
offers the potential for monitoring neuronal activity (Weinshilboum et al., 1971). However, 
this assumption has been questioned (Weinshilboum, 1978). Indeed, higher levels of DBH 
plasma are found in patients with MDD compared to healthy controls (Markianos et al., 
1976; Matuzas et al., 1982) and higher levels of plasma DBH are associated with higher 
scores on MDD scales in a heterogeneous sample of outpatients awaiting medical, surgical, 
or psychiatric appointments (Friedman et al., 1978). However, other studies did not find 
differences in DBH plasma levels between depressed patients and healthy controls 
(Lamprecht et al., 1974; Mathew et al., 1981; Shopsin et al., 1972). Consistent with the 
above prediction, there are to our knowledge no studies published that found decreased 
levels of DBH plasma in depressed patients. This supports the idea that dopamine levels are 
more important for mood than norepinephrine levels.  
Levels of plasma DBH are largely genetically determined (Ross et al., 1973; 
Weinshilboum et al., 1973). We would expect that a polymorphism in the DBH gene which 
causes high levels of DBH, will make a person vulnerable to develop MDD.  
The DBH gene (OMIM accession number 609312) is located on chromosome 
9q34 (Craig et al., 1988). The polymorphism C1021T in the 5’ UTR of the DBH gene 
(rs1611115) accounts for 35-52  of the variation in plasma DBH activity (Zabetian et al., 
2001). It consists of the more common C-allele and less common T-allele which leads to 
lower levels of plasma DBH. Recently, one study has investigated the association between 
this polymorphism and MDD and indeed did not find an association (Hess et al., 2009). 
There is also no difference between the subtype MDD with psychotic features and MDD 
without psychotic features (Cubells et al., 2002). 
Two other polymorphisms have been investigated in relation to MDD: A444G in 
exon 2 and a 19-bp insertion/deletion polymorphism. The A444G is comprised of either a G 
or A base and the G-allele is associated with higher DBH activity (Cubells et al., 1998). 




psychosis in MDD (Wood et al., 2002). The A-allele appears to cause lower DBH activity, 
and hence higher dopamine levels. This is in line with findings of low plasma DBH levels 
(Cubells et al., 2002; Meltzer et al., 1976; Meyers et al., 1999; Mod et al., 1986) and high 
dopamine levels in psychotic MDD (Schatzberg et al., 1992).  
The 19-bp insertion-deletion (ins/del) gives rise to two alleles with or without 
these 19 base pairs. The insertion allele is associated with higher plasma DBH (Cubells et 
al., 2000). One study investigated the association between this polymorphism and MDD 
and found that the del-allele (causing lower plasma DBH) was more frequent in depressed 
patients than in healthy controls (Togsverd et al., 2008). The subjects in this study were 
only elderly women (mean age = 69.2), so we cannot draw conclusions for the general 
population, but an association between the del-allele and MDD is not in line with the idea 
of lower dopamine levels in MDD. 
To conclude, despite theoretical background of why the DBH gene could be a 
logical candidate for vulnerability to MDD, there are only few studies on this topic. The 
only polymorphism, for which an association is found, is the 19-bp ins/del polymorphism. 
The finding was in the opposite direction from our expectation, but this was in a sample 
consisting of only elderly women. Up to now there is scarce evidence for genetically 
determined elevated DBH levels in MDD caused by genetics.  
Catechol-O-methyltransferase gene 
Catechol-O-methyltransferase (COMT) inactivates extraneuronal dopamine and the 
distribution in the brain is homogenous with the exception of the amygdala were COMT 
has the lowest expression (Hong et al., 1998). One could expect that higher COMT activity, 
with as consequence lower dopamine levels, is associated with MDD. Consistent with this 
expectation is the fact that depression severity decreases after treatment with the COMT 
inhibitor tolcapone (Fava et al., 1999). The biochemical characteristics of COMT in 
erythrocytes and the brain are similar (Bade et al., 1976). Increased erythrocyte COMT 
activity is reported in depressed patients (Gershon et al., 1975; Puzynski et al., 1983), but 
there are also studies which reported reduced (Briggs et al., 1973; Cohn et al., 1970; 
Dunner et al., 1971; Karege et al., 1987) or normal (Dunner et al., 1977; White et al., 1976) 
erythrocyte COMT activity in MDD.  
The COMT gene (OMIM accession number 116790) is located on chromosome 
22q11.2 (Grossman et al., 1992; Winqvist et al., 1992). The most investigated 
polymorphism in the COMT gene is the val158met polymorphism. This polymorphism 
causes a G to A substitution at codon 158 which lies within the coding region of the gene. 
This leads to an amino acid substitution of val to met (val158met, rs4680). The met-allele is 
associated with a three- to fourfold reduction in activity of the COMT enzyme (Lachman et 




Opposite findings are reported in the literature regarding the association between 
MDD and COMT. One study found that the val-allele is a risk for early-onset MDD 
(Massat et al., 2005), but other studies found that the met-allele was a risk for MDD with 
onset in adulthood (mean age of onset 44 years, (Ohara et al., 1998)) and with more 
depressive symptoms in women during pregnancy (Doornbos et al., 2009). Most studies 
(including a meta-analysis) did not find an association between the val158met 
polymorphism and MDD (Lopez-Leon et al., 2008; Garriock et al., 2006; Cusin et al., 
2002; Huuhka et al., 2008; Frisch et al., 1999; Massat et al., 2005; Baune et al., 2008; 
Funke et al., 2005; Jabbi et al., 2007; Kunugi et al., 1997; Serretti et al., 2006) nor with 
scores on depression scales (Henderson et al., 2000; Anttila et al., 2008; Baekken et al., 
2008; Illi et al., 2010; Wray et al., 2008). Therefore, it is not likely that there is a direct 
relationship between the val158met polymorphism and vulnerability to MDD.  
A major confounding or mediating factor in the aetiology of MDD is stress. The 
met-allele is associated with higher endocrine and subjective stress response in healthy 
controls (Jabbi et al., 2007). The relationship between the endocrine response and 
subjective stress response is different for patients with MDD (Jabbi et al., 2007). The met-
allele also showed an association with the onset of mood disorders after exposure to 
adverse events (Mandelli et al., 2007). These findings suggest that the met-allele genotype 
could enhance predisposition to MDD by altering the reactivity to stressors.  
The utility of this polymorphism for population stratification is unclear. Studies 
report better antidepressant treatment outcome for the met-allele (Yoshida et al., 2008; 
Baune et al., 2008; Benedetti et al., 2009), the val-allele (Anttila et al., 2008; Szegedi et al., 
2005) or no differences (Illi et al., 2010; Szegedi et al., 2005; Arias et al., 2006; Serretti et 
al., 2002). Huuhka et al.  (2008) only found an association with treatment response for the 
met-allele in combination with the T allele of the C957T polymorphism in the DRD2 gene. 
There is also a recent report on an association between three different SNPs in the COMT 
gene (rs165599, rs165774 and rs174696) and treatment response in MDD patients (Perlis et 
al., 2009).  
Three other SNPs in the COMT gene are reported in relationship to MDD. There 
are no associations found for the polymorphisms rs737865 (Funke et al., 2005; Wray et al., 
2008) or rs165599 (Garriock et al., 2006; Funke et al., 2005; Wray et al., 2008). One study 
reported a relationship for the SNP rs2097603 and MDD (Funke et al., 2005). This SNP 
causes an A to G substitution in the promoter region and the A-allele was more often found 
in patients with MDD than in healthy controls (Funke et al., 2005).  
To conclude, it is possible that the val158met polymorphism in the COMT gene 
plays a role in the vulnerability to MDD. This polymorphism changes the response to 
stressful live-events. Consistent with our hypotheses, it appears that carriers of the met-
allele are more likely to develop a MDD in combination with stress. The rs2097603 





MAO-A is one of the two isozymes of the enzyme MAO. Like COMT, MAO inactivates 
dopamine. It has been reported that dopamine is primarily metabolized by MAO-B in 
humans (Garrick et al., 1980), but there is also a study that reports that MAO-A is more 
important in the metabolism of dopamine (Lenders et al., 1996). Higher activity or 
expression of MAO would result in lower dopamine levels which in turn could give rise to 
MDD. Indeed, levels of brain MAO-A are elevated in patients with MDD (Meyer et al., 
2006) and accordingly, MAO-A inhibitors are effective antidepressants (Priest et al., 1995).  
The MAO-A gene (OMIM accession number 309850) is located on the X 
chromosome: Xp11.23 (Levy et al., 1989). As a consequence, men only have one allele and 
therefore also recessive variants will be influential, and this makes men more vulnerable to 
the consequences of polymorphisms in this gene.  
The most investigated polymorphism is a 30-bp VNTR in the promoter region. 
This VNTR has 5 different alleles (2, 3, 3.5, 4 and 5 repeats), the longer of which (3.5, 4 
and 5) cause a higher MAO-A activity than the shorter ones (Deckert et al., 1999). 
Although, an association between the longer alleles and MDD was found in both males (Yu 
et al., 2005) and females (Yu et al., 2005; Schulze et al., 2000) and Kersting et al. (2007) 
found an association for the longer alleles with higher grief in depressed females; Kersting 
et al. (2007) did not find an association with severity of depression and indeed, most studies 
show no association between the 30-bp VNTR and MDD (including a meta-analysis, 
(Lopez-Leon et al., 2008; Cusin et al., 2002; Du et al., 2004; Gutierrez et al., 2004; Kunugi 
et al., 1999; Syagailo et al., 2001) or with depression scores (Serretti et al., 2002; 
Christiansen et al., 2007; Cicchetti et al., 2007). The 30-bp VNTR is not a promising 
candidate to be involved in the susceptibility for MDD. Doornbos et al. (2009) found that in 
women the short alleles are associated with more depressive symptoms during pregnancy. It 
is also not likely that this VNTR is associated with other subtypes of MDD. Gutierrez et al. 
(2004) investigated this option and they found a trend, but not significant, for the longer 
alleles to be associated with the seasonal and psychotic subtypes. Hahn et al. (2008) did not 
find a trend for association for this VNTR and specific aspects of depression, like 
suicidality, age of onset, psychosis and number of episodes. So, the 30-bp VNTR in the 
MAO-A is not likely to be involved in MDD.  
It is unclear if this polymorphism could also be used for population stratification. 
Studies report a better response to antidepressant treatment for the shorter alleles (Yu et al., 
2005; Domschke et al., 2008a) or no differences (Serretti et al., 2002; Muller et al., 2002; 
Yoshida et al., 2002).  
Four other polymorphisms in the MAO-A gene are described in the literature in 
relation to MDD. No associations were found between MDD or symptoms of MDD and a 




polymorphism in exon 8 (Furlong et al., 1999a; Muramatsu et al., 1997; Sasaki et al., 1998; 
Tadic et al., 2003), nor with a dinucleotide repeat of CA in intron 2 (Furlong et al., 1999a; 
Muramatsu et al., 1997; Lin et al., 2000). However, the CA-repeat is associated with 
depression scores in an elderly (>70 years old) sample (Christiansen et al., 2007). 
Therefore, it seems that depressive symptoms at an old age may have different genetic 
underpinnings than depression with onset in adulthood.   
The 2-allele of the EcoRV RFLP at position 1460 causes higher activity of MAO-
A. The 2-allele of this polymorphism was more common in depressed males than in healthy 
controls, this was not the case for depressed females (Du et al., 2004; Du et al., 2002). In 
the first study of Du et al. (2002) the subjects were all depressed patients who committed 
suicide. In the second study Du et al. (2004) found no differences in the mean scores of 
suicidality between patients with the 2-allele and patients with the 1-allele. This suggests 
that the increased frequency of the 2-allele observed in depressed male patients is related to 
MDD rather than suicidality.  
To conclude, there are multiple known polymorphisms for the MAO-A gene, with 
the 30-bp VNTR as the most investigated in association with MDD. According to the 
current evidence this polymorphism may not be strongly associated with MDD. The EcoRV 
RFLP is a very plausible polymorphism in the MAO-A gene to cause vulnerability for 
MDD in males.  
MAO-B gene 
MAO-B is the other isozyme of MAO. According to some evidence, it is a potent degrader 
of dopamine. Selegiline is a selective and irreversible MAO-B inhibitor and a transdermal 
formulation of selegiline has antidepressant effects (Culpepper et al., 2008). This makes the 
MAO-B gene an interesting gene for the aetiology of MDD.   
The gene coding for the enzyme MAO-B (OMIM accession number 309860) is 
located near that for the MAO-A gene, namely at Xp11.23. There are two reported studies 
which investigated an association of two polymorphism in this gene (a dinucleotide GT 
repeat and a dinucleotide TG repeat, both in intron 2) and MDD, but neither found an 
association (Muramatsu et al., 1997; Lin et al., 2000).  
In sum, there are a few association studies regarding MAO-B and MDD and they 
found no association. The focus is currently more on the A isozyme of MAO, because its 
role in the metabolism of dopamine, norepinephrine and serotonin is better established. 
However, the antidepressant effects of transdermal selegiline make the genetics of MAO-B 





We reviewed the literature on the role of genes for dopaminergic neurotransmission in the 
vulnerability to MDD. Many genes have not been extensively investigated like TH, DRD2 
and DBH and many genes have remained outside the scope of this review. Nevertheless, 
there is evidence that certain genetic polymorphisms play a role in MDD aetiology, 
especially in interaction with each other or in combination with environmental factors. The 
most notable of these are VNTRs in the DRD4 and DAT gene. Strikingly, these genes are 
also the most useful for patient stratification aimed at optimal pharmacotherapy. However, 
it seems that there are many studies not supporting an association between specific 
polymorphisms and MDD. Potential explanations for the discrepancy in findings are the 
problem of phenotype definition and a comprehensive model of MDD aetiology should 
incorporate more than one variable. Therefore, an association study on one polymorphism 
can be negative because of too few variables included in the study. 
Future Directions 
To investigate the association between genes in the dopamine system and MDD, the 
potential causes of discrepant findings need to be addressed. In table 2.3 we summarize the 
major potential causes of discrepant findings which we encountered on basis of this 
literature review. We will discuss our view on what these causes might be and formulate 
some recommendations for future research.    
Phenotype definition 
MDD has a high heterogeneity and a major drawback in genetic association studies to 
MDD is phenotype definition. The differences in findings between association studies 
could very well be caused by heterogeneity in phenotypes. The great variability of MDD 
phenotype is a result of the definition of MDD. The diagnosis MDD is made by 5 out of 9 
symptoms (table 1.1) and therefore individuals with the diagnosis MDD might have a very 
different clinical presentation. Subtypes of MDD have been proposed based on differences 
in symptom presentation, onset characteristics, course of illness, and severity (Rush, 2007). 
For association studies, where it is important to have a clear phenotypical definition, it is 
possible that better results are found when studies focus more on association between 
polymorphisms and subtypes of MDD or individual symptoms.  Also, more studies need to 
be conducted to investigate associations between psychiatric symptoms across diagnostic 
disorders. For example, bipolar disorder and MDD have certain symptoms in common and 
vulnerability for these symptoms may be more highly associated with the same 
polymorphisms than a specific diagnosis.  
Changes in brain structure and function are an intermediate or endophenotype in 




phenotype definition, it is also possible to make use of biological endophenotypes, for 
example variation in the neural system.   
For future studies, we recommend to focus more on association studies between 
polymorphisms and subtypes of MDD or endophenotypes, like symptoms or neural 
variation to overcome the problem of heterogeneity and create a clearer phenotype. 
Haplotype studies 
It is likely that not just one polymorphism of a gene increases vulnerability, but that more 
polymorphisms are necessary. Multiple polymorphisms on one chromosome are often 
highly correlated and a string of alleles is called a haplotype (Burton et al., 2005). By 
investigating a haplotype of a gene instead of just one locus, a larger area of the gene is 
described resulting in more explained variation in protein structure and function. A good 
example of a stronger association between a haplotype and major depression instead of a 
single SNP is the study by Hettema et al. (2008). They showed that the val158met 
polymorphism in the COMT gene was associated with major depression in women, but that 
a haplotype of this SNP in combination with rs165599 was even more strongly associated 
with MDD.   
Gene by gene interactions 
Interactions between polymorphisms of different genes could increase MDD vulnerability.  
As mentioned before, MDD is a very heterogeneous disorder and proteins from 
multiple genes are likely to interact in susceptibility to the MDD phenotype (Raymer et al., 
2005). For MDD this possibility is very little investigated at the moment. Many of the 
previous mentioned studies to the association of genes with MDD investigate multiple 
genes, but unfortunately not the interaction effects.  
Huuhka et al. (2008) investigated the interaction of two genes in the dopamine 
system. They investigated the influence of both DRD2 and COMT in the response to 
electroconvulsive therapy (ECT). They found that the combination of the COMT met-allele 
and the T-allele of the C957T SNP in DRD2 predicted more severe depressive symtpoms 
and a worse treatment response. Doornbos et al. (Doornbos et al., 2009) found that the 
development of depressive symptoms in women during the course of pregnancy is 
influenced by the low activity alleles of polymorphisms in MAO-A (p = 0.044) and COMT 
(p = 0.026). However, the combination of low activity variants of MAO-A and COMT 
made this effect even stronger (p < 0.001). Mandelli et al. (2007) describe the interaction of 
genes coding for proteins in two different neurotransmitter systems. They showed that the 
met-allele in the COMT gene was associated with higher depression scores after adverse 
life-events, but this effect was even stronger when these individuals also carried the short 




association between MDD and genes becomes stronger when gene x gene interactions are 
investigated.  
Other interesting studies to gene x gene effects are done in research to phenomena 
closely related to MDD. The val-allele in the COMT gene and the met-allele in the gene 
coding for brain-derived neurotrophic factor (BDNF) together cause disturbances in 
executive functioning and working memory (Nagel et al., 2008). The allele of the 
val158met in the COMT gene and the 40-bp VNTR in the DAT gene together modulate the 
response of reward related brain areas during functional MRI (Dreher et al., 2009). Lower 
scores on neuroticism are associated with carriers of at least one copy of the 9-repeat allele 
of the 40-bp VNTR in the DAT gene in combination with the met-allele in the BDNF gene 
(Hunnerkopf et al., 2007). The 10/10 genotype in this same 40-bp VNTR in the DAT gene 
in combination with 7/7 genotype of the 48-bp VNTR in the DRD4 gene predicts 
comorbidities of dysthymia, MDD, phobic and anxiety disorders in ADHD patients 
(Gabriela et al., 2009). Thus, gene x gene interactions influence phenotypes which are 
closely linked to MDD. Therefore, association of multiple genes with MDD phenotype is 
also very likely to occur. 
To conclude, at the moment there are very little studies undertaken to the 
combined effect of two or more genes on MDD phenotype. However, the studies that exist 
look very promising that multiple genes interact in susceptibility to MDD. 
Gene by environment interactions 
The aetiology of MDD incorporates, besides genetic, also environmental factors like stress. 
It has been postulated that both genes and environmental factors need to be present for the 
development of MDD. A risk genotype would only lead to the development of MDD in 
reaction to exposure of environmental stress factors and an environmental stressor known 
to increase vulnerability to MDD is particularly a risk for development of MDD for those 
carrying particular risk genotypes which renders them more susceptible to that stressor 
(Wermter et al., 2010). Stressful life events are such an environmental factor that give an 
increased risk for MDD (Risch et al., 2009). As mentioned in the introduction, stress is 
highly correlated to dopamine release. Therefore, in research to genes in the dopamine 
system it looks almost essential to include stressful life-events in the design. 
Good example for the additional effects of environmental factors and genes on 
each other, are the studies on the val158met polymorphism in the COMT gene. This 
polymorphism has attracted most research attention, but the results do not support a simple 
association. However, the results do indicate a role for this polymorphism in vulnerability 
to MDD by altering the reactivity to stressors. The met-allele is associated with higher 
endocrine and subjective stress response in healthy controls (Jabbi et al., 2007). This 
relationship between the endocrine response and subjective stress response is different for 




onset of MDD after exposure to adverse life events (Mandelli et al., 2007). These findings 
suggest that the met-allele genotype could enhance predisposition to MDD by altering the 
reactivity to stressors.  
In the DAT gene, the T/T genotype of the SNP rs40184 is associated with 
depressive symptoms in male adolescents in response to perceived maternal rejection 
(Haeffel et al., 2008). Cicchetti et al. (2007) did not find a relationship between the 30-bp 
VNTR in the MAO-A gene and depression scores, but the low activity alleles were 
associated with depression scores in those adolescents with more then three maltreatment 
subtypes. Thus, the combination of severity of maltreatment and genotype was associated 
with higher depression scores. 
Also for the dopamine receptor D2 coding gene it appeared crucial to include both 
stressful life events and genotype. Elovainio et al. (2007) did not find a relationship 
between depressive symptoms and DRD2 genotype. However, only in carriers of the 
A2/A2 genotype lead stressful life events to an increased risk for depressive symptoms, not 
in carriers of the other genotypes.  
These studies show that the combined contribution of environment and genes 
explain MDD phenotype better then only one of these factors. Therefore, it seems crucial to 
include stressful life events in the design of studies to genetics of MDD, especially for 
genes in the dopamine system.   
 
These considerations may explain why simple association of one polymorphism with MDD 
often fails. This underscores our conclusion that the DRD4 and the DAT gene influence 
MDD vulnerability: despite the presence of factors that are not controlled for (haplotypes, 
gene-gene interactions and gene-environment interactions), these genes still correlate not 
only with the behavioural syndrome that MDD is, but also with antidepressant treatment 
outcome.  
 
Table 2.3. Potential causes of discrepant findings in association studies to MDD and genes in the 
dopamine system and recommendation for future studies 
Potential causes of discrepant findings Recommendation 
Phenotype definition Defining subtypes of MDD 
 Study association between polymorphism and 
symptoms, also across diagnosis 
 Study association with biological endophenotypes 
Unknown genetic variation of a gene Include haplotype analysis 
Interaction with other genes Include interaction analysis with other genes. These 
genes could influence the same or another 
neurotransmitter system 
Interaction with environmental factors, most 
importantly stressors 
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Table 2.2 Association studies in MDD of genes involved in the dopamine system 






Souery 1996 35 MDD, 70 
bipolar, 50 
controls 
ns   chi-square test on 
three groups 
    Oruc 1997 41 MDD,  
71 controls  
ns     
    Furlong  1999b 126 MDD, 242 
controls and a 
meta-analysis: 
204 MDD, 359 
controls 
ns   Also a meta-analysis 
    Serretti 1998a 57 MDD, 84 
controls 
less allele 1 in 
depression 
group 
    









  with depression as 
symptom in affective 
disorder 
    Ho 2000 139 MDD   ns with number 
of episodes and 
age of onset 
same patients as 
Furlong et al. (1999b) 
  pstI Furlong 1999b 136 MDD, 246 
controls 
allele B vs allele 
A 
  pooled analyses of 
two samples 
    Ho 2000 139 MDD   ns same patients as 
Furlong et al. 




more in MDD 
group 
  chi-square test on 
three groups 
  BglII Korner 1990 33 MDD, 99 
controls 
ns     





ns     
    Yoshida 2008 81 MDD ns to 
milnacipram 
    
DDC 4-bp deletion Borglum  1999 63 MDD, 572 
controls 
ns     
    Jahnes 2002 183 MDD, 234 
controls 
ns     
  1-bp deletion Borglum  1999 63 MDD, 572 
controls 
ns     
    Jahnes 2002 183 MDD, 234 
controls 
ns     
DRD1 1403 T-->C Garriock 2006 97 MDD, 85 
control 
ns     
  -1251 G to C in 
5'-UTR  
      ns     
  rs265981         ns     
  rs4532       ns     
        
        
        




gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
  -2218 T to C in 
5'-UTR 





ns     
  -2102 C to A in 
5'-UTR  
      association, but 
not after 
correction 
    
  -2030 T to C in 
5'-UTR  
      ns     
  -1251 G to C in 
5'-UTR  
      ns     
  rs265981         ns     
  rs5326       ns     
  rs4532       ns     
DRD2 Taq1A 
(rs1800497) 




boys 12-16 years old 
    Vaske  2008 2380   A1 allele 
associated with 






















    Massat 2002 133 MDD 133 
controls 
ns     





ns     
  rs1799732 Furlong  1998 128 MDD 262 
controls 
ns     





ns     
    Ho 2000 139 MDD    associated with 
psychosis in 
MDD 
same patients as 
Furlong et al. (1998) 
  rs1801028 Manki  1996 49MDD, 100 
controls 




gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
    Cusin  2002 212 MDD, 338 
bipolar, 663 
controls 
Ns     





ns     





ns     
    Huuhka  2008 122 MDD, 383 
controls 











  -7054C/A in 
5’UTR 





ns   investigated 91 SNPs 
in 21 genes, did not 
investigate 
interactions between 
SNPs or genes 
  rs1799978        ns     
  rs1079597        ns     
  rs1079598        ns     
  286T/C in intron      ns     
  rs2734834        ns     
  rs2234689        ns     
  rs1800498        ns     
  CA-repeat in 
intron 2 
Massat  2002 133 MDD, 133 
controls 
ns     






    










ns     
    Manki  1996 49 MDD100 
controls 
ns     
    Massat  2002 136 MDD 136 
controls 
ns     
    Garriock 2006 97 MDD, 85 
controls 
ns     







gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 





 ns     
  rs1800827        ns     
DRD4 48-bp VNTR Cusin  2002 212 MDD 338 
bipolar 663 
controls 
ns ns with time-
course of illness 
  
    Frisch 1999 102 MDD 172 
controls 
ns     













more frequent in 
controls than in 
MDD 
  Japanese population 
    Oruc 1997 83 MDD, 71 
controls 
ns     
    Serretti  2002a 103 bipolar, 58 
MDD 
  ns with 
depression 
severity 
family based study 
    Serretti  1999b 126 MDD, 471 
controls 
ns     
  multiple SNPs Koks  2005 177 MDD, 160 
controls 
ns     
DRD5 rs1967551 Koks  2005 177 MDD, 160 
controls 
ns     
DAT 40 bp VNTR Frisch  1999 102 MDD, 172 
controls 
ns     
    Manki  1996 62 MDD ns     














  rs40184 Haeffel  2008 17 MDD, 159 
controls 











gene x environment 
interaction and MDD 





gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
  rs6347         Ns   
  rs2652511         Ns   
  rs8179029 Dong 2009 272 MDD, 264 
controls 








investigated, but no 
interactions are 
tested 
  rs2550936       AA genotype 
associated with 
MDD. Not an 
allelic 
association 
    




  in elderly women 




ns   also looked to only 
MDD group 
compared to controls 





  Ns   
  A444G Wood  2002 164   ns with 
depression 











    Cusin  2002 212 MDD 338 
bipolar 663 
controls 
ns ns with time 
course of illness 
  
    Henderson  2000 848 ns   depression scales 
and PANAS (negative 
and positive affect) 
    Baune  2008 256 MDD, 557 
controls 




























    Frisch  1999 102 MDD, 172 
controls 




gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
    Funke  2005 394 patient (30 
MDD)      467 
controls 
ns     
    Garriock  2006 97 MDD, 85 
controls 
ns     
    Jabbi  2007 25 high risk, 21 
MDD, 22 
controls 








    Kunugi  1997 62 MDD, 121 
controls 
ns     
    Serretti  2006 359 MDD    
446 BP     116 
controls 
ns     
    Illi 2010 106 MDD, and 
395 controls 
ns ns to treatment 
response 
  









    Arias  2006 207 and 139 
(two samples) 
- ns treatment 
response to 
SSRI’s 
two samples were 
analysed separately 










    Wrayl 2008 2045   Ns   
    Mandelli  2006 686 MDD 
(UP=323) 
























gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 















    Huuhka 2008 122/383   met-allele in 
combination 











  rs2097603         
rs737865      
rs165599 
Funke  2005 394 patients 




    
  rs165599   Garriock  2006 97 MDD, 85 
controls 
ns     
  rs737865 
rs165599 
Wray  2008 2045 ns     
  rs165599  
rs165774 
rs174696 




investigated, but not 
in interaction with 
COMT 











only 3-repeat and 4-
repeat alleles were 
investigated 
        






    
    Kersting 2007 66   Longer allele 
associated with 
higher grief in 
depressed 






    Cusin  2002 212 MDD, 663 
controls 
ns     
    Kunugi  1999 98MDD, 258 
controls 
ns     





gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
    Syagailo  2001 74 MDD, 229 
controls 
ns     
    Gutierrez 2004 301 MDD and 
156 controls 















    Domschke  2008 340 Longer alleles 




    
    Muller  2002 62 ns in response 
to moclobemide. 
    
    Yoshida  2002 66 ns in response 
to fluvoxamine.  
    





    Christiansen  2007 684   ns with 
depression 
scores 
population >70 years 
old 




    Serretti  2002a 103 bipolar 
disorder, 58 
MDD 
  ns with 
depression 
severity 
family based study 
        
    Cicchetti  2007 339   ns with 
depression 












  VNTR in intron 
1 
Muramatsu  1997 52 MDD, 100 
controls 
ns     
    Furlong  1999a 125 MDD, 250 
controls 
ns     
    Ho 2000 139 MDD (53 
male, 86 
female) 
  ns with number 
of episodes and 
age of onset 
same patients as 
Furlong et al.(1999a) 





gene polymorphism First author year subjects depression vs. 
Controls 
other remarks 
    Sasaki 1998 43 MDD, 169 
controls 
ns     
    Furlong  1999a 125 MDD, 250 
controls 
ns     
    Tadic  2003 108 MDD, 
2769 controls 
ns     
  EcoRV RFLP Du  2002 44 MDD, 92 
controls 
  Depressed 
suicide 
associated with 
allele 2 in 
males. 
  





    
  Dinucleotide CA 
repeat in intron 
2 
Muramatsu  1997 52 MDD, 100 
controls 
ns     
    Furlong  1999a 125 MDD, 250 
controls 
ns     




population >70 years 
old 
    Lin  2000 67 MDD, 88 
controls  
ns     
MAO-B Dinucleotide GT 
repeat in intron 
2 
Lin  2000 67 MDD, 88 
controls 
ns     
  Dinucleotide TG 
repeat in intron 
2 
Lin  2000 67 MDD, 88 
controls 
ns     
  Dinucleotide GT 
repeat in intron 
2 
Muramatsu  1997 52 MDD, 100 
controls 
ns     
ns means non significant association 
  
Chapter 3 
Emotional valence modulates brain functional 
abnormalities in depression: evidence from a meta-
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Abstract  
Models describing the neural correlates of biased emotion processing in depression have 
focused on increased activation of anterior cingulate and amygdala and decreased activation 
of striatum and dorsolateral prefrontal cortex. However, neuroimaging studies investigating 
emotion processing in depression have reported inconsistent results. This meta-analysis 
integrates these findings and examines whether emotional valence modulates such 
abnormalities. A systematic literature search identified 26 whole-brain and 18 region-of-
interest studies. Peak coordinates and effect sizes were combined in an innovative 
parametric meta-analysis. Opposing effects were observed in the amygdala, striatum, 
parahippocampal, cerebellar, fusiform and anterior cingulate cortex, with depressed 
subjects displaying hyperactivation for negative stimuli and hypoactivation for positive 
stimuli. Anterior cingulate activity was also modulated by facial versus non-facial stimuli, 
in addition to emotional valence. Depressed subjects also showed reduced activity in left 
dorsolateral prefrontal cortex for negative stimuli and increased activity in orbitofrontal 
cortex for positive stimuli. Emotional valence is a moderator of neural abnormalities in 











Major depressive disorder is characterized by maladaptive and persistent emotional 
responses to stressors (Hammen, 2005). Such an emotional response has the potential to 
interfere with functioning in all aspects of daily life. Therefore, depression is likely to be 
associated with fundamental abnormalities in emotional processing, which continuously 
influence the processing of incoming sensory information (Harmer et al., 2009). Research 
has indeed demonstrated preferential processing of negative compared to positive 
information in depressed patients for multiple cognitive domains, such as perception, 
attention and memory (Disner et al., 2011; Roiser et al., 2012). Neuroimaging research 
provides a tool to visualize the core of the emotional dysfunction that  occurs in the brain of 
depressed patients.  
Several models of emotion processing in the depressed brain have been proposed, 
in which several brain regions are hypothesized to play a key role, with models differing in 
their emphases regarding the functions involved (for instance compare Leppanen, 2006; 
Phillips et al., 2003b; Mayberg, 1997; Drevets et al., 2008a; Krishnan et al., 2008). Emotion 
identification is generally attributed to subcortical structures such as the ventral striatum 
and amygdala, integration of somatic responses is subserved by the insula and anterior 
cingulate cortex (ACC) and affective state monitoring is related to medial and dorsolateral 
prefrontal cortex (DLPFC) function. However, the predictions arising from these models 
have not been systematically evaluated in the light of recent literature. Moreover, the 
models do not make clear predictions regarding interactions between activation 
abnormalities and emotional valence. 
Emotional processing could be abnormal in depressed patients at different levels 
of processing. The initial appraisal of incoming information may be biased, leading to 
preferential processing of negative information and an amplified emotional response. In 
particular, it has been suggested that the amygdala may be highly sensitive to negative 
information (Murray et al., 2011), whereas the ventral striatum, an area predominantly 
involved in processing positive information, has been hypothesized to be less sensitive in 
depressed patients (Diekhof et al., 2008). Monitoring of the affective state may also be 
compromised by reduced cognitive control from the DLPFC and ACC, leading to 
insufficient capacity to downregulate the response of the amygdala (Beck, 2008; Pizzagalli, 
2011). Although these general models of emotional dysfunction in depression lead to 
specific predictions, empirical studies investigating the neural correlates of emotional 
dysfunction in depressed patients have produced inconsistent results. It is still insufficiently 
known which levels are affected during the basic processing of emotional stimuli in 
emotion perception tasks and whether activation abnormalities are modulated by emotional 




Meta-analysis of functional magnetic resonance imaging (fMRI) studies in 
depressed patients is critical to validate and advance models of emotional dysfunction in 
depression. To date, two such meta-analyses have been performed (Fitzgerald et al., 2008a; 
Diekhof et al., 2008). Their findings however were not fully consistent. In particular, while 
Fitzgerald and colleagues found that processing negative stimuli resulted in hypoactivation 
in depressed patients in pregenual anterior cingulate, Diekhoff and colleagues found that 
negative stimuli resulted in hyperactivation of the same area. Similarly, the amygdala is 
identified as hyperactive during negative emotional processing in one of the meta-analyses 
(Fitzgerald et al., 2008a), but not the other one. This variation in results is probably due to 
methodological limitations, as these previous meta-analyses included a limited sample of 
studies (6 in Fitzgerald et al., 2008; 10 in Diekhof et al., 2008), and employed a potentially 
biased fixed-effects meta-analytical approach  that does not adequately incorporate 
between-study variance , and as a consequence has since been superseded (Eickhoff et al., 
2009). Furthermore, these studies did not take into account negative findings or region-of-
interest studies, and thereby introduced bias in their selection of study samples. 
In the present work, the brain activation patterns of depressed patients were 
compared to healthy subjects in a meta-analysis on the processing of negative and positive 
emotion. An up-to-date systematic literature search was conducted to identify a larger 
number of studies relative to previous meta-analyses. In addition, an innovative analytical 
procedure for the pooling of results was employed. This approach employs not only the 
locations of significant effects, but also their effect size. Because statistical thresholds are 
taken into account during this analysis, this method allows for the combination of results 
from studies investigating the whole brain and specific regions of interest. It was 
hypothesized that depressed patients would show greater activation in amygdala and 
anterior cingulate cortex and less activation in ventral striatum and prefrontal areas. 




A literature search was performed to identify relevant fMRI studies investigating 
processing of emotional information in depressed patients. The search was conducted using 
standardized search strings capturing the key elements “(f)MRI AND depression OR MDD 
AND emotion(*) OR affect(*) OR reward”. Articles were retrieved from the electronic 
databases PubMed, EMBASE and Web of Science until September 1, 2011. The search 




“magnetic resonance imaging”, “depressive disorder”, “emotions” and “affect”. After 
completing the database search, reference lists from eligible articles and major reviews 
were examined for additional relevant articles. 
Study selection 
A two-step procedure was used to identify articles eligible for inclusion. First, articles were 
assessed by reviewing their titles and abstracts for matching the following inclusion 
criteria: written in English language; reported as an empirical article; making use of fMRI; 
including a patient group with a primary diagnosis of current major depressive disorder 
(MDD); including a healthy control group. Articles were excluded when a diagnosis of 
depression was secondary to a somatic condition such as temporal lobe epilepsy or multiple 
sclerosis. Articles were also excluded when depression was investigated solely as a 
comorbid psychiatric condition or as post-partum depression. In case the abstract provided 
insufficient information to make a final decision, the study was selected for full-text review. 
The title/abstract review was conducted by two independent assessors (NG and EO) and 
inconsistencies were resolved by asking a third independent assessor (AA). 
Next, the methodology of the selected articles was critically examined in a full-
text review. Only data from adult participants (age >18) were included, to ensure a 
homogeneous sample. The minimal sample size for inclusion was 5 participants in each 
group. Experimental paradigms had to contain a visual emotional element, such as 
displaying emotional faces or words. This criterion was adopted to promote homogeneity in 
the included data, as auditory emotional tasks have been shown to recruit different neural 
systems than primary visual emotional tasks (Phan et al., 2002). Moreover, visual 
emotional paradigms are commonly employed. The contrasts of interest were positive or 
negative emotion versus non-emotional control condition. This had to be an active 
experimental condition, in order to adequately control for task effects. The full-text review 
was conducted by two assessors (NG and EO). Studies making a whole-brain or a region-
of-interest comparison between depressed patients and healthy controls in at least one of the 
contrasts of interest were included in the first stage of the meta-analysis. It was ensured that 
the same study sample was not included twice after repeated analysis in separate articles. In 
the next step, studies using a Region-Of-Interest (ROI) approach were omitted from the 
analysis to investigate the robustness of the results. Finally, the analyses were repeated 
separately for studies presenting facial and non-facial task paradigms, to examine whether 






A modified version of parametric voxel-based meta-analysis (PVM; Costafreda et al., 
2009a) was employed allowing the pooling of both ROI-based and coordinate-based 
findings from individual studies. These modifications are summarized in the following 
paragraphs, and further details on the original method can be found in the original 
publications (Costafreda et al., 2009a; Costafreda, 2012). From the studies included in the 
functional meta-analysis, the coordinates of activation, their associated effect size, the 
statistical threshold below which findings were considered non-significant in that study 
(e.g. p < 0.001 uncorrected) and the anatomical labels as provided in the paper were 
extracted, for both whole-brain and ROI contrasts. When appropriate, coordinates were 
transformed from Talairach to the Montreal Neurological Institute coordinate system by 
using a non-linear transformation (Brett et al., 2001). Effect sizes were also converted from 
Z, T or P values to Z-scores, using as appropriate the cumulative probability function for 
the T distribution and the cumulative distribution function for the standard normal 
distribution. Both the total sample size as well as the number of subjects in each diagnostic 
group were used to compute the degrees of freedom, resulting in exact transformations. 
Summary maps for each study were then created by convolving the effect sizes for 
each focus with a uniform kernel (radius 20mm). This radius size was selected on the basis 
of previous empirical evidence suggesting that kernels of 15-25 mm offer optimal 
sensitivity without loss of specificity, when evaluated against a gold standard of image-
based meta-analysis. Optimizing sensitivity is of particular importance when using a 
conservative analytical approach (Radua et al., 2009; Salimi-Khorshidi et al., 2009). The 
effect of this convolution was that for brain locations located within radial distance of a 
focus, the effect size was estimated to be the same Z-value as at the focus (referred as 
“exact observations”). For areas located outside radial distance of a focus in whole-brain 
contrasts, the effect size estimate was an interval, determined by the statistical threshold 
(e.g. a nonsignificant finding with threshold p < 0.001 implies |Z| < 3.09; these are further 
referred as “interval observations”). ROI contrasts contributed effect size estimates only for 
the relevant region of interest, as determined after conversion of anatomical labels as 
described by the study’s authors to the standard labelling system of the automated 
anatomical labelling (AAL) scheme described by (Tzourio-Mazoyer et al., 2002). When a 
study reported whole brain and ROI contrasts, the most precise measurement available (i.e. 
either an exact measurement for a significant finding or the most conservative threshold for 
a null result) was used in the summary map for that study. Significant findings from 
contrasts of greater brain activity in depressed patients than in healthy controls were 
represented by positive Z-values, while findings from greater activity in controls than 




In the estimating procedure, it was assumed that the voxelwise exact and interval 
Z-values were independently and identically distributed across studies, and generated by a 
Normal overarching distribution. The hypothesis to be tested was whether the mean of this 
distribution is significantly different from zero. Statistical inference therefore required 
integration of exact and interval data, precluding standard methods of model fitting such as 
least squares which require exact inputs. Therefore, maximum likelihood estimates of the 
population mean and standard deviation under normality distributional assumptions were 
obtained by direct (numerical) optimisation of the likelihood function (Nelder et al., 1965). 
In the likelihood function, the contributions from exact observations were represented by 
their exact (point) probability value according to the probability density function of the 
normal distribution, while interval observations contributions were represented by the 
corresponding integral under the same normal probability density function. This procedure 
allowed valid inference on the parameters that maximise the likelihood of obtaining the 
observed results (both exact and interval values) given the data and our assumption of a 
normal distribution of the Z-values. That is, this procedure resulted in the value of a mean 
effect most compatible with the available data. 
Statistical tests on the estimated mean of this distribution of Z-values across 
studies for each voxel were then conducted based on normality assumptions, with a 
voxelwise null hypothesis H0: || = 0. The assumption of normality is common in 
neuroimaging, and underpins many analytical approaches, such as Gaussian random field 
theory as implemented in SPM. As a correction for multiple comparisons, we employed the 
false discovery rate (Benjamini et al., 1995). Voxels with a p-value in this test below the 
FDR threshold were deemed to show significant evidence for the alternative hypothesis  
||>0, i.e. evidence of differential brain activation between depressed patients and healthy 
controls. The template employed was the Montreal Neurological Institute (MNI) atlas, with 
dimensions 2x2x2 mm. The software was implemented using the R statistical software 




Figure 3.1: Schematic representation of the selection procedure for articles to be included in the final 
analyses on whole-brain (WB) comparisons and region of interest (ROI) comparisons.  
 
 
Literature search in Embase, Pubmed,   
Web of Science: 
2885 unique titles (1111 duplicates) 
Title/abstract review: 
2896 unique titles 
Full text review: 
197 unique titles 
References from articles included  
in full text review and review articles:  
11 additional unique titles 
Excluded after title/abstract review: 
2699 unique titles 
 
Not meeting inclusion critera; English, 
empirical study, fMRI, patient group primary 
depression, control group. 
Excluded after full text review: 
153 unique titles 
 
Not meeting inclusion criteria;  
1. sample size >5 each group (1), 
2. adults (12), 
3. current depression group (20), 
4. control group (16), 
5. visual emotional task (45),  
6. testing contrasts of interest (59). 
Included in WB analysis: 
18 unique titles 
WB + additional ROI data: 
8 unique titles 
Included in ROI analysis: 






The initial database search elicited 2896 results (search strategy depicted in Figure 1). In 
the title-abstract review 197 articles were selected that fulfilled the inclusion criteria. The 
inter-rater reliability of the two independent observers was good (Cohens κ = 0.90). In total, 
44 studies met our inclusion criteria (described in Table 1), including data from a total of 
795 depressed patients and 792 healthy controls (HC). A variety of emotional tasks was 
represented in every contrast. The tasks consisted of paradigms involving reward or loss 
feedback and the presentation of emotional faces, words or pictures. Most studies presented 
a neutral stimulus well-matched to the active stimuli except for emotional valence (e.g., 
faces with neutral expressions compared to faces with negative expressions), however some 
studies used low-level baseline tasks, such as comparing emotional faces to geometrical 
shapes or a scrambled face. The reported smoothing parameters ranged from 4mm to 
10mm. Some studies did not report the smoothing procedure. There were 18 studies that 
examined the contrasts in a region-of-interest (ROI) analysis. Seven studies performed a 
ROI analysis next to a whole-brain analysis. 
Meta-analysis on both whole-brain and region-of interest studies 
Meta-analysis including both studies using a whole-brain method and studies using a 
region-of-interest method showed differences between patients and HC in several areas 
(Figure 2). Full results for the contrasts of interest including coordinates, Brodmann areas 
(BA) and Z-scores are presented in table 2. 
In response to negative emotions versus a neutral baseline, there was more activity 
in patients than in HC in bilateral basal temporal areas (including parahippocampal gyrus 
and amygdala), cingulate gyrus (dorsal anterior BA24/32 and middle BA24), right 
cerebellum, left putamen and left fusiform gyrus. In addition, patients showed less activity 
in the left dorsolateral prefrontal cortex (superior frontal gyrus).  
Processing of positive emotions compared to a neutral baseline resulted in more 
activity in patients than in HC in the lingual gyrus and orbitofrontal cortex. Patients had 
less activity in the left cerebellum, a cluster in left temporal/parietal area (including 
superior temporal gyrus, supramarginal gyrus and insula), cingulate gyrus (dorsal anterior 
BA24 and pregenual BA25), fusiform gyrus, and a cluster including right insula, striatum, 





Table 1a:  Study characteristics extracted from articles reporting whole-brain results included in the 




Note: For clarity purposes, the amygdala and anterior cingulate cortex are shown as regions of interest. 
Other regions were included in the meta-analysis as well. 
Abbreviations: ROI region of interest, pos positive, neu neutral, neg negative, HC healthy control group, 
DP depressed group, ACC amygdala, ACC anterior cingulate cortex, IFG inferior frontal gyrus, PFC 
prefrontal cortex, SVC small volume correction.
Study Reference N N Task paradigm Control stimuli Smoothing ROI-selection 
Patients Controls HC > DP DP > HC HC > DP DP > HC
1 Wang et al. (2008a) 19 20 Emotional distraction Neutral distractor 8.0 mm x
2 Wang et al. (2008b) 12 20 Emotional distraction Neutral distractor 8.0 mm ns x
3 Fu et al. (2004) 21 19 Emotional faces Low  sad face - ns x
4 Gotlib et al. (2005) 18 18 Emotional faces Neutral face 8.0 mm x x x x
5 Surguladze et al. (2005) 16 14 Emotional faces Neutral face - ACC + AMG x ns ns x
6 Frodl et al. (2009) 12 12 Emotional faces Geometric shapes 8.0 mm x
7 Scheuerecker et al. (2010) 13 15 Emotional faces Geometric shapes 8.0 mm ns x
8 Surguladze et al. (2010) 9 9 Emotional faces Neutral face 7.2 mm x x
9 Tow nsend et al. (2010) 15 15 Emotional faces Geometric shapes 5.0 mm Marsbar AMG + IFG x ns
10 Frodl et al. (2011) 24 15 Emotional faces Geometric shapes 8.0 mm ns ns
11 Zhong et al. (2011) 29 31 Emotional faces Geometric shapes 6.0 mm SVC AMG x x
12 Demenescu et al. (2011) 59 56 Emotional faces Scrambled face 8.0 mm ns x ns ns
13 Derntl et al. (2011) 15 15 Emotional faces Neutral face 8.0 mm x x x ns
14 Canli et al. (2004) 15 15 Emotional w ords Neutral w ord 8.0 mm x ns x x
15 Epstein et al. (2006) 10 12 Emotional w ords Neutral w ord 7.5 mm SVC striatum x x x
16 Mitterschiffthaler et al. (2008) 17 17 Emotional w ords Neutral w ord 8.0 mm Marsbar ACC x
17 Hsu et al. (2010) 15 15 Emotional w ords Neutral w ord 8.0 mm ns ns
18 Keedw ell et al. (2005) 12 12 Faces and stories Neutral face - x x x x
19 Mitterschiffthaler et al. (2003) 7 7 IAPS pictures Neutral picture 7.0 mm x x
20 Abler et al. (2007) 13 12 IAPS pictures Neutral picture 8.0 mm SVC AMG ns x ns x
21 Erk et al. (2010) 17 17 IAPS pictures Neutral picture 8.0 mm AMG + dorsolateral PFC ns ns
22 Knutson et al. (2008) 14 12 Monetary rew ard Nongain outcome 4.0 mm Medial PFC x ns ns x
23 Pizzagalli et al. (2009) 30 31 Monetary rew ard Nongain outcome 6.0 mm x x x x
24 Remijnse et al. (2009) 20 27 Monetary rew ard Nongain outcome 6.0 mm ns x x x
25 Smoski et al. (2009) 16 15 Monetary rew ard Nongain outcome 5.0 mm x x
26 Kumari et al. (2003) 6 6 Picture-caption pairs Incongruent pairs - x x x x
Total WBR N = 454 N = 457 8 additional ROI 14 13 22 23
pos > neu neg > neu
Study Reference N N Task paradigm Control stimuli Smoothing ROI-selection
 Patients Controls AMG ACC AMG ACC
1 Sheline et al., 2001 11 11 Emotional faces Neutral face 8.0 mm Manual HC > DP DP > HC
2 Matthew s et al., 2008 15 16 Emotional faces Geometric shapes 4.0 mm Talairach Daemon DP > HC
3 Lee et al., 2008 21 15 Emotional faces Neutral face - Marsbar ns ns
4 Fales et al., 2008 27 24 Emotional faces Neutral faces 9.0 mm Manual ns DP > HC
5 Dannlow ski et al., 2008 28 28 Emotional faces Neutral face 6.0 mm Marsbar ns ns
6 Peluso et al., 2009 14 15 Emotional faces Geometric shapes 5.0 mm Coordinates 8mm DP > HC
7 Victor et al., 2010 22 25 Emotional faces Neutral faces 8.0 mm SVC HC > DP DP > HC
8 Almeida et al., 2010 15 15 Emotional faces Neutral face 8.0 mm Pickatlas ns ns
9 Suslow  et al., 2010 30 30 Emotional faces Neutral faces 8.0 mm Pickatlas HC > DP DP > HC
10 Baeken et al., 2010 12 12 Emotional faces Scrambled face 8.0 mm Marsbar DP > HC DP > HC
11 Aizenstein et al., 2011 33 27 Emotional faces Geometric shapes 10.0 mm SVC ns DP > HC
12 Siegle et al., 2006 14 21 Emotional w ords Neutral w ords 6.0 mm SVC ns DP > HC
13 Brassen et al., 2008 13 13 Emotional w ords Neutral w ords 8.0 mm Coordinates 10mm ns HC > DP
14 Irw in et al., 2004 12 14 IAPS pictures Neutral picture - Manual ns
15 Lee et al., 2007 15 15 IAPS pictures Neutral picture - Marsbar ns ns ns ns
16
Hamilton and Gotlib, 
2008 14 12 IAPS pictures Neutral picture 4.0 mm SVC ns DP > HC
17 Friedel et al., 2009 21 21 IAPS pictures Neutral picture 8.0 mm Pickatlas ns
18 Sheline et al., 2009 24 21 IAPS pictures Neutral picture 9.0 mm Functional DP > HC DP > HC
Total ROI N = 341 N = 335 8 3 16 7





Figure 3.2: Group differences in activation from the combined  meta-analyses on whole-brain and 
region-of interest-studies; presented separately for negative and positive emotion. 
Top Row: Negative emotions (MDD>HC in red, HC>MDD in blue). From left to right: Sagittal section at 
X = +3 mm showing increased activation in patients during negative emotional processing in mid and 
anterior cingulate cortex; Rendering of the basal brain showing increased activation in patients in basal 
temporal lobes and limbic areas; Rendering of increased left dorsal prefrontal activations in controls 
relative to patients during negative emotional processing.  
Bottom Row: Positive emotions (MDD>HC in red, HC>MDD in blue). From left to right: Sagittal section 
at X = +1 mm showing increased activation in patients in orbitofrontal cortex, with relatively reduced 
activation in patients relative to controls in dorsal cingulate and cerebellum; Axial section at Z = 0 mm 
showing increased activation in controls relative to patients in right insula, striatum and thalamus, and 
left lingual gyrus; Coronal section at Y = +30 mm showing increased activation in orbitofrontal cortex 
and decreased activation in anterior cingulate cortex. 






Table 2: Peak coordinates of significant group differences in activation for negative and positive 
emotional stimuli from the combined meta-analysis on whole-brain and region-of-interest studies. 
Anatomical label BA Volume  MNI coordinates mean Z-score 






x   
Negative emotion versus neutral baseline           
Areas of increased activity in patients           
Left basal temporal             
  Fusiform Gyrus 20 263 -36 -26 -28 2.44 
  Superior Temporal Pole 38 82 -36 10 -20 2.43 
  Cerebellum - 10 -24 -24 -30 2.31 
  Middle Temporal Pole 35 71 -22 -2 -36 2.34 
  Parahippocampal Gyrus 36 86 -20 -10 -34 2.30 
  Inferior Temporal Gyrus 20 172 -38 -24 -28 2.33 
  Middle Temporal Gyrus 20 13 -48 -16 -20 2.29 
  Insula 48 9 -36 8 -12 2.25 
Right basal temporal             
  Parahippocampal Gyrus 35 212 26 0 -32 2.18 
  Olfactory cortex 48 31 26 12 -18 2.04 
  Superior Temporal Pole 34 17 26 6 -22 2.09 
  Fusiform Gyrus 20 14 28 -4 -38 2.12 
  Insula 48 1 28 12 -18 1.90 
  Hippocampus 28 9 24 -2 -22 2.06 
  Amygdala 28 41 24 0 -22 2.07 
Medial cingulate gyrus             
  Middle Cingulate Cortex 24 115 -6 24 34 2.32 
  Middle Cingulate Cortex 24 173 2 28 34 2.29 
  Dorsal Anterior Cingulate  24 47 -8 4 32 2.11 
  Superior Medial Frontal Gyrus 32 4 0 30 36 2.15 
Right cerebellum - 29 22 -70 -38 2.15 
Left occipital / temporal             
  Middle Occipital Gyrus 39 46 -34 -62 24 2.23 
  Middle Temporal Gyrus 37 3 -36 -62 14 2.28 
Left putamen 48 68 -30 6 6 2.18 
Left fusiform gyrus 37 39 -30 -42 -18 2.05 
                
Areas of decreased activity in patients           
Left superior frontal gyrus 8 24 -22 26 58 -2.54 




Table 2 continued 
  
Anatomical label BA Volume mean Z-score
# voxels x.max y.max z.max
Positive emotion versus neutral baseline
Areas of increased activity in patients
Right occipital / temporal
Lingual Gyrus 18 135 26 -92 -14 2.54
Calcarine Sulcus 18 7 22 -96 -6 2.36
Inferior Occipital Gyrus 18 38 28 -92 -8 2.36
Medial orbitofrontal cortex
Olfactorius Cortex 11 4 4 22 -14 2.55
Rectus 11 78 2 30 -24 2.55
Rectus 11 58 0 24 -24 2.55
Areas of decreased activity in patients
Left cerebellum and occipital
Cerebellum - 2837 -22 -76 -28 -2.93
Lingual gyrus 18 988 -18 -62 -6 -2.91
Fusiform gyrus 18 184 -22 -74 -14 -2.79
Calcarine Sulcus 19 106 -20 -54 4 -2.71
Left temporal / parietal
Rolandic opperculum 48 141 -40 -24 20 -2.74
Superior Temporal Gyrus 41 8 -40 -36 12 -2.74
Heschl Gyrus 48 1 -46 -16 12 -2.72
Postcentral Gyrus 48 55 -50 -18 18 -2.69
Supramarginal Gyrus 48 26 -50 -22 18 -2.66
Insula 48 37 -34 -30 22 -2.18
Medial cingulate gyrus
Anterior Cingulate Cortex 24 60 -6 32 12 -2.83
Anterior Cingulate Cortex 25 15 4 30 12 -2.81
Right subcortical / basal temporal
Putamen 48 517 28 -4 8 -2.55
Pallidum 48 170 18 0 -4 -2.58
Thalamus - 37 14 -12 0 -2.52
Insula 48 84 38 10 -12 -2.07
Hippocampus 35 16 16 -6 -14 -1.96
Left parahippocampal gyrus 28 21 -14 -2 -26 -2.42
Left angular gyrus 39 24 -38 -56 26 -2.41
Right parahippocampal areas
Parahippocampal gyrus 36 124 24 -14 -30 -2.20
Fusiform gyrus 36 22 28 -10 -34 -2.20





Meta-analysis on whole-brain studies only 
To investigate the robustness of results after excluding region-of-interest studies, the meta-
analysis was repeated on whole-brain studies only. This analysis showed a comparable 
pattern of findings as the meta-analysis on both whole-brain and region-of-interest studies 
(supplementary Table 1), but the amount of significant differences between patients and HC 
was less in this second analysis. This may be due to a loss of power especially in basal 
temporal regions, as the amygdala in particular was investigated by a number of ROI 
studies. 
In response to negative emotional stimuli compared to a neutral baseline, patients 
had more activity than HC in left basal temporal/occipital clusters, the left putamen and 
insula. These clusters included the middle occipital and middle temporal gyrus. A third 
cluster showing more activity in patients than in HC was seen in the right cerebellum. 
Patients showed less activity in the left dorsolateral prefrontal cortex (DLPFC).   
In addition, during processing of positive stimuli compared to a neutral baseline, 
patients showed more activity in regions of the right lingual gyrus, left hippocampus and 
bilateral orbitofrontal cortex. Less activity was seen in patients than in HC in bilateral 
cerebellum, the anterior cingulate cortex (ACC; BA24), a cluster including the regions left 
insula, superior temporal gyrus and supramarginal gyrus and in a cluster including the right 
amygdala, insula, putamen and caudate nucleus.   
Meta-analysis on tasks presenting facial stimuli and non-facial stimuli separately 
To investigate potential task-specific effects, the analyses were repeated separately on data 
from studies using facial stimuli (23 studies included for the negative emotion contrast and 
11 studies for the positive emotion contrast) and on combined data from the tasks using 
non-facial stimuli (19 studies included for the negative emotion contrast and 13 studies for 
the positive emotion contrast). Both analyses showed a comparable pattern of findings to 
the previous meta-analyses, particularly for negative facial stimuli (supplementary Table 2). 
For positive facial stimuli some previously significant clusters did not reach significance 
after correction for multiple comparisons, possibly due to reduced power as relatively few 
studies investigated these contrasts. Noteworthy, task-specific differential activation 
between groups was found in the pregenual ACC (BA24/25). In this area, patients 
demonstrated increased activation relative to controls during processing of facial stimuli 
and reduced activation during processing of non-facial stimuli. This effect was found for 
both the negative and positive emotion contrasts, although for positive facial stimuli the 
effect did not survive multiple comparison correction (Figure 3). There was no further 





Figure 3.3: Group differences in anterior cingulate cortex activation from the combined  meta-analyses 
on facial and non-facial stimuli; presented separately for negative and positive emotion. 
Top row: Negative emotions (MDD>HC in red, HC>MDD in blue). Left side: Decreased activation for 
non-facial stimuli in patients compared to controls in anterior cingulate cortex (BA25). Right side: 
Increased activation for facial stimuli in patients compared to controls in anterior cingulate cortex 
(BA25), accompanied by increased dorsal anterior cingulate activation (BA24/32). 
Bottom row: Positive emotions (MDD>HC in red, HC>MDD in blue). Left side: Decreased activation for 
non-facial stimuli in patients compared to controls in anterior cingulate cortex (BA24/25). Right side: 
Increased activation for facial stimuli in patients compared to controls in pregenual anterior cingulate 
cortex (BA25). 
All maps corrected at FDR p < 0.05, except for positive facial  stimuli, which is p < 0.001 uncorrected.
 
Discussion 
A meta-analysis of neuroimaging studies on emotion processing in major depression was 
conducted to test predictions from models about the brain areas involved in dysfunctional 
emotion processing and to examine whether emotional valence modulates activation 
abnormalities. We were able to include 44 studies that contrasted MDD patients to healthy 
controls performing tasks with emotional stimuli during fMRI measurements. For the 
processing of negative emotion, depressed patients showed more activation in the right 
amygdala, left striatum, dorsal anterior cingulate and parahippocampal areas than healthy 
controls. In contrast, during processing of positive emotion these same areas (including 
right instead of left striatum) showed less activation in depressed patients compared to 
healthy controls. Moreover, depressed patients demonstrated less activity in the left 
dorsolateral prefrontal cortex (DLPFC) during processing of negative emotion and more 
activity in the medial orbitofrontal cortex (OFC) during processing of positive emotion. In 
summary, opposing effects of emotional valence were found in limbic and visual brain 




Opposing effects of emotional valence in limbic brain areas: Negativity bias 
The current meta-analysis showed abnormal activation in the amygdala and striatum, 
subcortical structures which have been implicated in emotion identification by models 
describing the neural correlates of emotional dysfunction in depression (e.g. Leppanen, 
2006; Phillips et al., 2003b). The amygdala is involved in directing attention at emotional 
information, facilitating emotional memory and generating an autonomic emotional 
response (Pessoa, 2010). Amygdala activation has been associated with the processing of 
both negative and positive emotions (Costafreda et al., 2008; Murray, 2007), and is 
involved in relevance detection in the brain, i.e. responding to stimulus features relevant for 
the subject’s interests (e.g. survival), and prioritizing processing in other brain areas (Jacobs 
et al., 2012; Sander et al., 2003). According to a review by Haber and Knutson (2010), the 
ventral striatum receives input from and interacts with the amygdala, but is more often 
associated with the processing of positive emotion. As a central part of the reward circuit it 
is sensitive to the anticipation and receipt of reinforcers, and in this way contributes to 
emotional learning. Stronger activation for negative emotional stimuli and less activation 
for positive emotional stimuli in amygdala and striatum might contribute to the negativity 
bias often reported in depression (Harmer et al., 2009; Roiser et al., 2012), by stimulating 
negative information and inhibiting positive information for further processing. 
The evidence for negativity bias given by the opposing effects of emotional valence in 
limbic brain areas was complemented by similar mirroring effects in the fusiform region, a 
secondary visual area linked to face processing. Facial stimuli depicting specific emotions 
were used by over half of the studies in this meta-analysis, and the activation in the 
fusiform areas was substantially more extensive for the studies presenting facial stimuli 
than for the studies presenting non-facial stimuli. Patients with depression showed 
increased activation relative to healthy controls in left fusiform cortex during the processing 
of negative emotional stimuli, and, conversely, decreased activation during positive 
emotional processing. This finding suggests that the negativity bias may be initiated as a 
perceptual bias towards negative, and away from positive stimuli, early in the perceptual 
processing stream as has been proposed before (Leppanen, 2006; Fales et al., 2008; Poulsen 
et al., 2009). This modulation of fusiform activity may be understood as part of a visual-
limbic feedback loop that is biased in depression, given a strong bidirectional interaction 
between amygdala and fusiform gyrus during emotional facial processing (Herrington et al., 
2011; Morris et al., 1998).  
A similar modulating effect of emotional valence was observed in the anterior 
cingulate cortex (ACC). During processing of negative emotion, depressed patients showed 
stronger activation than HC in a cluster in the dorsal ACC (with the peak located at the 




contrast, the dorsal perigenual ACC (BA24/25), a cluster located slightly more rostral than 
the cluster for negative emotion, was less active during processing of positive emotion. The 
dorsal ACC has been associated with attention and learning from negative feedback 
(Shackman et al., 2011). Furthermore, the dorsal ACC is thought to work in concert with 
the amygdala to generate the bodily response to emotion (Etkin et al., 2011). It has been 
suggested that the ACC, as part of the default-mode network, plays an important role in 
rumination and self-associations (Pizzagalli, 2011). Hence, abnormal dorsal ACC 
functioning could contribute to a multitude of depressive symptoms, ranging from biased 
attention to negative stimuli and rumination to increased sensitivity to stress.  
Interestingly, when investigating whether the activation differences between depressed 
patients and controls were related to the type of stimulus used, an effect of stimulus type 
was found in the pregenual ACC (BA25). This area showed increased activation to facial 
stimuli and decreased activation to non-facial stimuli in depressed patients, irrespective of 
emotional valence. It is noteworthy that the large majority of studies included a neutral 
stimulus as control condition, so the activation differences could be associated with 
hyperresponsivity to emotional faces and hyposensitivity to non-facial emotional stimuli. It 
would be interesting to examine the effects of other social cues for emotional states such as 
body language, to investigate whether the hyperresponsivity applies to social stimuli in 
general. Moreover, it is interesting that this area has been proposed to play a central role in 
integrating cognitive and emotional processes (Mayberg, 1997). The presentation of facial 
stimuli depicting emotional states might elicit more integration of cognitive and emotional 
processes than the presentation of non-facial stimuli in depressed patients. 
Almost all the differences identified in medial frontal regions concerned pregenual and 
dorsal ACC. While precise location of findings is arduous in meta-analysis, it is striking 
that we did not find differences in the subgenual part of the ACC, because this structure is 
thought to play a prominent role in depression (Mayberg, 1997; Drevets et al., 2008b; 
Hamani et al., 2011). One possible explanation for this negative finding is that most tasks 
did not target processes that are deviant in the subgenual ACC of depressed patients. For 
instance, the subgenual ACC has been associated more with the experience rather than 
perception of emotion, and may be targeted by explicit mood induction (Berna et al., 2010) 
or self-referential instructions (Lemogne et al., 2009). On the other hand, the differences 
may be more pronounced in resting state activity rather than reactivity to emotional stimuli 
(Mayberg, 1997; Drevets et al., 2008b). It should be noted that considering the conservative 
analytical procedure, it remains possible that there are modest effects of emotional 
processing that went undetected. Future research should investigate the conditions under 




Valence-specific effects in prefrontal areas: Impaired affective state monitoring 
The left DLPFC was less active in depressed patients than in HC during processing of 
negative emotion. This is consistent with the hypothesis of impaired affective state 
monitoring in depression (e.g. (Beck, 2008; Phillips et al., 2003b). This finding also 
supports the rationale for use of transcranial magnetic stimulation over the left DLPFC to 
enhance cortical activation of this region in patients with MDD (George et al., 2011). The 
left DLPFC is thought to inhibit amygdala activity during voluntary emotion regulation 
using suppression, attention redirection or reappraisal strategies. These voluntary strategies 
have been contrasted with automatic emotion regulation by medial prefrontal structures 
(Phillips et al., 2008). Accordingly, depressed patients might make limited use of emotion 
regulation strategies during emotional perception. The studies included in the present meta-
analysis did not instruct the participants to regulate their emotions. However, active 
emotion regulation might be part of typical emotional functioning.  
During processing of positive emotion, the medial OFC was more active in 
depressed patients than in HC. The OFC is thought to code an abstract representation of 
value that is sensitive to change. Therefore, it acts as a complex dynamic system that is 
involved in different stages of affective state monitoring (Rolls et al., 2008). Neurons in the 
OFC have been shown to compute and compare values between stimuli before decision 
making occurs, compute the actual outcomes after stimulus presentation, compare the 
outcome to the prediction and adjust the value of the stimulus accordingly (Peters et al., 
2010). Therefore the temporal pattern of activation is crucial for the interpretation of 
activation differences. Higher activation in depressed patients might represent the drive that 
projects a correct value representation to the striatum and other limbic areas. Decreased 
feedback from the striatum might induce prediction errors in the OFC. 
Comparing results to predictions from models on emotion processing in depression 
Previous models describing the neural basis of emotion processing in depression have 
hypothesized three processes to be critical to depression; namely emotional appraisal, 
integration of the somatic response and affective state monitoring. The models have 
mapped these processes to neural systems. The results from our meta-analysis are mostly 
supportive of abnormalities in structures thought to be involved in appraisal and affective 
state monitoring, but less supportive of abnormalities in the integration of the somatic 
response. At the appraisal level, the fusiform areas is suggested to project to the amygdala 
and striatum, and these areas are thought to work in concert to generate a negative bias in 
emotion recognition (Leppanen, 2006). This bias might be operational for the processing of 
both negative and positive emotional information.  
Decreases in activity in the left DLPFC in response to negative stimuli and 
increases in the OFC in response to positive stimuli might both reflect impaired affective 




authors have described the OFC as part of the somatic response network together with the 
subgenual ACC (Leppanen, 2006; Phillips et al., 2003b). Indeed, an increase in OFC 
activity during processing of positive emotional stimuli could be associated with lower 
somatic responsivity through inhibitory pathways. On the other hand, the findings are also 
in line with the hypothesis that OFC activity reflects affective state monitoring, as has been 
suggested by other authors (Krishnan et al., 2008; Rolls et al., 2008; Beer et al., 2003) and 
in a later publication by Phillips and colleagues (2008). In summary, the role of the OFC 
appears to be broader than somatic integration alone, as it has also been associated with 
more complex functions such as decision making and motivated behavior. Unfortunately, 
there is a paucity of research on the monitoring of positive affective states in depressed 
patients. 
The dorsal ACC was hypothesized to be less active in depression as a part of the 
affective state monitoring network. Instead, we found increased dorsal ACC activity for 
processing negative emotion and decreased activity in dorsal pregenual ACC for processing 
positive emotion. This may be associated with decreased input from the DLPFC and 
increased output to the amygdala, providing a link between the dorsal and ventral networks 
as proposed by Mayberg (1997) for the pregenual ACC. Future research should test this 
hypothesis. On the other hand, the dorsal ACC may be involved in appraisal or generating 
an emotional response.  
The results of the meta-analysis are not fully consistent with the predictions from the 
models. Some important areas were not consistently found, most notably the subgenual 
ACC implicated in generating the emotional response (Phillips et al., 2003b; Mayberg, 
1997; Drevets et al., 2008a; Krishnan et al., 2008). However, the outcomes do grossly 
resemble the model by Leppanen (2006) that was specifically developed to reflect biased 
processing of emotional information in depressed patients and takes emotional valence into 
account. Our results suggest two potential modifications to the network proposed by 
Leppanen. The first is related to the frontal areas involved in emotion regulation. The 
involvement of OFC and DLPFC might be valence-specific, the OFC mostly involved in 
positive and DLPFC in negative emotion. The dorsal ACC and dorsomedial PFC might 
provide a link between the frontal and subcortical areas. The second potential modification 
concerns the evidence for a role of the cerebellum and parahippocampal areas. Both areas 
have been consistently implicated in typical emotion processing (Lindquist et al., 2012; 
Phan et al., 2002; Schutter et al., 2005). The hypothesized role of the parahippocampal 
areas is to establish contextual information (Bar et al., 2003), and the cerebellum might  
play an integrative and regulatory role in emotion processing (Schmahmann, 2000), 
comparable to the ACC. These areas deserve more investigation to determine which 




Comparison to the previous meta-analyses on emotion processing in depression. 
The results of the current meta-analysis corroborate and extend the results from two 
previous meta-analyses on emotion processing in depression (Fitzgerald et al., 2008a; 
Diekhof et al., 2008) in demonstrating lower activation in prefrontal and higher activation 
in limbic areas for the processing of negative emotion. We demonstrated higher activity in 
the dorsal ACC (BA32) in accordance with Diekhof and colleagues (2008), whereas 
Fitzgerald and colleagues (2008) found lower activity. However, we found stronger activity 
in the left amygdala, whereas Fitzgerald and colleagues (2008) found higher activity in the 
right amygdala and Diekhof and colleagues (2008) did not report any differences in the 
amygdala. It is noteworthy that the 16 region-of-interest studies investigating the 
amygdalae did report stronger activation for depressed patients fairly consistently. 
Therefore, the results remain inconclusive with respect to amygdala activation. For positive 
emotion, the main results were consistent as well (Fitzgerald et al., 2008a). However, the 
other meta-analyses did report a large number of additional activation differences that could 
not be replicated even though 41 studies were included in the current meta-analysis 
compared to 6 (Fitzgerald et al., 2008a) and 10 (Diekhof et al., 2008) in the others. 
Therefore, the current meta-analysis is higher in power and has less sensitivity to outliers. 
Moreover, both previous meta-analyses employed an approach designed to test for above-
chance clustering of individual foci rather than consistency of results across studies. This 
may result in summaries biased towards those studies artificially reporting more 
activations, for example by employing a more lenient statistical threshold. This source of 
bias has been corrected in later versions of the method (Eickhoff et al., 2009).  
Robustness of results when including only whole-brain studies in the meta-analyses 
To examine the robustness of the results, the meta-analyses were repeated including only 
the 26 studies using a whole-brain rather than a region-of-interest (ROI) approach. The 
results were comparable to the main analyses, although for processing of negative emotions 
three important clusters of stronger activation in depressed patients did not reach 
significance. The clusters were located in the bilateral temporal areas surrounding 
hippocampus and amygdala and ACC. These areas were repeatedly investigated in ROI-
studies , where for the left amygdala 9 additional peaks and for the ACC 5 additional peaks 
were recorded. Similarly, two clusters in the parahippocampal areas disappeared for the 
positive emotion contrast, although the pre-existent limbic cluster came to include a peak in 
the amygdala. Presumably, this is also due to the large number of ROI studies examining 
the amygdala.  
The discrepant findings between whole-brain and ROI approaches may be 




in ROI studies. The consistency in results from whole brain studies was remarkably low. 
This could indicate that the true effect sizes are relatively small and need more power and 
thus larger sample sizes to be detected. Relatively weak but widespread functional 
abnormalities during negative emotional processing have been shown to have diagnostic 
value when classifying patients with depression versus healthy controls, further suggesting 
that small but real effects exist in areas beyond those usually associated with depression 
(Costafreda et al., 2009b; Fu et al., 2008; Nouretdinov et al., 2011). Increased power for 
meta-analysis would be achieved through the integration of the full measurements (i.e. 
before statistical thresholding), as provided in statistical parametric images (Salimi-
Khorshidi et al., 2009).  
Strengths and limitations 
This meta-analysis is characterized by substantial methodological strengths. First, a major 
strength is the combination of ROI and whole-brain studies. Since most ROI studies 
targeted the amygdala, this approach generated a lot of additional power to investigate the 
limbic areas. Furthermore, the sensitivity analysis demonstrated that the ROI studies 
provided valuable information that was not revealed in whole-brain studies. Second, the 
parametric testing provided information about effect sizes that is lacking in classic 
neuroimaging meta-analysis approaches. Testing was performed conservatively by treating 
study as a random factor and applying a false-discovery rate correction. The systematic 
search strategy was standardized and the independent assessment of eligibility showed good 
inter-rater reliability. Finally, heterogeneity according to facial versus non-facial stimuli 
was investigated through separate analyses, which suggested that the presence of faces in 
the visual stimuli was a substantial moderator of activation, particularly in anterior 
cingulate cortex. 
 Even after taking this factor into consideration, substantial sources of 
heterogeneity are likely to remain that we did not test for. There was for instance 
substantial task heterogeneity, however unfortunately there was not enough power to 
investigate all the tasks separately. The activation abnormalities might not be generalizable 
to all the different tasks. A potential influential factor that we did not take into account is 
differences in the control condition. However, only faces tasks showed a plurality of control 
conditions. Most of the results were replicated in the non-faces tasks, suggesting that the 
influence of control condition was limited. Furthermore, the contrasts were structured by 
valence of emotion. While this stratification allowed for data pooling across a sufficiently 
large number of studies, it may obscure differences associated to specific emotions, such as 
anger or disgust. Similarly, it would be informative to investigate the effects of arousal 




biased by underrepresentation of unpublished negative results, although the innovative 
method presented here allows for the integration of null results in the meta-analytical 
summary. Smoothing may have influenced the results as well, although the smoothing 
parameter of 20mm applied to the data before meta-analysis has been reported to give 
accurate results for the range of smoothing kernels that were used in the included studies 
(Salimi-Khorshidi et al., 2009). The studies that did not report smoothing may have resulted 
in an underestimation of the effect. 
To examine a homogeneous depressed state, studies investigating depressed 
children, remitted depressives and groups at risk for depression were excluded. It would be 
very interesting to see if the activation abnormalities that were identified are generalizable 
to these groups. Moreover, several studies were identified that did collect data in which the 
contrasts of interest could be investigated, yet opted for a different analysis such as testing 
for functional connectivity, interaction effects and combinations of negative and positive 
emotion. From the perspective of facilitating future meta-analyses, we would recommend 
the analysis of basic contrasts including full reports of statistical thresholds, effect sizes and 
coordinates, as these data would allow the application of more advanced meta-analysis 
techniques, as well as ensuring potential replication of findings. 
Conclusions 
In conclusion, this extensive meta-analysis showed that depressed patients display 
activation abnormalities in brain areas implicated in emotion identification, affective state 
monitoring and generation of autonomic emotional responses. These brain areas were 
generally consistent with predictions from models on emotional dysfunction in the 
depressed brain. The processing of incoming emotional information appears to be strongly 
altered in depressed patients at multiple levels of processing. This includes multiple 
emotional networks, with nodes at the amygdala and striatum at the early stages of 
processing, and cognitive control networks in prefrontal areas subserving affect monitoring 
and regulation. The direction of effects in limbic areas was opposite across emotional 
valence, demonstrating the pertinence of taking emotional valence into account when 
investigating emotion processing. Considering the large body of work on emotion 
perception tasks in depression, further research should be aimed at explicating functional 
mechanisms by innovative experimental manipulation. Advanced connectivity analyses and 
longitudinal designs which allow for investigation of the temporal dynamics of activation 






The authors are grateful to the anonymous reviewers for their valuable comments and 






Supplementary Table 1: Peak coordinates of significant group differences in activation for negative and 
positive emotional stimuli from the meta-analysis including selectively whole-brain studies. 
Anatomical label BA Volume mean Z-score
# voxels x.max y.max z.max
Negative emotion versus neutral baseline
Areas of increased activity in patients
Left striatum and insula
Insula 48 338 -32 8 8 2.48
Putamen - 68 -30 6 6 2.48
Left occipital / temporal / parietal
Middle Temporal Gyrus 37 54 -36 -62 14 2.54
Middle Occipital Gyrus 39 46 -34 -62 24 2.53
Right cerebellum - 29 22 -70 -38 2.35
Areas of decreased activity in patients
Left dorsolateral prefontal cortex
Superior Frontal Gyrus 9 48 -22 38 32 -2.52





Supplementary Table 1: continued 
  
Anatomical label BA Volume mean Z-score
# voxels x.max y.max z.max
Positive emotion versus neutral baseline
Areas of increased activity in patients
Right lingual gyrus 18 107 26 -92 -14 2.54
Medial orbitofrontal cortex
Olfactorius Cortex 11 4 4 22 -14 2.55
Middle Orbitofrontal 11 6 2 26 -14 2.55
Rectus 11 78 2 30 -24 2.55
Middle Orbitofrontal 11 1 0 26 -12 2.55
Rectus 11 58 0 24 -24 2.55
Areas of decreased activity in patients
Left cerebellum and occipital
Cerebellum - 1551 -16 -74 -28 -2.83
Lingual Gyrus 18 988 -18 -62 -6 -2.82
Fusiform Gyrus 18 184 -22 -74 -14 -2.79
Inferior Occipital Gyrus 19 2 -30 -80 -12 -2.51
Left temporal / parietal
Rolandic Operculum 48 141 -40 -24 20 -2.75
Insula 48 37 -36 -24 22 -2.75
Superior Temporal Gyrus 48 8 -40 -36 12 -2.74
Heschl Gyrus 48 1 -46 -16 12 -2.71
Postcentral Gyrus 48 55 -50 -18 18 -2.69
Supramarginal Gyrus 48 25 -50 -22 18 -2.66
Medial cingulate gyrus
Anterior Cingulate Cortex 24 81 -2 28 16 -2.84
Anterior Cingulate Cortex 24 17 4 32 14 -2.83
Left cerebellum and occipital
Lingual Gyrus 19 431 -18 -62 -6 -2.63
Cerebellum - 144 -6 -58 -4 -2.49
Calcarine Sulcus 19 55 -20 -54 4 -2.43
Fusiform Gyrus 19 39 -26 -58 -12 -2.27
Precuneus 19 1 -20 -52 2 -2.16
Right basal temporal
Pallidum 48 170 18 0 -4 -2.58
Putamen 48 514 28 -4 8 -2.56
Thalamus - 37 14 -8 0 -2.52
Insula 48 25 38 10 -12 -2.28
Amygdala 34 26 30 -2 -12 -2.40
Caudate - 80 16 26 6 -2.28
Right cerebellum and occipital
Fusiform 37 27 44 -62 -20 -2.16





Supplementary Table 2: Peak coordinates of significant group differences in activation for negative and 
positive facial stimuli from the combined meta-analysis on whole-brain and region-of-interest studies. 
        
Anatomical label BA Volume  MNI coordinates mean Z-score 
      # voxels x.max y.max z.max   
Negative emotion versus neutral baseline 
     Areas of increased activity in patients 
     Medial cingulate gyrus 
      
 
Middle Cingulate Cortex 24 462 -8 10 32 2.66 
 
Anterior Cingulate Cortex 24 95 -2 22 28 2.46 
 
Supplemetary Motor Area 6 81 2 -4 48 2.44 
Anterior cingulate cortex 25 95 -4 32 10 2.39 
Left striatum and insula 
      
 
Putamen - 187 -28 4 6 2.66 
 
Insula 48 65 -32 8 8 2.59 
Left basal temporal 
      
 
Putamen - 151 -28 -12 2 2.64 
 
Superior Temporal Gyrus  48 147 -46 0 -12 2.62 
 
Insula 48 294 -36 -4 8 2.56 
 
Superior Temporal Pole 38 168 -30 10 -22 2.50 
 
Pallidum - 45 -24 -8 -2 2.48 
 
Parahippocampal Gyrus 28 563 -20 4 -22 2.47 
 
Middle Temporal Pole 36 74 -24 4 -36 2.43 
 
Middle Temporal Gyrus 20 79 -46 -14 -12 2.40 
 
Fusiform Gyrus 20 502 -36 -14 -26 2.37 
 
Inferior Temporal Gyrus 20 408 -40 -12 -30 2.37 
 
Amygdala 28 170 -22 4 -22 1.96 
Right basal temporal 
      
 
Putamen 48 61 32 8 -6 2.45 
 
Insula 48 22 38 12 -12 2.41 
 
Olfactorius Cortex 48 52 28 12 -12 2.29 
 
Parahippocampal Gyrus 28 338 20 12 -26 2.28 
 
Fusiform Gyrus 20 39 28 -4 -38 2.16 
 
Middle Temporal Pole 36 25 24 4 -36 2.16 
 
Superior Temporal Pole 28 38 26 10 -26 2.16 
 
Hippocampus 28 9 24 -2 -22 2.02 
 
Amygdala 28 52 24 0 -22 1.78 
        Areas of decreased activity in patients 





Supplementary Table 2 continued 
        
Anatomical label BA Volume  MNI coordinates mean Z-score 
      # voxels x.max y.max z.max   
Positive emotion versus neutral baseline 
     Areas of increased activity in patients 
     Medial cingulate  / orbitofrontal 
      
 
Anterior Cingulate Cortex 32 187 -6 40 6 3.52 
 
Anterior Cingulate Cortex 25 544 2 34 0 3.47 
        Areas of decreased activity in patients 
     No significant results.             





Supplementary Table 3: Peak coordinates of significant group differences in activation for negative and 
positive non-facial stimuli from the combined meta-analysis on whole-brain and region-of-interest 
studies. 
        Anatomical label BA Volume  MNI coordinates mean Z-score 
      # voxels x.max y.max z.max   
Negative emotion versus neutral baseline 
     Areas of increased activity in patients 
     Left basal temporal 
      
 
Inferior Temporal Gyrus 20 7 -42 -40 -28 2.61 
 
Fusiform Gyrus 37 75 -38 -46 -24 2.26 
        Areas of decreased activity in patients 
     Anterior Cingulate Cortex 25 410 6 28 4 2.84 
        
Anatomical label BA Volume  MNI coordinates mean Z-score 
      # voxels x.max y.max z.max   
Positive emotion versus neutral baseline 
     Areas of increased activity in patients 
     No significant results. 
      
        Areas of decreased activity in patients 
     Medial cingulate gyrus 
      
 
Anterior Cingulate Cortex 24 370 -6 36 6 -2.51 
 
Anterior Cingulate Cortex 25 167 4 34 4 -2.51 
 
Superior Medial Frontal 
Gyrus 10 21 8 46 2 -2.86 
Left occipital and cerebellum 
      
 
Lingual gyrus 18 117 -6 -58 -4 -3.00 
 
Lingual gyrus 18 96 -12 -68 -8 -2.88 
 
Cerebellum - 12 -4 -70 -6 -2.88 
Left cerebellum and occipital 
      
 
Lingual Gyrus 18 46 -32 -76 -18 -2.88 
 
Crus Cerebellum 19 219 -20 -68 -30 -2.88 
 
Cerebellum - 275 -26 -66 -28 -2.88 
Right subcortical / basal temporal 
      
 
Pallidum - 81 26 -6 2 -2.82 
 
Putamen - 217 26 2 2 -2.82 
  Thalamus - 17 14 -12 0 -2.82 
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Abstract  
Background: Abnormal brain activations during processing of emotional facial expressions 
in depressed patients have been found consistently and treatment studies have suggested 
that these abnormalities are state-dependent.  
Aims: To investigate the natural course of brain activation in response to emotional faces in 
depression, indexed by functional magnetic resonance imaging (fMRI) scans preceding and 
following change in depressive state. 
Method: A two-year longitudinal fMRI study was conducted as part of the Netherlands 
Study of Depression and Anxiety (NESDA). We included 32 healthy controls and 52 
depressed patients. During the second scan 30 patients were in remission (recoverers), the 
other 22 were not (non-recoverers). All participants viewed faces with emotional 
expressions during scanning. 
Results: Anterior cingulate cortex (ACC) activation during processing of happy facial 
expressions was predictive of a decrease in depressive state. In addition, recoverers showed 
decreased activation of the insula over time, specifically during happy facial expressions. 
Non-recoverers displayed increased abnormalities in emotion recognition circuitry on the 
second scan compared to the first. No effect of SSRI use was observed. 
Conclusions: Our results demonstrate that ACC activation may predict changes in 
depressive state even at two-year outcome. The association between change in depressed 
state and change in insula activation provides further evidence for the role of the insula in a 
network maintaining emotional and motivational states. Results also support the view that 









Depressive disorder is characterized by a diminished ability to recognize emotions of other 
people (Demenescu et al., 2010), an ability that is important for adequate social interactions 
and adequately perceiving the world around us. Research regarding processing and 
recognizing emotional facial expressions in depression has concentrated on an emotional 
processing bias in depression, resulting in attention to be directed toward negative and 
away from positive cues (Leppanen, 2006).
 
Most neuroimaging studies on related changes 
in brain activity in depression focused on abnormal amygdala activity (i.e.Victor et al., 
2010; Suslow et al., 2010; Sheline et al., 2001; Surguladze et al., 2005), but abnormal 
activity in insula, pre- and subgenual anterior cingulate cortex (ACC), ventral prefrontal 
cortex (PFC) and dorsal lateral PFC (DLPFC) has also been linked to face processing in 
depression (Fitzgerald et al., 2008a; Surguladze et al., 2005; Dannlowski et al., 2007; Frodl 
et al., 2009; Lee et al., 2008; Mitterschiffthaler et al., 2003; Siegle et al., 2007).
 
However, 
whether these abnormalities reflect state or trait characteristics, and are predictive of 
remission, is largely unknown.  
Investigating the effects of remission from depression on the brain has mostly been 
investigated in relation to response to antidepressant medication. A resting state positron 
emission tomography (PET) study has shown that following remission after six weeks of 
selective serotonin reuptake inhibitors (SSRI) treatment, insula and subgenual ACC glucose 
uptake was decreased while in the DLPFC it was increased (Mayberg et al., 1999). Also, in 
functional magnetic resonance imaging (fMRI) studies the effects of antidepressant 
treatment have been investigated. The most replicated finding is a decrease in amygdala 
activity in response to successful treatment with an SSRI (Sheline et al., 2001; Fu et al., 
2004; Anand et al., 2007; Ruhe et al., 2012),
 
but also decreased activity has been reported 
in the ACC (Fu et al., 2004; Anand et al., 2007)
 
 and insula (Fu et al., 2004).
 
 Meta-analyses 
of both PET and fMRI studies (Fitzgerald et al., 2008a; Delaveau et al., 2011) have 
confirmed decreased activity during emotional processing following SSRI treatment of the 
rostral ACC, insula, amygdala, inferior frontal gyrus (IFG) and hippocampal regions. This 
was accompanied by increased DLPFC, dorsal posterior cingulate gyrus and putamen 
activity. These changes have also been demonstrated following cognitive behavioral 
therapy (CBT, Fu et al., 2008; Ritchey et al., 2011). 
Ruhé et al. (2012)
 
 recently have made a direct comparison between responders 
and non-responders to SSRI use and have shown that amygdala responses change in 
responders only, suggesting that altered activation is not primarily a pharmacological effect 
but is driven by a change in depressive state as a result of treatment. However, SSRI use 
has also been related to decrease in amygdala, ACC and insula activity in healthy people 




the use of antidepressant medication. Therefore, it is still insufficiently known whether 
changes in response to treatment are secondary to medication use per se or reflect altered 
mood. Moreover, the effects of mood states have been predominantly studied in cross-
sectional studies which do not allow inferences on within-subjects effects of remission. 
Brain activation patterns have also been used to predict treatment response. The 
predictive value of increased pre- and subgenual ACC activity during emotional processing 
is a commonly replicated finding (reviewed by Pizzagalli, 2011; Kemp et al., 2008; 
MacQueen, 2009) and has been demonstrated for responsiveness to SSRIs (Davidson et al., 
2003; Chen et al., 2007), other antidepressant medication (Keedwell et al., 2009),
 
and CBT 
(Costafreda et al., 2009b).
 
The ACC has been implicated in emotional (rostral part) and 
cognitive processing (dorsal part) and has extensive connections to other brain areas 
involved in emotional processing (Bush et al., 2000)
 
and therefore is an important hub in 
adequate emotion regulation. In addition, also increased amygdala activity has been shown 
to be predictive of remission (Canli et al., 2005; Siegle et al., 2006). However, these studies 
investigated short-term improvement only (6-12 weeks) in response to antidepressant 
treatment. Thus, it is not yet clear whether regional brain activity may predict sustained 
symptom improvement.  
The aim of this study was to investigate neural activity patterns in response to 
emotional stimuli related depressive state in a naturalistic setting over a period of two years. 
We hypothesized a decrease in activation in the amygdala, ACC and insula related to a 
decrease in depressive pathology. In addition, based on the literature, we expected 
increased ACC activation to predict a decrease in depression pathology. We controlled for 
time effects by comparing a group of patients who changed in mood state (recoverers) to 
two groups who did not (non-recoverers from depression and stable healthy controls).  
Methods en Materials 
Participants 
Participants were recruited from the MRI study of the large-scale longitudinal multi-center 
Netherlands Study of Depression and Anxiety (NESDA, Penninx et al., 2008),
 
which 
involved the University Medical Center Groningen (UMCG), VU Medical Center (VUMC) 
Amsterdam, and Leiden University Medical Center (LUMC). Participants were recruited 
through general practitioners, primary care, and specialized mental care institutions. All 
participants provided written informed consent and the ethical review boards of each 
participating center gave approval for this study. No financial compensation was offered to 
the participants, except for travel expenses. Exclusion criteria for all participants were 1) 




contraindications, 3) dependence or recent abuse (past year) of alcohol or drugs, and 4) 
hypertension.  
For this analysis, we selected out-patients from the NESDA-database who met the 
following additional criteria: 1) diagnosis of depression indexed by the fourth edition of the 
diagnostic manual of mental disorders (DSM-IV) based on the Composite International 
Diagnostic Interview (CIDI) – lifetime version 2 (Andrews et al., 1998) assessed during an 
interview session (I1) before the first scanning session. 2) Montgomery-Åsberg depression 
rating scale (MADRS, Montgomery et al., 1979) score above 10 at day of first scanning 
session, indicating at least mild depressive pathology and not in remission (Zimmerman et 
al., 2004). 3) No use of other psychotropic medication than SSRIs or infrequent use of 
benzodiazepines (oxazepam or diazepam, maximum of three times a week, max 20 mg and 
not within 48 hours before scanning). In addition, we selected healthy controls (HC) 
without a history of any axis-I disorder.  
On the first scanning session (S1) 56 HC and 182 patients completed the faces task 
(these results are described elsewhere, Demenescu et al., 2011). For 32 HC and 52 patients 
with a current depression at the time of the first scanning session we obtained whole-brain 
functional MRI data for the second scanning sessions (Figure 4.1). The patients were 
divided into recoverers (n=30) and non-recoverers (n=22) on basis of MADRS-score at 
moment of the second scanning session (having a MADRS-score below 10 was regarded as 
recoverer).  
We focused our analyses on differences related to depressive state. As this was a 
naturalistic study, no therapeutic intervention was suggested after the initial interview (I1). 
Patients received care as usual. Comorbidity with anxiety disorders was not taken into 
account, as this would lead to loss of power. The two depressive groups were equal in 
anxiety symptomatology at moment of scanning (indicated by equal BAI-scores). The 
demographic and clinical details are shown in Table 4.1.  
Sessions 
The study consisted of an interview session (I1) followed within on average two months by 
a scanning session (S1). This was repeated two years later (I2 and S2). During the interview 
sessions the CIDI and life chart interview (Lyketsos et al., 1994) were administered by 
trained research assistants. To assess the clinical state of the participants at the time of 
scanning, depression and anxiety severity were measured using the MADRS and the Beck 
Anxiety Inventory (BAI, Beck et al., 1988))
 





Figure 4.1 Flow chart of the inclusion in this study.  
At baseline measurement, 56 healthy controls (HC) and 182 patients had good scans during the 
emotional faces paradigm (Demenescu et al., 2011). 118 of these patients had a MADRS score above 
10 at moment of scanning, indicating a depressed state and where therefore included in this study. 
From 57 of these patients we did not had scan data to analyze (lost to follow-up or stopped scanning 
before end of protocol) and 2 patients used medication at S2 which was an exclusion criteria (seroqual 
and mirtazapine). Leaving 59 patients of which 57 had analyzable data. In addition, we lost 12 HC to 
follow-up and 6 because the scanning was stopped before the end of the protocol. Two HC have 
developed their first depressive episode between the scanning sessions. Leaving 36 HC of which 34 
had analyzable data. *Exclusion from the final analysis was based on movement (>3mm in either 





Table 4.1. Demographic and clinical variables 
*HC differed from both depression groups, but depression groups did not differ; ** all groups differed 
from each other; *** HC differed from non-recoverers. VAS = Visual Analogue Scale(Huskisson, 1974); 
S1= first scanning session; S2 = second scanning session.  
  
HC recoverers non-recoverers p
32 30 22
Number 14/10/8 11/13/6 5/9/8 .46
Number 11/13/8 8/16/6 6/9/7 .78
Mean (SD) 24.47 (1.50) 25.63 (3.33) 25.00 (1.98) .17
Mean (SD) 38.62 (9.06) 39.48 (10.26) 39.52 (10.39) .86
Mean (SD) 15.19 (2.45) 12.03 (2.53) 11.50 (3.42) <.001*
Number (%) 20 (62.5) 19 (65.5) 11 (52.4) .63


















no professional help 5 3
mental health care 15 16
2 1
6 1
company doctor 2 0
Mean (SD) - 25.66 (11.98) 25.00 (10.82) .88
Mean (SD) - 10.97 (11.51) 5.62 (9.48) .12
Number (%) 9  (31) 7 (33.3) .86
Mean (SD) - 29.11 (25.28) 33.26 (30.61) .89
Mean (SD) - 36.58 (28.09) 50.77 (31.66) .11
Number (%) - 23 (76.67) 16 (72.72)
Social Phobia Number (%) 12 (40.00) 10 (45.45) .69
Panic Disorder Number (%) 13 (43.33) 10 (45.45) .88
General Anxiety Disorder Number (%) 9 (30.00) 7 (31.81) .89
Number (%) 9 (30.00) 16 (72.72)
Social Phobia Number (%) 3 (10.00) 6 (27.27) .10
Panic Disorder Number (%) 5 (16.67) 6 (27.27) .36
General Anxiety Disorder Number (%) 1 (3.33) 8 (36.36) .002**
Mean (SD) 1.69 (2.72) 17.97 (6.02) 20.95 (8.45) <.001*
Mean (SD) 0.94 (2.00) 4.97 (2.66) 17.64 (4.36) <.001*
*Mean (SD) 2.31 (2.96) 15.83 (8.12) 16.82 (11.13) <.001*




independent psychiatrist or psychotherapist
f irst line psychologist, a social w orker or a social psychiatric nurse 





# episodes in past 5 years before I1
Patients w ith f irst episode
Comorbidity w ith anxiety disorder S1
Comorbidity w ith anxiety disorder S2 
Percentage of months w ith depressed feelings betw een I1 and I2






Education (years including primary school)
Months betw een scans





On both occasions participants performed the same task (see also Demenescu et al., 2011), 
which consisted of viewing color photographs of angry, fearful, happy, neutral, and sad 
facial expressions, taken from a widely used set (Lundqvist et al., 1998), as well as pictures 
of scrambled faces. Participants were requested to make gender judgments during 
presentation of the facial expressions. On the scrambled faces an arrow was shown to 
indicate which button the participant had to press. For each emotion 24 photographs were 
presented and 80 baseline pictures. Each picture was shown for 2.5 seconds. Reaction times 
(RT) were recorded.  
Imaging data acquisition 
All participants were scanned using a Philips 3T MR-scanner. A sense-8 channel head coil 
was used for radio frequency transmission and reception in Groningen and Leiden. In 
Amsterdam a sense-6 channel head coil was used for the first scanning session and a sense-
8 channel head coil during the second scanning session.  
After two dummy scans, a series of echo planar images (EPI) was obtained, 
entailing a T2*-weighted gradient echo sequence using axial whole brain acquisition, with 
an interleaved slice acquisition order and with the following settings: repetition time 
(TR)=2300ms, echo time (TE)=28.0 at Groningen and 30 at Amsterdam and Leiden, and a 
flip angle of 90°. At Groningen 39 slices per EPI-volume were acquired on S1, with a 
matrix size of 64x64 voxels and an in-plane resolution of 3x3mm. At Amsterdam, Leiden 
and in Groningen on S2 35 slices per EPI-volume were acquired, with a matrix size of 
96x96 voxels and an in-plane resolution of 2.29x2.29mm. The slices had a 0mm gap and 
3mm thickness. The images were acquired parallel to the anterior-posterior commissure 
plane.  
In addition, a T1-weighted anatomical scan was made (TR=9ms, TE=3.5ms, 
matrix size 256x256, voxel size: 1x1x1mm). 
 Statistical analysis 
Clinical variables and behavioral data 
Group effects on clinical, demographic, and behavioral data were analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, Il, USA). For the clinical and demographic data we used 
analysis of variance (ANOVA), Chi-square and non-parametric tests as appropriate.  
For the behavioral data (RTs), repeated measures ANOVA was conducted with 
condition and time as within-subject variables and diagnosis as between-subject variable. In 
case of a significant F-test, the direction of the effect was tested post-hoc with Bonferroni-





Preprocessing: Data were analyzed in UMCG with SPM5 (http:// 
www.fil.ion/ucl.ac.uk/spm/), implemented in Matlab 7.1 (The MathWorks Inc.,). 
Preprocessing included slice time correction, image realignment, registration of the T1-scan 
to the mean EPI, warping to MNI-space as defined by the SPM5 T1-template, reslicing to 
3x3x3 mm voxels and spatial smoothing using an 8mm full width half maximum (FWHM) 
Gaussian kernel. Movement of the participant of >3mm or 3 degrees rotation in any 
direction resulted in exclusion of the data from further analysis (n = 1 on S1 and n = 4 on 
S2, included in figure 1). Following spatial preprocessing, data were analyzed within the 
framework of the general linear model.  
First-level models: For every participant, hemodynamic responses for each stimulus for 
both sessions were modeled. The model included regressors for each condition (angry, 
fearful, happy, neutral, and sad) and for baseline trials (scrambled faces). Low frequency 
noise was removed by applying a high-pass filter of 128 s. For every participant, contrast 
images were calculated for “angry>scrambled”, “fearful>scrambled”, “happy>scrambled”, 
“neutral>scrambled” and “sad>scrambled” for each scanning session.  
 
Second-level model: Using full-factorial, the contrast maps for the five conditions were 
combined at group level to a 3 (group) by 2 (time) by 5 (condition) repeated-measures 
ANCOVA, with group as between-subject variable and time and condition as within-
subject variables. Scanning centers (two dummy variables), medication status on both time 
points, and education were included as covariates.  
We tested for interactions of group by condition on S1, group by condition on S2 
and group by time by condition effects. Post-hoc t-tests focused on group differences over 
time and/or condition and were masked for the relevant F-test (p < .05). Activated clusters 
were regarded significant if the F-test reached a threshold of p < .005 uncorrected whole-
brain and post-hoc t-tests p < .05 family wise error (FWE) corrected for the spatial extent of 
our regions of interest (ROIs) with a small volume correction (SVC). Based on the 
literature, we selected amygdala, ACC and insula as our ROIs. We used the Automated 
Anatomical Labeling atlas (Maldjian et al., 2003), implemented in the WFU-Pick Atlas 
toolbox to define these ROIs (Wake Forest University School of Medicine).  
For additional explorative whole-brain analysis the same contrasts were inspected 
and  clusters were regarded significant if post-hoc t-tests reached a threshold of p < .05, 
FWE whole-brain corrected.  
 
Medication effects: To test for the effects of medication, we extracted a representative 
contrast value per participant and session for each significant area by taking the first 




exported to SPSS and were used as a dependent variable in repeated-measures ANOVA 
with time as within-subject variable and group and medication use as between-subject 
variables. Medication use was entered with four levels: both time points no medication, 
both time points medication, started with medication between sessions, stopped with 
medication between sessions. We investigated 1.) main effect of medication, 2.) two-way 
group by medication and time by medication interaction effects and 3.)  three-way 
interaction. Effects were considered significant at a threshold of p < .05.   
 
Consistency checks: A couple of approaches were undertaken to investigate the consistency 
of the results for the group by time interaction.  
First, the influence of different options of handling within-subject error was 
investigated. On first-level, for each condition a contrast was calculated including the factor 
time (e.g. “S2[angry vs. scrambled] vs. S1[angry vs. scrambled]). Accordingly, per subject 
a map was calculated with the maximum deviation from zero of the five conditions 
retaining the sign. Thus, per person a map was calculated including time and condition 
information. With statistical nonparametric mapping (SnPM), we performed a permutation 
test to test whether the three groups differed in time differences in response to any of the 
conditions.    
Second, to test whether the effects were related to emotional processing or facial 
processing, we replicated the analysis with neutral as a baseline condition.  
Third, to test whether findings were related to the cut-off on the MADRS-
questionnaire, we replicated the analysis with a continuous approach in which we tested for 
the correlation between relative change in MADRS scores [(MADRS S2 - MADRS 
S1)/MADRS S1] and change in brain activity between S2 and S1 (using the first-level 
contrast with the time effect).  
Results 
Follow-up analysis 
We compared participants who participated in the follow-up scan (n = 117) to those who 
did not (n = 57). There was no difference in age (t(172) = 0.79, p = .43), gender (χ²(1) = 
0.11, p = .74), education (t(172) = 1.39, p = .17), or BAI-scores (t (172) = 0.85, p = .39). 
We did observe trendwise higher MADRS-scores (t(172) = 1.88, p = .06) within drop-out 
participants (mean = 16.02, SD = 10.36) compared to those who did participate in the 






There was a main effect of condition on RT (F(4,78) = 19.42, p < .001): all participants 
were faster during gender classification of angry faces (p < .001). There were no main 
effects of group or time nor an interaction of condition by group, time by group, condition 
by time or condition by time by group (all F < 1.4, p > .25, Table 4.2).  
 
Table 4.2 Mean RTs for groups and conditions.  
There was a main effect of condition on RT (F(4,78)=19.42, p<.001): all participants were significantly 
faster during gender classification of angry faces (p<.001). There was no main effect of group 
(F(2,81)=0.037, p=.96) or time (F(1,81)=1.23, p=.27) nor an interaction of condition by group 
(F(8,158)=0.77, p=.63), time by group (F(2,81)=0.55, p=.59), condition by time (F(4,78)=1.32, p=.27) or 
condition by time by group (F(8,158)=1.08, p=.38).   
RT is given as mean (stdev) in ms. S1 means scanning session 1 and S2 means scanning session 2. 
 
Imaging data 
Main effect of task 
In each group and on each session, viewing faces (vs. scrambled faces) was associated with 
increased activation in bilateral fusiform gyrus, bilateral amygdala, right middle frontal 
gyrus (MFG) extending to the insula and inferior frontal gyrus (IFG), and bilateral 
sensorimotor areas and right superior temporal gyrus (supplement Table S1 and Figure S1).  
Group by time interaction effects 
From our regions-of-interest, group by time by condition interaction effects were present 
within in the insula and amygdala (Table 4.3). There was an increase in activation over time 
in the left insula for “happy>scrambled” within HC and non-recoverer.s, whereas 
recoverers showed a decrease in activation over time within this area (Figure 2). Also in the 
right insula, recoverers showed a decrease in activation, whereas non-recoverers showed an 
HC Recoverers Non-recoverers
N=32 N=30 N=22
Angry S1 816.17 (162.37) 817.73 (157.99) 837.20 (146.76)
Angry S2 818.34 (142.43) 818.05 (138.05) 825.59 (191.88)
Fear S1 867.53 (159.67) 858.12 (166.04) 886.45 (168.51)
Fear S2 837.30 (131.16) 858.06 (163.25) 835.29 (180.55)
Happy S1 877.41 (136.39) 884.67 (165.25) 882.25 (133.22)
Happy S2 872.00 (145.01) 871.28 (135.69) 864.92 (164.51)
Neutral S1 883.16 (151.69) 861.39 (172.99) 891.47 (172.25)
Neutral S2 855.46 (122.68) 881.27 (152.02) 846.94 (150.53)
Sad S1 859.83 (158.66) 865.78 (143.67) 887.59 (147.57)




increase for “happy>scrambled”. There was no time-effect within HC in the right insula. In 
addition, non-recoverers showed a decrease in activation within the amygdala in response 
to “happy>scrambled” (Figure 4.3), whereas HC and recoverers did not show changes over 
time in the amygdala.   
 
Figure 4.2. Insula activity associated with recovery from depression.  





Figure 4.3. Areas which are associated with a change in activity over time within non-recoveres. On the 
first slide a decrease in activity in the amygdala is shown for the contrast “happy vs. scrambled”. In the 
second slide increased activity in the bilateral insula is shown for this same contrast. Threshold was set 








Table 4.3: Results from the fMRI analyses in the amygdala, insula and anterior cingulate cortex.  
Brain areas showing a significant group difference on S1, S2 or an interaction with time. All these 
clusters were significant for the F-test with p<.005 and survived post-hoc t-tests with p<.05 FWE small 
volume corrected (SVC) for the spatial extent of the ROI. The post-hoc t-tests were masked for the 
corresponding F-test. *the number of voxels is reported at p<.001 uncorrected.  
 
 
Explorative whole brain analysis, showed additional group by time by condition 
effects within the right fusiform gyrus extending to the parahippocampal gyrus (PHG, 
[x=39 y=-45 z=-9], F(8,806) = 4.41, puncorr < .001), left MFG (BA9, [x=-30 y=42 z=39], 
F(8,806) = 3.15, puncorr = .002), right IFG (BA43, [x=63 y=3 z=21], F(8,806) = 2.88, puncorr 
= .004) and caudate nucleus ([x=9 y=12 z=0], F(8,806) = 3.19, puncorr = .001). Post hoc tests 
revealed that these effects were all related to an increase in activation over time within non-
recoverers and there were no changes over time in these areas in HC and recoverers. The 
increase in PHG (t = 5.47, pFWE = .001, whole-brain corrected [WBR]), IFG (t = 5.07, pFWE 
= .006, WBR) and MFG (t = 4.71, pFWE = .03, WBR) were only present in response to 
“happy>scrambled”, whereas the increase in the caudate was only in response to 
“fear>scrambled” (t = 4.67, pFWE = .035, WBR).   
We repeated the analyses with the emotional faces contrasted against the neutral 
faces instead of the scrambled faces and found highly similar patterns of brain changes. In 
addition, regression analysis with difference in MADRS-scores between S2 and S1 did not 




emotion Direction of effect k*
x y z t -value p -value 
(FWE)
Group effects S1
Anterior cingulate cortex R 15 42 18 4.46 happy Recoverers > Non-recoverers 33 4.62 .001
Insula R 48 6 12 4.94 happy Non-recoverers > Recoverers 39 4.73 .001
happy HC > Recoverers 116 4.39 .006
Insula L -27 -3 9 3.89 happy Non-recoverers > Recoverers 17 4.1 .018
Group by time 
Insula L -36 18 12 3.57 happy ↓ Recoverers 26 4.23 .011
↑ Non-recoverers 20 4.57 .003
↑ HC 8 4.04 .022
Insula R 42 -15 -9 3.12 happy ↓ Recoverers 26 3.99 .026
Insula R 39 0 15 4.05 happy ↑ Non-recoverers 21 3.96 .029








Between group differences during first session (S1) 
On S1, a group by condition effect was present within the ACC (Table 4.3). This effect was 
driven by an increased activation for recoverers compared to non-recoverers at S1 only for 
the contrast “happy>scrambled” (Figure 4.4). There were no differences between HC and 
both depressed groups.  
Explorative whole-brain analyses showed no additional differences.  
 
Figure 4.4. The Anterior Cingulate Cortex as predictor of symptom improvement.  
The figure shows increased activity in recoverers compared to non-recoverers for the contrast “happy 
vs. scrambled” on S1. Threshold was set at p<.001 uncorrected for display purposes.  
 
 
Between group differences during second session (S2) 
On S2, there was a group by condition effect in bilateral insula (Table 4.3). Within the left 
insula, recoverers showed decreased activity compared non-recoverers in response to 
“happy>scrambled” faces. There was a trend for decreased activity within non-recoverers 
compared to HC (t = 3.62, pFWE = .087, SVC). There was no difference between recoverers 
and HC. Within the right insula recoverers showed decreased activity compared to both 
non-recoverers and HC in response to “happy>scrambled”.  
Explorative whole brain analyses showed also a group by condition effect on S2 in 
the precentral gyrus ([x=45 y=-9 z=42], F(8,806) = 3.68, puncorr < .001). Post hoc tests 
showed that in this area activity in response to “happy>scrambled” was increased in non-
recoverers compared to both HC (t = 4.64, pFWE = .039 WBR) and recoverers (t = 4.62, pFWE 






Medication effects  
No significant effects of medication, group by medication, medication by time or group by 
medication by time were observed.  
In addition, the analysis above was repeated with only unmedicated patients. The 
results were comparable, although less significant. Within this analysis there was also a 
group by time by condition effect in the bilateral insula ([x=-39 y=9 z=6], F(8, 500) =  
2.74, p = .006; [x=36 y=-27 z=12], F(8, 500) = 3.43, p = .001). There was a group by 
condition effect on S1 in the ACC ([x=12 y=24 z=15], F(8, 500) = 2.74, p = .006) and on 
S2 in the bilateral insula ([x=-36 y=-9 z=21], F(8, 500) = 3.25, p = .001; [x=45 y=6 z=9], 
F(8, 500) = 3.19, p = .002).  
Discussion 
The primary purpose of this study was to investigate patterns of neural activation in 
response to emotional facial expressions related to state of depression in a longitudinal 
design. This was investigated from two perspectives: fMRI at baseline (symptomatic phase) 
predictive of two-year outcome and longitudinal fMRI combining baseline and follow-up 
measurements after a two-year interval. As expected, ACC activation was predictive of a 
change in depressive state: during the first scanning session, recoverers showed more 
activation in the ACC than non-recoverers. Further, following decrease in depressive state, 
a decrease in activation was observed in the insula. This effect over time was not seen in 
HC or in non-recoverers, and therefore most likely reflects changes in mood state rather 
than general time effects. In addition, non-recoverers showed a progressive deviation from 
normality over time. To our knowledge, this is the first study to describe therapy-
independent changes in brain activations associated with changes in depressive state over a 
period of two years.  
Our finding that activation in the insula decreased during processing of happy 
facial expressions following a reduction in depressive symptoms is in line with treatment 
studies, which showed a decrease of insula activation in response to SSRIs (Delaveau et al., 
2011; Mayberg et al., 1999; Fu et al., 2004; Kennedy et al., 2001; Mayberg et al., 2000).  
However, in our sample this effect was related to a change in depression severity rather 
than associated with antidepressant use: when we repeated the analysis with only 
unmedicated patients, we replicated the pattern of results. The insula is an important region 
in emotional awareness (Craig, 2009) and has been shown to be part of a network which is 
activated during both perceiving and expressing positive facial affect (Hennenlotter et al., 
2005). Interestingly, increased insula activation has been found in response to induction of 
sadness (Mayberg et al., 1999), suggesting a role for the insula in mood change in either 
direction. Models have been proposed in which the insula and ACC jointly act in perceiving 




1999; Medford et al., 2010). The insula is proposed to be specifically involved in the 
generation of emotional states, whereas the ACC primarily has a role in directing attention 
and modulate responses (Medford et al., 2010). The specificity of our effect for happy faces 
could imply that symptom improvement is more related to a different response to positive 
stimuli rather than negative. It is not yet known if a decrease in insula activity precedes or 
follows decrease in depressive symptoms, but our study may add to the current evidence for 
the involvement of the insula in alteration of mood state.  
In the present study, rostral ACC activation in response to emotional expressions 
was found to be predictive of a decrease in depressive symptoms. This is a consistent 
finding in the literature, although only four small studies have been published (Costafreda 
et al., 2009b; Davidson et al., 2003; Chen et al., 2007; Keedwell et al., 2009). These studies 
have shown that greater activation in ACC during a depressive episode distinguishes 
patients who were going to respond to antidepressant treatment. We could not replicate the 
finding of increased amygdala activity as predictor of remission (Canli et al., 2005; Siegle 
et al., 2006). The two patient groups in our study were comparable to each other with 
respect to depression and anxiety severity at S1 so differences in brain activation between 
these groups could not be related to differences in severity of symptoms, but are likely to 
represent genuine remission predictors. This increased ACC activity could possibly reflect 
a subgroup with a more resilience against a chronic course of depression characterized by 
differential response of the emotion processing network. Recently, it has been shown that 
an early increase in positive affect after the start of treatment, rather than a decrease in 
negative affect, predicted remission of depression (Geschwind et al., 2011). Our results are 
in line with this finding, as the predictive value of ACC activation was most pronounced in 
response to happy faces and may reflect increased attention for mood-incongruent (i.e., 
positive) stimuli preceding remission.  
The task-related brain network we observed consisting of the fusiform gyrus, 
amygdala, middle frontal gyrus, extending to the inferior frontal gyrus and insula, 
sensorimotor areas, and superior temporal gyrus is in agreement with a proposed network 
for recognizing emotions from facial expressions (Adolphs, 2002) and a recent meta-
analysis (Sabatinelli et al., 2011) on fMRI studies to processing emotional facial 
expressions. However, it should be noted that we found few differences in brain activation 
on S1 between patients and HC, whereas previous studies (Victor et al., 2010; Suslow et al., 
2010; Sheline et al., 2001; Surguladze et al., 2005; Dannlowski et al., 2007; Frodl et al., 
2009; Lee et al., 2008; Mitterschiffthaler et al., 2003; Siegle et al., 2007)  have provided 
evidence for amygdala abnormalities in depression. This absence of such effects might be 
related to patient status (i.e., out-patients with mild to moderate psychopathology), or 
methodological issues (e.g., fMRI-paradigm). Nonetheless, robust amygdala activations 
were observed in the task effect. This “normal” amygdala set-off could explain why no 




activity in response to negative stimuli following treatment (Delaveau et al., 2011; Victor et 
al., 2010; Sheline et al., 2001). However, we found that amygdala activity in response to 
happy faces decreased over time in non-recoverers. This is in agreement with Victor et al. 
(Victor et al., 2010) who found decreased amygdala activity response to positive stimuli in 
depression. In addition, non-recoverers showed increased activity over time in several 
regions within the emotional recognition network (insula, parahippocampal gyrus, IFG, and 
MFG). These results suggest that depression is not a stable state, but that regional brain 
dysfunction progresses during illness. These more profound abnormalities after two years 
may reflect poor prognosis (Spijker et al., 2004; Penninx et al., 2011).  
This study had a relatively large sample size (n=84, paired design) and therefore 
ample power. The considerable follow-up period of two years between scan sessions is also 
unique. Because of the uniqueness of our study, the approach of this study was explorative 
and many factors (group, condition and time) have been taken into count. The main model 
of our analysis was quite conservative, but several options have been employed to test for 
the consistency of the results. In addition, we are aware that the post-hoc test results could 
have been inflated, because of the multiple testing, but they were used just to show the 
underneath directions of the results.  
It was a drawback in our study that not all patients were scanned in the same 
scanner and with the same head coil, which could have added unwanted variances in the 
data. However, the groups did not differ in percentages of participants scanned in each 
center. We investigated differences in neural activation related to depressive state at two 
discrete time points; therefore we cannot draw any conclusions regarding changes in neural 
activation related to the more detailed week-by-week course of depression. Participants 
were recruited from community, primary care and mental health care organizations to 
reflect a wide range of psychopathology and settings. Also, HC and participants 
experiencing depression were recruited and extensively screened using the same methods, 
which may have added to comparability between groups. In addition, participants included 
in our study were mild to moderately depressed, and therefore comparing results of this 
study to those investigating severely depressed and hospitalized patients is not 
straightforward. Our sample also included patients with comorbid anxiety symptoms, but 
these rates were equal in the two patient groups. However, it may also be argued that our 
heterogeneous sample of out-patients and our naturalistic design may increase 
generalizability, rendering the results of this study highly relevant to the population seen in 
daily clinical practice. Although we tried to control for medication use, caution in the 
interpretation of the results in light of medication use is needed. From our study we cannot 
infer causal relationship between alterations in regional brain activity and mood changes, 
which are difficult to establish but warrant further investigation.  
In conclusion, this is the first study that investigated changes in regional brain 




use, in a naturalistic design, during a two-year period. Following decrease in symptom 
severity, a decrease in activation was seen in the insula, which may be related to more 
mood-congruent processing. Furthermore, we replicated the finding of ACC activation as 
predictive of remission. Finally, our results support the view that prolonged depression is 
not a stable state but rather a progressive departure from normality.  
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Table S1 Main effects of the faces task (“all faces vs. scrambled face”) in the different groups on the 
different time moments. These clusters are depicted in figure 1. Threshold is p<.05 FWE corrected. S1 
means scanning session 1 and S2 means scanning session 2. 
Group Region Side T-value
x y z
HC S1 Fusiform gyrus R 39 -45 -18 8.57
Fusiform gyrus L -39 -42 -18 5.90
Amygdala R 21 -6 -12 7.98
Amygdala L -18 -6 -15 7.73
Middle temporal gyrus R 54 30 21 6.21
HC S2 Middle frontal gyrus R 48 36 12 8.90
Fusiform gyrus R 39 -57 -18 7.90
Amygdala L -21 -12 -15 6.15
Amygdala R 21 -6 -15 5.78
Recoverers S1 Amygdala R 21 -9 -9 8.68
Amygdala L -21 -6 -12 8.13
Fusiform gyrus R 45 -48 -18 5.87
Recoverers S2 Fusiform gyrus R 42 -51 -18 7.22
Fusiform gyrus L -39 -51 -21 6.25
Amygdala L -18 -6 -12 7.00
Amygdala R 21 -6 -12 6.64
Non-recoverers S1 Fusiform gyrus R 42 -51 -21 7.49








Figure S1 Main effects of the faces task (“all faces vs. scrambled face”) in the different groups on the 
two different moments. Activation patterns were similar between groups and reproducible within groups 




Figure S2: Effect of Happy vs. scrambled in all three groups on both time moments (threshold p < .001 
uncorrected). The crosshair is set on x=-39 y=12 z=9, which was the peak voxel of the group by time 
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Abstract 
Major depressive disorder (MDD) has been associated with abnormal prefrontal-limbic 
interactions and altered catecholaminergic neurotransmission. The val158met 
polymorphism on the catechol-O-methyltransferase (COMT) gene has been shown to 
influence prefrontal cortex (PFC) activation during both emotional processing and working 
memory (WM). Although COMT-genotype is not directly associated with MDD, it may 
affect influence MDD pathology by altering PFC activation, an endophenotype associated 
with both COMT and MDD. 125 participants, including healthy controls (HC, n=28) and 
MDD patients were genotyped for the COMT val158met polymorphism and underwent 
functional magnetic resonance imaging during emotion processing (viewing of emotional 
facial expressions) and a WM task (visuospatial planning). Within HC, we observed a 
positive correlation between the number of met-alleles and right inferior frontal gyrus 
activation during emotional processing, whereas during WM a negative correlation between 
the number of met-alleles and middle frontal gyrus activation was present. Within patients, 
the number of met-alleles was not correlated with PFC activation during emotional 
processing, whereas during WM the effect of genotype on activation was comparable to 
HC. In addition, exploratory analyses showed a positive correlation between the number of 
met-alleles and activation in the ventral tegmental area and the hippocampus during 
emotion processing (overall). These results demonstrate that COMT genotype is associated 
with relevant endophenotypes for MDD. In addition, presence of MDD only interacts with 












Major depressive disorder (MDD) is a disorder characterized by abnormal interactions 
between cortical and subcortical structures (Mayberg, 1997; Hamilton et al., 2012) and 
altered catecholamine neurotransmission (Schildkraut, 1965; Dunlop et al., 2007). These 
disturbances affect both emotion processing (Hamilton et al., 2012) and executive 
functioning (Elliott et al., 1997), and MDD is characterized by abnormal prefrontal 
activation during tasks tapping into these functions (Johnstone et al., 2007; van Tol et al., 
2011; Hamilton et al., 2012; Elliott et al., 1997; van Wingen et al., 2011; Fitzgerald et al., 
2008b; Goethals et al., 2005; Matsuo et al., 2007; Wagner et al., 2006).  
Catecholaminergic neurotransmission plays a central role in emotional and 
cognitive processing and it has recently been hypothesized that abnormal dopamine levels 
in the striatum contribute to altered cortical-subcortical interactions in MDD (Hamilton et 
al., 2012). Catechol-O-methyltransferase (COMT) is an enzyme that breaks down 
catecholamines such as dopamine and norepinephrine, and is mainly present in prefrontal 
and temporal cortical areas (Hong et al., 1998; Matsumoto et al., 2003). A common 
polymorphism in the COMT-gene (i.e. rs4680, val158met; leading to an amino acid change 
of valine [val] to methionine [met]) results in altered COMT activity. Met-homozygotes 
have a three to four fold lower activity of COMT compared to val-homozygotes, with 
heterozygotes showing intermediate levels (Lachman et al., 1996). Consequentially, met-
carriers have higher cortical concentrations of dopamine (Tunbridge et al., 2006). COMT-
genotype variability has been postulated as an evolutionary switch toward a more cognitive 
versus a more emotional mental processing style (Stein et al., 2006).   
In a meta-analysis investigating the effects of val158met genotype on PFC 
activation it was shown that during emotional processing tasks the number of met-alleles 
correlated positively with PFC activation (Mier et al., 2010), located primarily in the 
inferior frontal gyrus (BA 45 and 47, Drabant et al., 2006; Smolka et al., 2005; Lelli-Chiesa 
et al., 2011). This finding was interpreted as less efficient processing in met-carriers (Mier 
et al., 2010). In contrast, during working memory tasks the number of met-alleles was 
negatively correlated with activation in the middle and superior frontal gyri (BA 9 and 46, 
Egan et al., 2001; Mattay et al., 2003; Bertolino et al., 2006a; Bertolino et al., 2008; de 
Frias et al., 2010) and IFG (Meyer-Lindenberg et al., 2006a; Bertolino et al., 2006b), 
implying less efficient processing in val-carriers in analogy with Mier et al. (2010).    
In MDD a direct association between affective disorders and val158met genotype 
has not been demonstrated (Lopez-Leon et al., 2008). We propose, however, that the 
association between val158met genotype and depression could be mediated by PFC 
activation as an endophenotype for MDD. Endophenotypes are often investigated in 




effects of val158met genotype on brain activation (Lelli-Chiesa et al., 2011; Domschke et 
al., 2008b). To date, however, such modulatory effects of MDD on association between 
val158met and regional brain activation has not been investigated.  
The main aim of this study was to investigate the interaction between val158met 
genotype and depression using PFC activation as endophenotype. For this purpose, we 
investigated whether the presence of MDD affected the opposing effects of genotype on 
PFC activation during emotional and working memory tasks previously observed in healthy 
subjects. We measured brain activation during a facial expression task and the “Tower of 
London” task, which is a visuospatial planning task known to activate a similar brain 
network as other working memory tasks (Welsh et al., 1999). Because of the variety in 
findings of PFC locations related to COMT-genotype (Mier et al., 2010), the entire lateral 
PFC was taken as our region of interest. In addition, we performed a whole-brain analysis 
to identify activations in other areas associated with val158met genotype.  
Materials and Methods  
Participants 
Participants were selected from the multicenter Netherlands Study of Depression and 
Anxiety (NESDA, Penninx et al., 2008) which involved the University Medical Center 
Groningen (UMCG), VU University Medical Center Amsterdam (VUmc) and Leiden 
University Medical Center (LUMC). This study was approved by the Ethical Review 
Boards of each participating center and all participants provided written informed consent. 
Exclusion criteria for all participants were presence or history of major internal and 
neurological disorder with potential central nervous system sequelae; current use of a beta-
blocker; hypertension >180/130 mm Hg; age over 57 years; MRI incompatible implants or 
tattoos; use of psychotropic medication other than selective serotonin reuptake inhibitors 
(SSRIs) or infrequent use of benzodiazepines (oxazepam or diazepam, maximum of three 
times a week and not within 48 hours before scanning); and incomplete MRI data and/or 
performance below change level on one of the tasks. A memory task was also used as an 
exclusion criterion, to confirm good cognitive functioning.  
Genotype data were obtained in addition to functional MRI data during emotional 
and working memory processing from 125 participants. Of these, 97 had experienced major 
depressive disorder (MDD) during their life as established using the Composite 
International Diagnostic Interview (CIDI, Andrews et al., 1998), and were therefore 
considered  to have the phenotype depression vulnerability whereas the other 28 were 






Genotyping was performed in the context of the genome wide association (GWA) study of 
the Genetic Association Information Network (GAIN), its method having been described in 
detail elsewhere (Sullivan et al., 2009). Perlegen Sciences (Mountain View, CA, USA) 
performed all genotyping according to standard operating procedures. High-density 
oligonucleotide arrays were used yielding 599,164 single nucleotide polymorphisms (SNP). 
These arrays included the val158met SNP (rs4680). In this sample, the genotype 
distribution of the rs4680 did not differ significantly from the expected numbers calculated 
on the basis of observed allele frequencies according to the Hardy-Weinberg equilibrium 
(HWE, χ²(1)=0.2, p>.65).  
 
Table 5.1 Demographic and clinical details 
Table 1a shows the demographic and clinical data divided by genotype. Table 1b shows the same data 




met/met met/val val/val test p
N 31 65 29
Gender #females (%) 22 (71.0) 38 (58.5) 19 (65.5) χ²(2)=1.50 .47
Age mean (SD) 34.19 (10.03) 38.43 (9.73) 37.62 (9.77) F(2,122)=1.99 .14
Education (in years) mean (SD) 13.32 (2.62) 12.66 (3.41) 12.21 (3.08) F(2,122)=0.96 .39
Diagnosis HC/MDD 11/20 10/55 7/22 χ²(2)=4.94 .08
MADRS mean (SD) 8.29 (7.71) 13.05 (10.49) 12.21 (10.49) F(2,122)=2.49 .09
BAI mean (SD) 9.16 (7.86) 11.38 (10.70) 12.10 (11.45) F(2,122)=0.71 .49
SSRI use N (%) 6 (19.4) 16 (24.6) 10 (34.5) χ²(2)=1.87 .39
Table 1b
HC patients test p
N 28 97
Genotype mm/mv/vv 11/10/7 20/55/22 χ²(2)=4.94 .08
Gender #females (%) 14 (50%) 65 (67%0 χ²(1)=2.70 .10
Age mean (SD) 40.93 (8.67) 36.11 (9.99) t(123)=2.31 0.02#
Education (in years) mean (SD) 14.79 (2.50) 12.12 (3.08) t(123)=4.19 <.001#
MADRS mean (SD) 1.25 (1.99) 14.68 (9.33) t(123)=7.55 <.001
BAI mean (SD) 2.14 (2.58) 13.56 (10.20) t(123)=5.85 <.001





Emotion processing: The paradigm used in this study was described before (Demenescu et 
al., 2011). Briefly, participants viewed photographs from a widely used set of emotional 
facial expressions (Lundqvist et al., 1998, angry, fearful, happy, neutral and sad) and were 
requested to make gender judgments. Twenty-four stimuli were selected for each of five 
facial expressions, comprising 12 female and 12 male faces. Each face was not presented 
more than four times. As control condition, a scrambled face with an arrow (“<<” or “>>”) 
was shown indicating which button to press. The control condition (scrambled faces) was 
presented 80 times. The pictures were shown for 2.5 seconds. Responses and reaction times 
were recorded.   
Working memory: The Tower of London (ToL) task was used to measure working memory 
(van Tol et al., 2011; van den Heuvel et al., 2003). On the screen two pictures were shown 
with colored balls on rods, representing two configurations, one start and one goal. In the 
task condition, participants had to work out the number of steps (ranging from one to five) 
needed to reach the target configuration. In the control condition, they were instructed to 
count the number of blue and yellow balls. We used a pseudorandomized, self-paced design 
with maximal response duration of 60 seconds for each trial. Responses and reaction times 
were recorded.  
Image acquisition 
All participants were scanned using a Philips 3T MR-scanner at the three different sites. A 
SENSE-8 -channel head coil was used for radio frequency transmission and reception in 
Groningen and Leiden. In Amsterdam a SENSE-6 channel head coil was used.  
For every participant, echo planar images (EPI) were obtained, entailing a T2*weighted 
gradient echo sequence using axial whole brain acquisition, with an interleaved slice 
acquisition order and the following settings: repetition time (TR) = 2300 ms, echo time 
(TE) = 28.0 at UMCG and 30 at AMC and LUMC, and a flip angle of 90°. At UMCG 39 
slices per EPI volume were acquired, with a matrix size of 64x64 voxels and an in-plane 
resolution of 3x3 mm. At AMC and LUMC 35 slices per EPI volume were acquired, with a 
matrix size of 96x96 voxels and an in-plane resolution of 2.29x2.29 mm. The slices had a 0 
mm gap and 3 mm thickness. The images were acquired parallel to the anterior-posterior 
commissure plane. In addition, a T1-weighted anatomical MRI was made (TR = 9 ms, TE = 






Demographic, clinical and behavioral data 
For the analysis of clinical and behavioral data SPSS version 16.0 was used. To test for 
genotype and presence of psychopathology effects on demographic data, Chi-square test or 
analysis of variance was used, whenever appropriate. To investigate an association between 
genotype and depression and anxiety symptoms, a multivariate analysis of variance 
(MANOVA) was performed with genotype as independent variable and MADRS and BAI-
scores as dependent variables.  
For behavioral data, repeated measures ANOVAs were used for reaction times 
(faces task and TOL) and accuracy (TOL) with emotional expression as a within-subject 
factor and presence of psychopathology and number of met-alleles as between-subject 
factors.  
Preprocessing of functional data 
Functional imaging data were preprocessed and analyzed using Statistical Parametric 
Mapping software (SPM5; http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 
7.1.0. (The MathWorks Inc., ) Preprocessing included slice time correction, image 
realignment, registration of the T1-scan to the mean EPI, warping to MNI-space as defined 
by the SPM5 T1-template, reslicing to 3×3×3 mm voxels and spatial smoothing using an 8-
mm FWHM Gaussian kernel. Movement of the participant of >3 mm in any direction 
resulted in exclusion of all data from further analysis.  
First-level analyses 
Emotion processing: For every participant, hemodynamic responses for each stimulus were 
modeled, including regressors for each condition (angry, fearful, happy, neutral and sad) 
and for baseline trials (scrambled faces). Low frequency noise was removed by applying a 
high pass filter of 128 s. For each participant, contrast images were produced for “negative 
vs. scrambled”, consisting of the expressions angry, fear and sad and “positive vs. 
scrambled”, including happy facial expressions.  
Working memory: For every participant, hemodynamic responses for each stimulus were 
modeled. The model included regressors for each number of steps and for baseline items. 
Again, low frequency noise was removed by applying a high pass filter of 128 s. For each 
participant, contrast images for “task load” [with trial types 1–5 having weights (-1.5, -1, -





Second level analyses 
We performed separate multiple regression analyses for each contrast (i.e. negative faces 
vs. scrambled, positive faces vs. scrambled, and ‘task load’ [ToL]). Comparable to previous 
studies (e.g. Smolka et al., 2005; Egan et al., 2001; Swart et al., 2011), gene-dose of COMT 
genotype was entered as regressor, coded as the number of met-alleles (0, 1 or 2). In 
addition, diagnosis was entered as factor, which was modeled in interaction with the 
regressor genotype. The main effect of diagnosis was not investigated in the present study, 
for which we refer to (van Tol et al., 2011; Demenescu et al., 2011). To control for 
potential confounding effects of gender on genotype, we added gender, center (two dummy 
variables), age, education (last two adjusted for the group mean) as covariates. A small 
volume correction was used for our regions of interest (ROIs). Based on the literature (see 
introduction), we chose the entire left and right lateral PFC (based on AAL library 
implemented in WFU pickatlas: superior frontal gyrus, middle frontal gyrus, inferior frontal 
gyrus, medial frontal gyrus, see also supplemental Figure S1) as our ROI (left and right 
separately).  
We tested for correlations between genotype and PFC activation independent of 
diagnosis and differences in these correlations between HC and patients, all within one 
model. For the main effect of genotype, a threshold was set at p < .05 family wise error 
(FWE) corrected for the spatial extent of the search volume of our ROIs. The interaction 
between genotype and diagnosis was inspected with an F-test at a threshold of p < .001. 
The post-hoc t-tests had to meet p < .05 FWE corrected for the spatial extent of the search 
volume of our ROIs. For completeness, we also report whole-brain analyses at a threshold 
of p < .05 family wise error (FWE) whole-brain corrected.  
 We extracted the first eigenvariate of the clusters as a measure of the strength of 
the brain activation per participant to visualize the data in a scatterplot.  
Results 
Demographic and Clinical data 
Genotype was not related to gender (χ²(2) = 1.50, p = .47), age (F(2, 122) = 1.99, p = .14) 
or education (F(2, 122) = 0.96, p = .34). The multivariate ANOVA did not reveal an 
association between genotype and MADRS and/or BAI-scores in the total sample (Pillai’s 
trace F(4, 244)=1.41, p=.23) or in patients only (Pillai’s trace F(4, 188) = 0.60, p = .66). There 
was also no significant association between genotype and diagnosis (χ²(6) = 7.12, p = .31) 





Emotional processing task 
Behavioral responses 
A main effect of emotional expression was present on reaction times (F(4, 114) = 5.55, p < 
.001): all participants were faster in responding to angry faces than to other emotional 
expressions. The number of met-alleles or presence of psychopathology or interactions 
between these variables did not affect RTs, also not in interaction with emotional 
expression (all F < 1.06, all p > .37).  
Neural responses 
There was no significant correlation between genotype and activation during processing of 
negative emotional expressions in the PFC in the overall sample. However, we observed an 
interaction between genotype and presence of MDD (Brodmann area [BA] 45, [x=39 y=33 
z=21], F(1, 117) = 15.65), reflecting a positive correlation between the number of met-
alleles and activation in the right inferior frontal gyrus (IFG) in HC (BA 45, Figure 5.1, Z = 
4.18, k = 15, pFWE = .034), which was absent in patients. In addition, the whole-brain 
analysis revealed a positive correlation with the number of met-alleles in the overall sample 
in the ventral tegmental area (VTA, Figure 5.2, [x=3 y=-15 z=-15], Z = 4.82, k = 20, pFWE = 
.023, whole brain corrected).  
During processing of positive emotional expressions, there were no significant 
correlations within the PFC in HC, MDD or over all participants. Our whole-brain analysis 
showed a positive correlation between the number of met-alleles and activation in the left 
hippocampus in all participants (Figure 5.2, [x=-33 y=-3 z=-21], Z = 4.67, k = 34, pFWE = 
.044, whole brain corrected).   
After excluding patients using SSRIs the results in the PFC were highly similar. 
The correlation in the hippocampus during positive emotional expressions was no longer 
significant in the overall sample, within HC it remained a trend (Z = 4.57, pFWE = .064). 
There were no significant correlations between number of met-alleles and brain activation 







Figure 5.1: Prefrontal cortical activity correlated with number of met-alleles during emotional and 
working memory processing: hypothesiss testing.  
Red represents a positive correlation between number of met-alleles during processing of negative 
emotional facial expressions only in HC. The graph depicting the correlation between activity and 
number of met-alleles is located on the left. Blue represents a negative correlation between number of 
met-alleles and activity during working memory over all subjects. The graph depicting the correlation 
between activity and number of met-alleles is located on the right. The threshold was set at p<.001 
uncorrected and the peak voxel had to survive p<.05 family wise error (FWE) corrected for the spatial 
extent of the PFC with a small volume correction (see methods). 
 
Working memory task 
Behavioral responses 
With increasing difficulty of the task (increase in number of steps), reaction times (RTs) 
became longer (F(1.71, 203.92) = 271.81, p < .001) and accuracy decreased (F(2.68, 
318.74) = 34.50, p < .001). There were no main effects of number of met-alleles or 
presence of psychopathology on RT or on accuracy nor in interaction with each other (all F 
< 1.21, p > .30) or in interaction with the number of steps (all F < 0.91, p > .40). 
Neural responses 
Over the whole sample, there was a significant negative association between number of 
met-alleles and right middle frontal gyrus (MFG, BA46/10) activation (Figure 5.1, [x=33 
y=48 z=12], k = 31, Z = 4.03, pFWE = .049). There was no significant correlation between 
genotype and PFC activation within HC or MDD separately. Also, no other areas appeared 
significant from the whole-brain analysis. Excluding medicated patients did not change 





Figure 5.2: Subcortical activations during emotional processing showing correlations with number of 
met-alleles: exploratory analysis.  
A.) positive correlation with the number of met-alleles was present with activity in the ventral tegmental 
area. B.) positive correlation between the number of met-alleles and activity in the left hippocampus.  




The aim of the current study was to investigate the influence of the val158met 
polymorphism in the gene coding for catechol-O-methyltransferase (COMT) on cortical 
functioning, and whether the presence of major depressive disorder (MDD) moderated 
these associations. Met-homozygotes have been associated with lower enzymatic activity of 
COMT compared to val-homozygotes (Lachman et al., 1996), with consequently higher 
cortical dopamine concentrations (Tunbridge et al., 2006). First, we replicated the finding 
of the meta-analysis by Mier et al. (2010) of an opposite effect of val158met genotype on 
PFC activation: in healthy participants the number of met-alleles was associated with 
increased activation during emotional processing, whereas during working memory it was 
associated with decreased activation. In patients with MDD, inferior frontal gyrus (IFG) 
activation during emotion processing was not affected by genotype, whereas during 
working memory patients showed similar genotype-related activation patterns of the middle 
frontal gyrus (MFG) as healthy participants. Thus, our results show a more extensive 
moderating effect of MDD on the relation between COMT genotype and PFC activation 




functioning, during emotional processing COMT genotype also influenced activation in 
subcortical structures, namely the ventral tegmental area (VTA) and hippocampus.  
A moderating effect was present of psychopathological status on the effect of 
val158met genotype on IFG (BA45) activation during processing of negative facial 
expressions. Within healthy participants the number of met-alleles was positively correlated 
with activation in the IFG, whereas within patients, there was no effect of val158met 
genotype in IFG activation. The IFG has been associated with emotional processing 
(Dolcos et al., 2004) and behavioral inhibition (van der Meer et al., 2011; Aron et al., 
2004). In addition, greater activation in this area has also been associated with inhibition of 
negative emotions (Johnstone et al., 2007; Dolcos et al., 2004; Ochsner et al., 2004). Our 
finding of more activation related to carrying the met/met-genotype in HC is in line with 
the suggestion that met/met-carriers are less emotionally stable than val/val-carriers (Stein 
et al., 2006), in that they have less efficient cortical functioning during implicit emotional 
processing. This might be associated with less efficient inhibition of emotional distraction 
due to negative facial expressions. Within patients, there was no effect of val158met 
genotype in IFG activation; the met/met-carriers showed a similar response as val/val-
carriers, but in general lower than HC. It could be suggested that the effects of depression 
on brain activation during emotional processing are greater than the effects of COMT-
genotype, obscuring any compensatory activation in depressed met/met-carriers as was 
found in healthy participants.  
Depression is primarily a disorder of emotion (Paykel, 2008). Therefore, it is an 
interesting finding that the interaction with psychopathology was only present during 
emotional processing. During working memory, there was less activation in the MFG 
related to the met-allele in both patients and healthy controls. The direction of this effect is 
in line with the meta-analysis of Mier et al. (2010) and suggests more efficient cortical 
processing in met/met-carriers during working memory. The lack of an interaction effect 
between psychopathology and genotype and brain activation was zorroborated by the 
absence of performance differences, indicating that WM was intact. In addition, the task 
was probably not too easy, given the increase in reaction times and decrease in accuracy 
with increasing planning load. Indeed, our findings are in agreement with other studies 
showing normal planning performance in MDD outpatients, suggesting relatively 
unaffected cognitive functioning (van Tol et al., 2011; Castaneda et al., 2008; Porter et al., 
2003; Purcell et al., 1997). Notably, impairments in working memory are particularly 
present in severely depressed patients (reviewed by Snyder, 2012; McDermott et al., 2009), 
whereas emotional processing is thought to be disturbed already before the onset of the first 
depressive episode (reviewed by Leppanen, 2006; Bistricky et al., 2011). This could 




moderated the effect of genotype only during emotional processing and not during working 
memory.  
 In addition to cortical areas, whole-brain analyses showed also an influence of 
COMT-genotype in subcortical areas. There was a positive correlation between the number 
of met-alleles and activation during processing of negative facial expressions in the ventral 
tegmental area (VTA), a brainstem area rich in dopaminergic neurons. COMT in itself has 
only mild effects in the VTA (Kastner et al., 1994), therefore altered VTA activation is 
likely related to an indirect effect of cortical projections to the VTA (Akil et al., 2003; 
Behan et al., 2012). The VTA (and dopaminergic transmission) has been shown to be 
involved in social interactions and motivation (Davey et al., 2010; Klein-Flugge et al., 
2011). Facial processing is a crucial part of social interactions. It has indeed been 
demonstrated that VTA activates during processing of human faces, especially to faces 
which are positive or from a beloved one (Xu et al., 2011; Acevedo et al., 2012; Oikawa et 
al., 2012). Because of the role of the VTA in motivating behavior and because this region 
has mostly been found responsive towards positive or rewarding stimuli, our association 
during processing of negative stimuli may seem surprising. However, the IFG also only 
showed an association during negative emotional processing; therefore it is interesting that 
the association in the VTA is also in response to negative associations. 
In addition, during processing of positive emotional facial expressions, there was a 
positive correlation between number of met-alleles and activity in the hippocampus. 
Besides the cortex, COMT is also strongly expressed in the hippocampal formation, 
especially the dentate gyrus (Matsumoto et al., 2003). Indeed, there are previous reports of 
positive correlations between number of met-alleles and hippocampal activity during 
memory processing (Bertolino et al., 2006; Krach et al., 2010; Di Giorgio et al., 2011) and 
also one report of a positive correlation between the number of met-alleles and activity in 
the left hippocampus during processing of unpleasant stimuli (Smolka et al., 2005). 
Although the hippocampus has primarily been associated with memory processing, it has 
also been associated with inhibition of stress responses (e.g. Radley et al., 2011) and 
emotion processing (Phelps, 2004). Our results indicate that COMT does not only influence 
functioning of the cortical structures, but a broader network of brain areas. It could be 
speculated that increased activation in these areas in met-carriers is associated with less 
emotional resilience, rendering carriers more vulnerable to affective disorders. 
A limitation of this study was the relatively small sample size, which does not 
allow for strong conclusions on genetic associations. Not with standing, we think our 
findings are of interest as this is the first study that replicates the meta-analysis results of 




genotype on PFC activation in one single sample. In addition, this is to our knowledge one 
of the first studies to suggest that this effect is moderated by psychopathology.   
To conclude, these results showed that the influence of COMT val158met 
genotype on prefrontal function is different in depressed patients compared to HC during 
emotional processing, but not during WM. This SNP thus appears to play a role in the 
etiology or expression of MDD or both with brain activation as a promising 
endophenotype. In addition, our study revealed that COMT-genotype  influenced activation 
during emotional processing in subcortico-limbic areas (VTA and hippocampus). It could 
be speculated that increased activation in these areas in met-carriers may contribute to less 
emotional resilience and render carriers more vulnerable to affective disorders.  
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Figure S1: Definition of regions of interest 
The left (red) and right (blue) prefrontal cortex were selected as our regions of interest based on the 
automatic atlas library regions: superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus, medial 









DISC1 genotype and affective psychopathology: a 
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The gene Disrupted-In-Schizophrenia-1 (DISC1) has been indicated as a determinant of 
psychopathology, including affective disorders, and has been shown to influence prefrontal 
cortex (PFC) and hippocampus functioning, regions of major interest for affective 
disorders. We aimed to investigate whether DISC1 modulates brain function and 
morphology relevant for affective disorders. 128 participants, with (n=103; 36 males; age 
18-57years) and without (controls; n=25; 13 males; age 23-54years) affective disorders 
underwent genotyping for Ser704Cys (with Cys-allele considered as risk-allele) and 
structural and functional (f) Magnetic Resonance Imaging (MRI) during visuospatial 
planning and emotional episodic memory tasks. For both voxel-based morphometry and 
fMRI analyses, we investigated the main effect of genotype and explored 
genotypeXdiagnosis interactions. Results are reported at pFWE <.05 corrected. Cys-carriers 
showed lower hippocampal activation during emotional recognition (Z=3.69), independent 
of psychopathology. Interactions of genotypeXdiagnosis were observed on hippocampal 
volume and PFC activation: Cys-carriers showed smaller bilateral parahippocampal volume 
compared with Ser-homozygotes only in controls (Z=4.09), but not in patients. 
Functionally, in controls, the Cys-allele was associated with less anterior cingulate cortex 
(ACC, Z=3.70) and dorsolateral PFC (Z=3.87) activation during visuospatial planning as a 
function of task load, a genotype effect that was reversed in anxiety patients in the ACC 
(Z=3.99), and absent in depressed patients. Results were independent of Leu607Phe 
genotype. We demonstrated that DISC1-genotype influences hippocampal structure and 
function during episodic memory performance and dorsal PFC during executive planning, 
predominantly in unaffected controls. Results suggest that presence of psychopathology 








The gene Disrupted-In-Schizophrenia-1 (DISC1) has been identified in a linkage-study as a 
determinant of schizophrenia and mood disorders (Millar et al., 2000; Blackwood et al., 
2001). This gene codes for a protein important for neural growth and synaptic modulation 
(Morris et al., 2003; Kamiya et al., 2006), and the single nucleotide polymorphisms (SNP) 
Ser704Cys on the DISC1-gene has indeed been demonstrated to influence neural growth 
(Kamiya et al., 2006).
 
The Cys-allele of this polymorphism has been associated with 
depression in a candidate gene study (Hashimoto et al., 2006), although genome wide 
associations studies failed to show this association (e.g. Sullivan et al., 2009; Wray et al., 
2012). However, genetic variations have been shown to be potent in explaining variance on 
a neurobiological level, an approach that might increase our understanding of the complex 
linkage of genetic variation and the endophenotype of affective disorders.  
DISC1-expression is highest in hippocampal regions and prefrontal cortex (PFC) 
(Porteous et al., 2006; Chubb et al., 2008), regions that have been linked with impairments 
during memory (e.g. Milne et al., 2011; Fairhall et al., 2010; Werner et al., 2009; Van Tol 
et al., 2012) and executive functioning (e.g. Fitzgerald et al., 2008b; Goethals et al., 2005) 
in affective disorders. Therefore, altered hippocampal and PFC function during these 
processes could be promising endophenotypes in studying the association between DISC1-
genotype and affective disorders. Supportive of this suggestion, the Cys-allele has been 
associated with less hippocampal activation during working memory and more 
hippocampal activation during episodic memory (Callicott et al., 2005), and with less 
activation of the dorsolateral prefrontal cortex (DLPFC) during both memory (Di Giorgio et 
al., 2008) and executive functioning (Prata et al., 2008) in healthy controls. Moreover, the 
hippocampus (Di Giorgio et al., 2008) and anterior cingulate cortex (ACC) (Hashimoto et 
al., 2006) were found to be lower in volume in Cys-carriers, whereas higher DLPFC 
volume has been observed (Brauns et al., 2011; Takahashi et al., 2009). Although 
inconsistencies in results have been reported, these observations suggest that Ser704Cys-
genotype is involved in functioning and structure of hippocampal, ACC and prefrontal 
regions. Whether presence of affective disorders moderates these genotype effects has not 
been studied to date. 
Recently, interest for the Leu607Phe, a second SNP on the DISC1-gene, has been 
growing. The Phe-allele of this SNP has been associated with cortical thinning in prefrontal 
regions (Raznahan et al., 2011) and lower grey-matter volume in the DLPFC and ACC 
(Szeszko et al., 2008), and hippocampal region (Cannon et al., 2005). Functionally, more 




et al., 2011). Therefore, this SNP may also influence relevant endophenotypes for affective 
disorders.  
The main objective of this study was to examine the role of DISC1-genotype 
(specifically on Ser704Cys) on endophenotypes relevant for affective disorders. The first 
aim of this study was to investigate the effects of Ser704Cys genotype on function and 
structure of the PFC and hippocampus. Additionally, we investigated the effects of the 
Leu607Phe SNP. We hypothesized that Cys-carriers on the Ser704Cys SNP will show 
smaller volume and less activation during tasks of visuospatial functioning and episodic 
memory of the PFC, ACC and hippocampal regions. Furthermore, we aimed to explore if 
presence of depression and/or anxiety influenced this association. For Leu607Phe, we 
hypothesized reduced grey matter volumes in the DLPFC and ACC and more activation in 
these regions in Phe-carriers. The distribution of the Leu704Phe SNP did not allow us to 
investigate interactions with psychopathology.  
Method 
Participants 
Participants were recruited from the large-scale longitudinal multi-site Netherlands Study 
of Depression and Anxiety (NESDA, Penninx et al., 2008). All participants were included 
on average two months after the initial NESDA measurement and provided written 
informed consent. The ethical review boards of each participating center (University 
Medical Center Groningen [UMCG], VU Medical Center [VUMC], and Leiden University 
Medical Center [LUMC]) gave approval for this study.  
Exclusion criteria for all participants for the MRI study were 1) presence or history 
of a neurological or somatic disorder with possible effects on the central nervous system, 2) 
general MRI contraindications, 3) dependence or recent abuse (past year) of alcohol or 
drugs, 4) hypertension and 5) use of other psychotropic medication than SSRIs or 
infrequent use of benzodiazepines (oxazepam or diazepam, maximum of three times a week 
and not within 48 hours before scanning). An additional exclusion criterion for the control 
group was a history of any DSM-IV axis-I disorder based on the Composite International 
Diagnostic Interview (CIDI) – lifetime version 2 (Robins et al., 1988). 
Diagnoses were defined based on half-year diagnosis assessed using the CIDI 
administered during an interview session. We included all genotyped participants who 
completed the full MRI-scanning protocol without technical problems and with sufficient 
task performance (see for criteria (van Tol et al., 2011; Van Tol et al., 2012)). For the 
analyses to Ser704Cys genotype, we included in total 128 participants: 25 controls, 38 




(SAD) and/or generalized anxiety disorder (GAD); ANX) and 37 patients with comorbid 
depression-anxiety (CAD). Groups were matched on age, education, and sex (Table 6.1A). 
Of these participants, it was not possible to genotype 17 of them for the Leu607Phe variant. 
Therefore, for these analyses we could include 111 participants (Table 6.1B). All 
participants were from Caucasian ancestry and participants were unrelated to each other.   
The effects of diagnosis on brain function during visuospatial planning (van Tol et 
al., 2011), episodic memory (Van Tol et al., 2012) and regional morphometry (van Tol et 
al., 2010) have been reported previously. 
Genotyping 
Genotyping was performed in the context of the genome wide association (GWA) study of 
the Genetic Association Information Network (GAIN, Sullivan et al., 2009). Perlegen 
Sciences (Mountain View, CA, USA) performed all genotyping according to standard 
operating procedures. High-density oligonucleotide arrays were used yielding 599,164 
SNPs. These arrays included the SNP rs821616 (Ser704Cys), a T to A base substitution, 
leading to a serine to cysteine substitution. The rs6675281 (Leu607Phe), a C to T base 
substitution, leading to a leucine to phenylalanine substitution, could be imputed with good 
quality. The imputation was performed by IMPUTE version 0.3.2 using the default settings 
and the recommended number 11418 for the effective population size of Caucasians 
(Marchini et al., 2007).  
For Ser704Cys, all the groups were in Hardy-Weinberg equilibrium (HWE, 
[Cys/Cys:Cys/Ser:Ser/Ser] controls 0:14:11 [χ²(1)=3.78, p=.05], MDD 1:19:18 [χ²(1)=2.38, 
p=.12], CAD 3:20:14 [χ²(1)=0.26, p=.26], ANX 2:14:12 [χ²(1)=0.60, p=.44]). Groups did 
not differ in genotype distribution (χ²=3.36, df=6, p=.76). We compared Cys-carriers 
(Cys/Cys- and Cys/Ser-genotypes) with Ser-homozygotes, based on the small amount of 
Cys-homozygotes and in agreement with the literature. (Hashimoto et al., 2006; Callicott et 
al., 2005; Di Giorgio et al., 2008; Prata et al., 2008; Brauns et al., 2011; Takahashi et al., 
2009).  
Also for Leu607Phe the groups were in HWE ([Leu/Leu:Leu/Phe:Phe/Phe] 
controls 19:2:0 [χ²(1)=0.05, p=0.82], MDD 23:8:1 [χ²(1)=0.09, p=0.76], CAD 23:9:0 
[χ²(1)=0.87, p=0.35], ANX 16:10:0 [χ²(1)=1.47, p=0.23]). Groups did not differ in 
genotype distribution (likelihood ratio=8.13, df=6, p=.23). We compared Phe-carriers 
(Phe/Phe- and Phe/Leu-genotypes) with Leu-homozygotes, based on the small amount of 
Phe-homozygotes and in agreement with the literature (Brauns et al., 2011; Raznahan et al., 






Table 6.1 Demographics and clinical variables 
The test-statistics are all statistics for the interaction effects of diagnosis with genotype (except for the 
statistic of the genotype distribution). Table A shows the demographics and clinical variables divided 
over Ser704Cys genotype and table B shows the demographics and clinical variables divided by 
Leu607Phe genotype. The diagnostic groups differed from each other on scores on Montgomery-
Åsberg Depression Rating Scale (MADRS, F(3, 118) = 24.16, p < .001) and Beck Anxiety Inventory 
(BAI, F(3,120) = 17.36, p < .001). MDD, CAD and ANX had higher scores on MADRS than controls, and 
CAD had higher scores than MDD and ANX. Both CAD and ANX showed higher BAI scores than MDD 
and controls, but did not differ from each other. 
 
* Post-hoc tests showed a different distribution of men between Ser/Ser and Cys within comorbid 
patients (Likelihood Ratio=4.65, df=1, p=.031) 
** A different distribution of medication use between Ser/Ser and Cys within ANX (Likelihood 
Ratio=6.10, df=1, p=.01)  
.  
  
Table A (test values are for the interaction of genotype and diagnosis)
test-value p
Ser/Ser Cys Ser/Ser Cys Ser/Ser Cys Ser/Ser Cys
11 14 18 20 12 16 14 23 χ²(3)=0.71 .87
5 (45.5) 8 (57.1) 10 (55.57) 5 (35) 2 (16.67) 6 (37.5) 2 (14.3) 11 (47.8) χ²(15)=27.58 .02*
40.00 (9.17) 37.93 (9.11) 37.00 (10.23) 36.30 (9.98) 34.33 (8.54) 35.62 (7.50) 33.71 (11.73) 37.22 (11.53) F(3, 120)=0.36 .78
14.18 (2.36) 14.07 (2.23) 13.44 (2.55) 12.75 (3.11) 12.00 (2.99) 12.81 (3.21) 13.07 (2.79) 12.13 (2.72) F(3, 120)=0.59 .62
Social Phobia - - - - 9 15 6 13
Panic Disorder - - - - 8 8 7 17
General Anxiety Disorder - - - - 1 5 8 10
0.73 (1.68) 1.00 (1.52) 12.06 (7.65) 12.37 (9.28) 15.75 (9.28) 11.19 (7.74) 15.64 (8.07 18.91 (7.96) F(3, 118)=1.40 0.25
2.27 (2.90) 2.43 (3.03) 2.89 (17.18) 7.85 (5.21) 16.17 (10.83) 15.31 (11.46) 17.36 (8.83) 18.96 (10.63) F(3, 120)=0.51 0.67
- - 5 5 1 8 6 13 χ²(15)=83.24 <0.001**
Table B (test values are all for main effect of genotype)
test-value p
Leu/Leu Phe Leu/Leu Phe Leu/Leu Phe Leu/Leu Phe
19 2 23 9 16 10 23 9
8 (72.7) 2 (100.0) 8 (34.8) 2 (22.2) 4 (25.0) 4 (40.0) 7 (30.4) 2 (22.2) χ²(1)=0.0 1
38.90 (9.55) 41.00 (16.97) 39.22 (8.95) 31.89 (10.53) 35.81 (8.39) 32.80 (7.22) 35.39 (11.56) 38.33 (13.41) t(109)=1.23 0.22
14.32 (2.21) 12.00 (4.24) 13.04 (3.13) 14.00 (2.5) 13.19 (3.08) 11.70 (3.2) 12.83 (2.84) 11.33 (2.65) t(109)=1.64 0.1
Social Phobia - - - - 14 9 13 3
Panic Disorder - - - - 10 4 15 7
General Anxiety Disorder - - - - 2 3 12 4
0.42 (1.22) 1.50 (2.12) 11.59 (7.72) 12.89 (11.11) 14.44 (7.53) 9.80 (6.97) 17.61 (9.43) 16.11 (3.76) t(109)=1.28 0.2
2.00 (2.71) 2.50 (3.54) 7.13 (4.92) 8.11 (5.47) 14.56 (10.41) 16.50 (10.67) 19.61 (10.12) 18.67 (9.31) t(109)=0.42 0.68
























Image acquisition parameters 
All participants were scanned using a Philips 3T MR-scanner located at each site. A 
SENSE-8 channel head coil was used for radio frequency transmission and reception in 
Groningen and Leiden. In Amsterdam, a SENSE-6 channel head coil was used. For each 
subject, a series of echo planar imaging (EPI) volumes were obtained, entailing a 
T2*weighted gradient echo sequence using axial whole brain acquisition, with an 
interleaved slice acquisition order and with the following settings for Groningen: repetition 
time (TR) =2300 ms; echo time (TE) = 28.0 ms; flip angle of 90°; 39 slices per EPI 
volume; matrix size: 64x64; in-plane resolution of 3x3 mm; slice thickness 3mm and no 
gap. In Amsterdam and Leiden the following settings were used: TE 30ms; 35 slices; 
matrix size: 96x96 voxels; in-plane resolution: 2.29x2.29 mm slice thickness. All images 
were acquired parallel to the anterior-posterior commissure plane. In addition, a T1-
weighted anatomical MRI was made (TR=9 ms, TE=3.5 ms, matrix size 256x256, voxel 
size: 1x1x1 mm, 170 slices).  
Task paradigms 
Memory processing: The task (for a full description see (Van Tol et al., 2012; Daselaar et 
al., 2003)) consisted of an implicit word encoding- and recognition phase. During the 
encoding phase, participants were asked to classify negative, positive and neutral words (40 
each) according to their valence (button press). In addition, 40 baseline trials were 
presented, which consisted of the words “left”, “middle” or “right” (in Dutch), indicating 
which button to press. Words were presented pseudo-randomized.  
After a retention interval of ten minutes, old encoding target words (120), new distracter 
words (120; matched on valence) and 40 baselines were presented pseudo-randomized and 
participants had to indicate whether they had seen the words previously, probably had seen 
it, or had not seen it before. The task was self-paced, but with a maximum presentation 
duration of five seconds. 
Tower of London: The Tower of London (ToL) task involves visuospatial 
planning with varying levels of difficulty that relies on the fronto-parietal executive system 
(Welsh et al., 1999). The task was designed as described by (van Tol et al., 2011; van den 
Heuvel et al., 2003). On the screen two pictures were shown with colored balls on rods, 
representing two configurations, one start and one goal (Figure 6.1). In the task condition, 
participants had to count the number of steps (ranging from one to five) needed to reach the 
goal configuration. In the control condition, instructions were to work out the number of 
blue and yellow balls. We used a pseudo-randomized, self-paced design with maximal 
presentation duration of 60 seconds for each trial.  





Figure 6.1 Tower of London task and genotype effects on response times.  
A.) On the screen two pictures were shown with colored balls on rods, representing two configurations, 
one starting configuration and one goal configuration. Participants had to count the number of steps 
(ranging from one to five) needed to reach the target configuration. We used a pseudorandomized, self-
paced design with maximal response duration of 60 seconds for each trial. Accuracy and response 
times (RTs) were measured.  
B.) A genotype by task difficulty effect was observed on RTs (F(1.7,198.4)=3.76, p=.03): Ser-
homozygotes had a significantly slower response for the five-step condition (t(126)=1.85, p=.03). Error 




Clinical, demographic and behavioral data 
Group effects on clinical, demographic, and behavioral data were analyzed using SPSS 
(version 16.0, SPSS Inc., Chicago, IL, USA). Chi-Square tests and analyses of variance 
(ANOVA) were used to analyze group differences. 
For the memory task, the proportion correct recognitions and proportion false 
alarms were analyzed with repeated-measures ANOVA with valence as within-subject 
variable and diagnosis and genotype as between-subject variables. Age and education were 
entered as covariates of no interest. This was repeated for the RTs during encoding on the 
subsequently remembered trials and the RTs to correctly recognized words during 
recognition.  
For the ToL, accuracy and RTs were analyzed by means of separate repeated-




dependent factors, and psychopathology and genotype as between-subject factors. Age and 
education were entered as covariates.  
Preprocessing and models for functional imaging  
Functional imaging data were preprocessed and analyzed using Statistical Parametric 
Mapping software (SPM5; http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 7.1.0 (The 
MathWorks Inc., ). Preprocessing included slice time correction, image realignment, 
registration of the T1-scan to the mean EPI, warping to MNI-space as defined by the T1-
template, reslicing to 3×3×3 mm voxels and spatial smoothing using an 8-mm Full Width at 
Half Maximum (FWHM) Gaussian kernel.  
For the memory task, analysis of the encoding phase was restricted to correctly 
recognized words in the subsequent recognition phase (successfully encoded words). 
Contrasts were made for ‘encoding_positive > encoding_neutral’ and ‘encoding_negative > 
encoding_neutral’. Also for the recognition phase analyses were restricted to correct trials 
and the contrasts ‘recognition_positive > recognition_neutral’, and ‘recognition_negative > 
recognition_neutral’, were calculated following the summary statistics approach. Low-
frequency noise was removed by applying a high-pass filter (cut-off of 128s) to the fMRI 
time series at each voxel. Modeling details are described elsewhere (Van Tol et al., 2012). 
On second level, for Ser704Cys, a 2 (genotype) by 4 (diagnosis) by 2 (valence) ANOVA 
was built for the encoding and recognition part separately. For Leu607Phe, we set up a 2 
(genotype) x 2 (valence) ANOVA with valence as within-subject variable.  
For the ToL task, regressors were constructed by convolving each event-related 
stimulus function (baseline, 1–5 step trials) with a canonical hemodynamic response 
function and modulated using RTs. In addition, error and no-response trials were included 
as a regressor of no interest. Again, low-frequency noise was removed by applying a high-
pass filter (cut-off of 128s) to the fMRI time series at each voxel. Contrast images for “task 
load” (with trial types 1–5 having weights [−1.5 −1 −0.5 1 2]) were calculated per subject 
on a voxel-by-voxel basis. On second level, for Ser704Cys a 2 (genotype) by 4 (diagnosis) 
ANOVA was built. For Leu607Phe, we set up a 1x2 ANOVA with genotype as 
independent factor. 
Preprocessing and model for Structural imaging 
Structural data were analyzed using voxel-based morphometry (VBM), following 
diffeomorphic anatomical registration through exponentiated lie algebra (DARTEL, 
Ashburner, 2007) using SPM5 software. Preprocessing of VBM-DARTEL on these data 
was described previously (van Tol et al., 2010). Briefly, we applied the DARTEL approach 




reoriented T1-images and smoothed the resulting grey matter (GM) images using an 8-mm 
FWHM Gaussian kernel.  
For Ser704Cys, a 2 (genotype) by 4 (diagnosis) ANOVA was built with total GM 
volume as covariate. Voxel-wise comparisons were masked with a comparison-specific 
explicit optimal threshold GM mask created using the Masking toolbox (Ridgway et al., 
2009). For Leu607Phe, we set up a 1x2 ANOVA with genotype as independent factor.  
Regions of interest and statistical thresholds 
Based on literature (see introduction) regarding executive and memory function in affective 
disorders and effects of DISC1 on neural processing, we selected the following regions of 
interest (ROIs): anterior cingulate cortex (ACC; BA 32 and 24), DLPFC (BA 9 and 46), 
hippocampus and parahippocampal gyrus (PHG) based on the anatomical automatic 
labeling (AAL) library (Maldjian et al., 2003) implemented in the Wake Forest University 
(WFU) pickatlas (http://fmri.wfubmc.edu/cms/software). These labels were used to 
construct ROIs, which were applied as masks for the small volume corrections. 
For all models, main effect of genotype are reported at p < .05, family wise error 
(FWE) corrected for the spatial extent of the ROI at the voxel level, with an initial voxel-
wise threshold of Z > 3.09 (equivalent to p < .001 uncorrected).  
For the Ser704Cys SNP, we explored interactions between genotype and 
diagnosis. This was done by performing an F-test to investigate the presence of a possible 
interaction, at a whole-brain threshold of p < .001, uncorrected. Post-hoc t-tests were used 
to investigate the direction of the significant interaction effects. Notably, for post-hoc t-tests 
to genotype-related effects within the diagnostic groups a strict threshold was chosen of p < 
.05 FWE voxel-wise corrected for the spatial extent of the ROI, with the initial voxel-wise 
height threshold set at Z > 3.09. We did not investigate interactions between genotype and 
diagnosis for the SNP Leu607Phe, because of the small sample size in some of the cells.   
Effects occurring outside of our predefined ROIs had to meet p < .05 FWE whole 







Demographic and clinical data are summarized in Table 6.1. Groups did not differ on 
genotype distribution, and no effect of genotype, diagnosis or genotype by diagnosis effect 
was observed on any of the demographic variables (all p > .05), except for SSRI use. For 
Ser704Cys, there was a genotype by diagnosis interaction on SSRI use within the patients 
groups (χ²(2) = 24.06, p = .01); within ANX fewer Ser-homozygote patients used 
medication than Cys-carriers (Table 6.1A)
 I
. 
Structural data: grey matter volumes 
No main effect of genotype was found on regional GM. However, interactions of genotype 
and diagnosis were observed in the ACC, bilateral DLPFC, bilateral PHG/hippocampus 
(Figure 2). Post hoc t-tests showed smaller bilateral PHG/hippocampus volume within 
controls for Cys-carriers compared to Ser-homozygotes (see Table 6.2 for statistics). Within 
ANX this pattern was reversed: Cys-carriers showed enlarged left (para)hippocampal 
volume. In MDD and CAD, there was no effect of genotype on hippocampal volumes.  
Within ANX, Cys-carriers had larger volumes in the rostral and dorsal part of the 
ACC and bilateral DLPFC compared to Ser-homozygotes, while genotype effects were 
absent in the other groups. Effects were unaffected by age, sex, education, scanning center, 
medication use or depression/anxiety severity.  
For Leu607Phe, Phe-carriers showed larger grey matter volumes of the DLPFC 
than Leu-homozygotes (Figure 6.2). 
 
Figure 6.2 Effects of Leu704Phe genotype on volume of the right dorsolateral prefrontal cortex. 
Phe-carriers showed larger volumes of the DLPFC than Leu-homozygotes (MNI coordinates [x=23 y=59 
z=31], t = 4.49, pFWE = .007). 
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 There was only one anxiety patient carrying Ser-homozygote genotype that used 






Effect of genotype on performance 
For Ser704Cys, neither genotype nor genotype by diagnosis interaction affected recognition 
accuracy (all F < 1.22, p > .27) or RTs (All F < 3.09, p > .08). Also Leu607Phe genotype 
did not affect recognition accuracy (F(1.7, 186.8) = 1.99, p = .16) or RT (F(1.9, 205.08) = 
1.59, p = .21). 
Effects of genotype on brain activation 
No main effect of genotype was observed during emotional memory encoding. However, a 
three-way interaction of genotype by diagnosis by valence was observed: Cys-carriers 
showed increased bilateral hippocampal activation compared with Ser-homozygotes only 
within ANX patients during encoding of positive words. No such effects were observed 
during encoding of negative words, nor in the other groups.  
During recognition, a main effect of genotype was observed on hippocampal 
activation: Cys-carriers showed decreased left hippocampal activation during recognition 
(Table 6.2). No interaction of genotype x valence or diagnosis x genotype x diagnosis 
occurred during recognition.  
Effects were unaffected age, sex, education, scanning center, medication use, 
depression/anxiety severity, or hippocampal volume.  
 There were no effects on brain activation during either encoding or recognition 
related to Leu607Phe.   
Spatial working memory: Tower of London 
Effect on performance 
For Ser704Cys, a genotype by task load effect was observed on RTs (see for statistics 
figure 1): Ser-homozygotes had a significantly slower response for the five-step condition. 
Overall, no effect of diagnosis or interaction of genotype and diagnosis was present on RTs 
(F < .73, p > .54). No effects of genotype, diagnosis, or interaction between genotype and 
diagnosis were observed on planning accuracy (F < 1.43, p > .44).  
 For Leu607Phe, there was no genotype x task load effect on RT (F(1.7, 183.7) = 





Effect of genotype on brain activation 
No significant main effect of genotype on brain activation during visuospatial planning was 
observed, but an interaction between diagnosis and genotype was present in the ACC and 
bilateral DLPFC. Post-hoc plotting and t-tests revealed that within right dorsal ACC, Cys-
carriers without psychopathology demonstrated less activation than Ser-homozygotes 
(Table 6.2, Figure 6.3), whereas within ANX the opposite pattern was observed (i.e. Cys-
carriers had greater activation than Ser-homozygotes) and no effect of genotype was 
observed in MDD and CAD patients. In the right DLPFC, Cys-carriers had less activation 
than Ser-homozygotes only in controls and not in patient groups, whereas in the left 
DLPFC this pattern was observed in CAD only (i.e. Cys < Ser) and not in controls, MDD, 
and ANX. Effects were unaffected by age, sex, education, scanning center, medication use, 
depression/anxiety severity, ACC and DLPFC volumes or RTs.  






Table 6.2 Genotype effects of Ser704Cys on structural and functional data in our regions-of interest.  
The post-hoc results are shown in this table. Results were regarded significant at p<.05 FWE corrected 
for the spatial extent for the region of interest.  
For the structural data, there was no main effect of genotype on total grey matter (GM) volume 
(F(1,117) = 0.13, p = .72) observed, but a genotype by diagnosis interaction was present for total GM 
volume (F(3,117) = 3.58, p = .02), corrected for age, sex and medication. Post-hoc t-tests showed that 
only within ANX, Cys-carriers had higher total GM volume compared to Ser-homozygotes (t = 2.77, p = 
.01), whereas no effect of genotype was observed within controls, MDD, or CAD. For the analysis on 
regional GM we took into account that genotype subgroups differed on this variable by subtracting the 
mean GM total volume of the subgroup.  
The results for the memory encoding were specific for positive words (pos). The results for memory 
recognition were independent of diagnostic group or word valence.  




The number of voxels of the entire clusters at p<.001 uncorrected. 
2
The p-value of the peak voxel of the cluster.  
  




Parahippocampal gyrus/hippocampus R controls: Ser/Ser > Cys 26 -1 -31 386 4.25 .007
Parahippocampal gyrus/hippocampus L controls: Ser/Ser > Cys -29 -4 18 226 3.91 .029
Parahippocampal gyrus/hippocampus L ANX: Cys > Ser/Ser -23 -26 -24 648 4.17 .015
Anterior Cingulate Cortex (rostral) L ANX: Cys > Ser/Ser -11 51 -3 370 5.42 <.001
Anterior Cingulate Cortex (dorsal) R ANX: Cys > Ser/Ser 7 6 37 273 4.07 .018
Dorsolateral Prefrontal Cortex R ANX: Cys > Ser/Ser 44 43 31 124 4.51 .006
Dorsolateral Prefrontal Cortex L ANX: Cys > Ser/Ser -41 25 33 162 4.05 .031
Memory Encoding
Hippocampus R ANX: Cys > Ser/Ser (pos) 24 -39 3 18 4.19 .012
Hippocampus L ANX: Cys > Ser/Ser (pos) -15 -33 9 43 4.20 .011
Memory Retrieval
Hippocampus L ALL: Ser/Ser > Cys -30 -39 -9 7 3.75 .047
Tower of London
Anterior Cingulate Cortex (dorsal) R controls: Ser/Ser > Cys 6 21 39 16 3.81 .042
Anterior Cingulate Cortex (dorsal) L ANX: Cys > Ser/Ser -3 24 39 45 4.13 .015
Dorsolateral Prefrontal Cortex R controls: Ser/Ser > Cys 33 42 30 20 4.00 .036





Figure 6.3. Effects of Ser704Cys genotype on brain volume (A) and function during ToL (B,C) within 
healthy participants.  
A.) Increased parahippocampal volume in Ser-homozygotes compared to Cys-carriers. B.) Increased 
anterior cingulate cortex activation in Ser-homozygotes. C.) Increased dorsolateral prefrontal cortex 







In this study, we examined the effects of DISC1-genotype on function and structure of 
hippocampal formation, anterior cingulate cortex (ACC) and dorsal lateral prefrontal cortex 
(DLPFC) in a single sample, consisting of participants with and without current affective 
psychopathology. Consistent with the literature, we found a main effect of genotype in the 
hippocampus during memory recognition: the Cys-allele of the Ser704Cys polymorphism 
showed less hippocampal activation than Ser-homozygotes. In addition, in non-affected 
control participants we found a Ser704Cys influence on hippocampal and PFC morphology 
and activation during executive functioning: the Cys-allele was associated with decreased 
volume and activation of the hippocampus, dorsal ACC, and dorsal PFC during episodic 
memory and executive functioning. These effects were absent in patients. To our 
knowledge, this is the first study that investigated effects of DISC1-genotype on structure 
and function during both memory and executive functioning, which have both been 
associated with abnormalities in depression and anxiety disorders.  
Irrespective of psychopathology, Cys-carriers showed less hippocampal activation 
during recognition of emotional information without an effect of genotype on recognition 
accuracy or response times, suggesting that the differences in activation are not related to 
differences in performance. The direction of genotype difference in hippocampal activation 
during episodic memory is in agreement with (Di Giorgio et al., 2008), although more 
hippocampal activation in Cys-carriers has also been described (Callicott et al., 2005). 
Discrepancies in findings may be related to the fact that groups within our sample and the 
converging study of Di Giorgio et al. (2008) were matched on years of education, whereas 
Callicott et al. (2005) failed to do so. Less hippocampal activation during memory 
processing has been associated with depression (e.g. Milne et al., 2011; Fairhall et al., 
2010; Van Tol et al., 2012). Previous studies of DISC1-mutant mice showed decreased 
neurogenesis, neuronal migration and showing depressive- and anxiety-like behavior 
(Clapcote et al., 2007; Haque et al., 2012; Lee et al., 2011). Therefore, it could be suggested 
that DISC1-genotype might predispose to affective disorders via hippocampal activation.  
During encoding of emotional information, executive functioning and on structural 
differences, there were interactions between genotype and diagnosis were observed. For 
most of these interaction effects, the genotype effects were in agreement with the literature 
in healthy participants, whereas the effect of genotype was abolished in patients. On brain 
volume, we demonstrated, in agreement with a previous report (Di Giorgio et al., 2008), 
that healthy Cys-carriers had smaller parahippocampal gyrus (PHG) volume than healthy 
Ser-carriers. The PHG has an important role in episodic memory (de Curtis et al., 2004; 
Eichenbaum et al., 2007). Additionally, the PHG, together with the hippocampus and the 




2001) and visuospatial information (de Curtis et al., 2004). This Ser704Cys-related 
difference in PHG volume may affect memory, visuospatial and emotion processing 
abilities, at least within healthy people. Notably, smaller PHG volumes have been found in 
anxiety disorders (Massana et al., 2003; Liao et al., 2011) and depression (Abe et al., 2010; 
Kempton et al., 2011). It has been proposed that volume reductions of hippocampal areas in 
depression are related to stress and related glucocorticoid levels (Bremner, 2006; Lee et al., 
2002; Tata et al., 2010). Based on our results, it could be propose that reduced PHG volume 
related to carrying the Cys-allele might also predispose to vulnerability for these disorders.  
During visuospatial planning, healthy Cys-carriers showed less activation in the 
ACC and DLPFC with increasing planning load compared to healthy Ser-homozygotes. 
Less PFC activation in Cys-carriers has been shown for other executive processes as well 
(Prata et al., 2008), but this is the first study that showed genotype-related variation in PFC 
activation during visuospatial planning. Decreased functionality of the PFC has been 
suggested to lead to a reduction in control over the emotional state and less flexibility in 
diverging attention (Phillips et al., 2003b), which may increase vulnerability for developing 
an affective disorder. Indeed, affective disorders have been associated with less DLPFC 
activation during executive functioning (Elliott et al., 1997; Goethals et al., 2005), although 
not consistently (van Tol et al., 2011; Fitzgerald et al., 2008b). 
A noteworthy finding in our study was that presence of an affective disorder 
moderated the effect of Ser704Cys on brain structure and function. Previous neuroimaging 
studies have also shown moderating effects of psychiatric diagnoses on the influence of 
genotype on the brain (Mechelli et al., 2008; Prata et al., 2009; Prata et al., 2011), that 
could be related to additional factors influencing brain physiology. One possible factor 
could be SSRI use. However, previous studies by our group have shown no effects of SSRI 
use in this sample on brain morphology or activation during visuospatial or memory 
processing (van Tol et al., 2011; van Tol et al., 2012; van Tol et al., 2010). Moreover, 
evidence from animal studies has shown that SSRI use might only affect neurogenesis in 
youth, not in adulthood or old age (Couillard-Despres et al., 2009; Navailles et al., 2008). In 
addition, we controlled for SSRI use in the current analyses. However, other factors related 
to affective psychopathology influencing brain physiology could have led to the moderating 
effects such as other genes (like brain-derived neurotrophic factor [BDNF], Molendijk et 
al., 2012), depressive state (van Tol et al., 2011), or epigenetic influences (Mechelli et al., 
2008). A recent animal study has shown that DISC1-mutations are leading to anxiety-like 
behavior only in the context of stress (Haque et al., 2012), which could suggest epigenetic 
influences. Moreover, for other genes it has also been demonstrated in humans that 




(Dempster et al., 2011; Fuchikami et al., 2011). Future research should test this hypothesis 
for the DISC1 gene.  
Besides Ser704Cys, we also showed an influence of the Leu607Phe SNP on brain 
volume: Phe-carriers had larger right DLPFC volumes compared to Leu-homozygotes. This 
is in contrast to previous findings of reduced DLPFC volume (Szeszko et al., 2008). 
However, besides healthy participants, the sample of Szeszko et al. (2008) consisted of 
schizophrenia patients (total n=44), whereas ours consisted of patients with affective 
disorders (total n=111). Therefore, to draw conclusions on the effect of this SNP on grey 
matter volume, future studies should focus on the effects in healthy people first. 
Unfortunately, our sample was too small to investigate this.   
This is to our knowledge the first study investigating the effect of DISC1 on brain 
activation in participants both with and without affective psychopathology. Despite this 
strength, some limitations have to be taken into account. First, the subgroups had a 
relatively small sample size, although with expected genotype proportions. We chose to 
only include participants who completed both tasks and had high-quality structural data in 
order to end up with the same sample for the three analyses. This approach was chosen to 
allow proper comparisons of genetic findings between the different tasks and to exclude the 
possible differences attributed to a different sample. The relatively small sample size could 
have influenced the unexpectedly large genotype differences in the anxiety group on 
regional volume differences. Therefore, caution must be taken in interpreting these results. 
However, the findings of genotype effect within controls were very consistent, which 
bolster confidence that reliable conclusions regarding a differential genotype effect related 
to diagnosis can be reached. In addition, there were many variables in our sample that could 
have been confounding factors (e.g. medication use, scanner site). For all effects, we have 
tested for a possible influence of these confounding factors. Despite not finding any 
influence of these possible confounders, such effects cannot be fully discarded due to our 
limited sample size. Finally, additional studies in other samples are necessary to replicate 
current findings. In genetic studies, it is common to have a replication sample. In 
neuroimaging genetics studies, this is not yet a common procedure, mostly because of the 
costs. However, additional studies are necessary to confirm our findings.  
In conclusion, we show that DISC1 moderates activation and structure in 
paralimbic structures crucial for emotional encoding and in dorsal frontal structures crucial 
for executive functioning, partially dependent on affective psychopathology. Our results 
indicate the Cys-allele of the Ser704Cys SNP influences endophenotypes relevant for 
affective disorders, although overt psychopathology may abolish this influence. Replication 
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Abstract 
Neuropeptide Y (NPY) has been associated with stress reactivity in affective disorders and 
is most densely expressed in the amygdala. An important stressor associated with affective 
disorders is the experience of childhood emotional maltreatment (CEM). We investigated 
whether the interaction of NPY risk-genotype and CEM would affect brain activation. From 
the Netherlands Study of Depression and Anxiety (NESDA) 33 healthy controls (HC) and 
85 patients with affective disorders were scanned with functional MRI while making 
gender decisions of emotional facial expressions. Results showed interactions between 
genotype and CEM: within carriers of the risk-genotype, CEM was associated with higher 
amygdala activation, whereas CEM did not influence activation in non-risk carriers. In the 
posterior cingulate cortex (PCC), less activation was seen in those with CEM and the risk-
genotype, whereas genotype did not influence PCC activation in those without CEM. In 
addition, those carrying the risk-genotype and with experienced of CEM made a faster 
gender decision than those without CEM. Thus, the combined effect of carrying NPY risk-
genotype and a history of CEM affected amygdala and PCC reactivity, areas related to 
emotion, self-relevance processing and autobiographical memory. These results are 










Depression and anxiety disorders are thought to result from maladaptive changes in the 
stress-response system (Holsboer, 2000). Under conditions of stress, one of many peptides 
which are released is neuropeptide Y (NPY, Thorsell et al., 1999). Increased NPY 
expression is hypothesized to accompany successful behavioral adaptation to stress and 
may be protective against developing depression or anxiety symptoms (Heilig et al., 2004). 
This hypothesis is supported by the finding that NPY expression inhibits the release of 
stress-related hormones, such as adrenocorticotrophic hormone (ACTH) and cortisol 
(Antonijevic et al., 2000). In addition, animal studies have shown that genetically 
determined low NPY levels are associated with an anxiety-related phenotype during 
stressful manipulations (Thorsell et al., 2000), which implies a moderating relationship 
between NPY-genotype and experienced stress on affective symptomatology.  
In the human gene coding for NPY, the C-allele of the polymorphism rs16147 has 
been associated with reduced NPY-gene expression in the brain (Sommer et al., 2010; Zhou 
et al., 2008). Given the evidence from animal studies, the C-allele is likely to predispose to 
a maladaptive stress response. The C/C-genotype has indeed been related to depression 
(Heilig, 2004; Mickey et al., 2011) and increased trait anxiety (Zhou et al., 2008). However, 
other evidence has shown that the association between genotype and depression and anxiety 
was found only in those C/C-carriers who had also experienced adverse life events 
(Sommer et al., 2010).  
Among stressful life-events, childhood emotional maltreatment (CEM) can be 
considered to be the strongest predictor for developing depressive and anxiety disorders 
(Hovens et al., 2010; Spinhoven et al., 2010), even more potent than sexual and/or physical 
abuse (Gibb et al., 2007). This is likely related to the finding that CEM is strongly related to 
disruptive cognitive styles (e.g. dysfunctional self-attitudes and rumination, Alloy et al., 
2006; Gibb, 2002). For example, experienced CEM has been associated with increased 
automatic negative self-associations (van Harmelen et al., 2010). In animals, adverse 
rearing environments such as maternal separation, loss, or isolation rearing induce changes 
at the level of gene expression, hypothalamic-pituitary-adrenal axis functioning, brain 
morphology and cognitive functioning (Sanchez et al., 2001). Notably, maternal separation 
has also been shown to reduce NPY levels in animal studies (Husum et al., 2002; Jimenez-
Vasquez et al., 2001). Therefore, it could be hypothesized that low NPY-expression coded 
by the C/C-genotype, may interact with the experience of CEM in affecting susceptibility 
for depressive and anxiety disorders.  
In the brain, the highest levels of NPY-gene expression have been found in the 




observed in other regions (e.g. anterior cingulate cortex, hippocampus) (Sommer et al., 
2010; Redrobe et al., 1999). The amygdala is a key region for identifying the emotional 
significance of stimuli (Phillips et al., 2003a) and in the reaction to stress (van Marle et al., 
2009). Amygdala function has been extensively investigated in association with affective 
disorders, but with conflicting results. Most studies have shown increased amygdala 
activation in response to emotional stimuli in depressed patients (Victor et al., 2010; 
Matthews et al., 2008; Peluso et al., 2009; Townsend et al., 2010),  but many reported no 
difference (Almeida et al., 2010; Irwin et al., 2004; Lee et al., 2007; Friedel et al., 2009; 
Gotlib et al., 2005; Lawrence et al., 2004), including the Netherlands Study of Depression 
and Anxiety (NESDA), of which the current study is part (Demenescu et al., 2011). 
Because NPY is predominantly expressed in the amygdala, amygdala function is likely to 
be affected by NPY-genotype. To date, only a few studies have reported on the association 
between NPY-genotype and emotional processing in the amygdala (Zhou et al., 2008; 
Domschke et al., 2010). In these studies, healthy people (Zhou et al., 2008) and anxious 
depressed patients (Domschke et al., 2010) with the C/C-genotype showed hyperactivation 
of the amygdala in response to negative stimuli. Childhood maltreatment has been 
associated with heightened amygdala activation in response to emotional stimuli (McCrory 
et al., 2011; van Harmelen et al., 2012). Recently, a study by our group has shown that 
specifically CEM was associated with increased amygdala activity in response to emotional 
faces (van Harmelen et al., 2012). In addition, as stated above, life events and NPY-
genotype may interact with respect to susceptibility for psychopathology. Therefore, it 
could be hypothesized that NPY-genotype and CEM interact on amygdala activation, which 
has been suggested to be an endophenotype, reflecting increased vulnerability for 
depression and/or anxiety disorders.  
The aim of this study was threefold. First, to investigate whether NPY-genotype 
influenced amygdala activity (and other brain areas involved in emotion processing); 
second, whether CEM could influence the effect of NPY-genotype on the amygdala and 
third, because of the possible associations between amygdala activity and affective 
psychopathology, whether these effects on the brain are different in the presence of 
affective disorders. We hypothesized that the combined effect of carrying the risk-genotype 






This study was part of the multi-center Netherlands Study of Depression and Anxiety 
(NESDA, Penninx et al., 2008), in which University Medical Center Groningen (UMCG), 
Leiden University Medical Center (LUMC) and VU University Medical Center Amsterdam 
(VUMC) participated. All participants provided written informed consent and the ethical 
review boards of each participating center gave approval.  
Exclusion criteria for all participants were 1) presence or history of a neurological 
disorder or somatic disorder with possible effects on the central nervous system, 2) general 
MRI contraindications, 3) dependency or recent abuse (past year) of alcohol or drugs, and 
4) hypertension. We chose to only include unmedicated patients in our primary analysis, to 
exclude a possible confounding effect of medication use on amygdala activity. Diagnosis of 
major depressive disorder (MDD) and/or anxiety (ANX, social anxiety disorder, panic 
disorder, generalized anxiety disorder) was based on the Composite International 
Diagnostic Interview (CIDI, Andrews et al., 1998) administered within three months before 
scanning by specially trained clinical research staff. The sample consisted of patients with a 
diagnosis in the past six months of MDD, ANX or comorbidity of MDD and ANX (CAD). 
For our primary analysis in the unmedicated sample, 118 unrelated Caucasian 
participants (33 healthy controls [HC], 85 patients) were included with complete imaging 
data (without artefacts) and genotyping (see for demographic details table 1). In an 
additional analysis, we also included patients using selective serotonin inhibitors (SSRIs), 
to explore possible effects of increasing our sample size. This sample consisted of 165 
participants in total (supplement Table 1). Participants in the current study were all also 
included in the previously described NESDA-MRI samples of Demenescu et al. (2011) and 
van Harmelen et al. (2012). However, this sample is smaller than the previously described 
samples, because high quality genotype data for the NPY-gene were not available from all 
subjects.  
Genotyping 
Genotyping was performed in the context of the genome wide association (GWA) study of 
the Genetic Association Information Network (GAIN) (Sullivan et al., 2009). Perlegen 
Sciences (Mountain View, CA, USA) performed all genotyping according to standard 
operating procedures. High-density oligonucleotide arrays were used yielding 599,164 
single nucleotide polymorphisms (SNP). On the basis of the linkage disequilibrium 
structure using the HapMap CEU data (release 22, build 36) as the reference database, the 




performed by IMPUTE version 0.3.2 using the default settings and the recommended 
number 11418 for the effective population size of Caucasians (Marchini et al., 2007).  The 
quality of the imputation was good (SNPTEST proper_info=0.99).  
 
Table 7.1. Demographic and clinical characteristics of the participants included. 
Table 1a shows the demographic and clinical data divided by genotype. Table 1b show the same data, 




Risk-Genotype Non-Risk-Genotype test p
Cases N (%) 38 (32.2) 80 (67.8)
CEM N (%) 10 (26.3) 46 (57.5) χ²(1)=10.05 .002
Gender #females (%) 26 (68.4) 54 (67.5) χ²(1)=0.10 .92
Age mean (SD) 39.79 (10.27) 36.54 (9.96) t(116)=1.64 .10
Education (in years) mean (SD) 13.21 (3.58) 12.76 (3.02) t(116)=0.71 .48
Diagnosis HC/MDD/ANX/CAD 14/12/5/7 19/21/16/24 χ²(3)=3.83 .28
MADRS mean (SD) 9.03 (9.27) 11.50 (10.49) t(116)=1.24 .22
BAI mean (SD) 7.97 (8.93) 10.66 (9.64) t(116)=1.45 .15
Reaction times (in ms)
Angry mean (SD) 809.83 (162.93) 851.35 (166.24)
Fear mean (SD) 860.27 (180.07) 885.93 (176.87)
Sad mean (SD) 857.76 (161.28) 887.72 (164.71)
Happy mean (SD) 873.06 (166.95) 891.32 (161.91)
Neutral mean (SD) 855.06 (158.56) 892.39 (172.36)
Table 1b
CEM no CEM test p
Cases N (%) 56 (47.5) 62 (52.5)
Genotype #risk-genotype 10 (17.9) 28 (45.2) χ²(1)=10.05 .002
Gender #females (%) 40 (71.4) 40 (64.5) χ²(1)=0.64 .42
Age mean (SD) 37.86 (9.59) 37.34 (10.67) t(116)=0.27 .78
Education (in years) mean (SD) 12.52 (3.08) 13.26 (3.30) t(116)=1.28 .21
Diagnosis HC/MDD/ANX/CAD 9/13/14/20 24/20/7/11 χ²(3)=12.98 .005
MADRS mean (SD) 13.25 (10.22) 8.40 (9.57) t(116)=2.66 .009
BAI mean (SD) 11.86 (8.59) 7.94 (9.89) t(116)=2.28 .02
Reaction times
Angry mean (SD) 837.98 (175.05) 837.97 (158.08)
Fear mean (SD) 875.66 (176.85) 879.47 (179.60)
Sad mean (SD) 891.13 (179.51) 866.28 (148.11)
Happy mean (SD) 884.64 (169.91) 886.57 (157.97)





Depression severity was determined by the Montgomery-Åsberg rating scale (MADRS, 
Montgomery et al., 1979) and anxiety severity was determined by the Beck Anxiety 
Inventory (BAI, Beck et al., 1988).   
Childhood emotional maltreatment (CEM) was assessed retrospectively using a 
semi-structured childhood trauma interview, previously used in the Netherlands Mental 
Health Survey and Incidence Study (NEMESIS, de Graaf et al., 2004a; de Graaf et al., 
2004b). In this interview, participants were asked whether they had experienced emotional 
neglect or psychological abuse before the age of 16 years. CEM was defined as multiple 
incidents of emotional neglect or psychological abuse. This definition has been used 
previously in the NESDA sample (van Harmelen et al., 2010; van Harmelen et al., 2012; 
van Harmelen et al., 2010) and is based on the definition provided by the American 
Professional Society on the Abuse of Children (APSAC, Egeland, 2009; Binggeli et al., 
2001).  
Emotional processing 
During scanning, participants performed an implicit emotional faces task, which was 
described previously (Demenescu et al., 2011). The experimental paradigm was presented 
using E-prime software (Psychological Software Tools, USA). Photographs with neutral or 
emotional facial expressions (angry, fearful, happy and sad) from a widely used set 
(Lundqvist et al., 1998) were shown. The facial expressions were expressed by amateur 
actors. Twenty-four stimuli were selected for each of five facial expressions, comprising 
twelve female and twelve male faces. Each face was not presented more than four times. 
Participants were asked to judge the gender of the person on the photograph and indicate 
this with a button press. As a baseline condition, 80 scrambled faces with an arrow (“<<” or 
“>>”) were shown indicating which button to press. To reduce anticipatory effects, an 
event-related design was used that involved a pseudo-random presentation of a total of 200 
stimuli against a black background. Each photograph/picture was shown for 2.5 seconds, 
with an interstimulus (black screen) interval varying between 0.5 and 1.5 s. Responses and 






All participants were scanned using a Philips 3T MR-scanner. A sense-8 channel head coil 
was used for radio frequency transmission and reception. In Amsterdam a sense-6 channel 
head coil was used.  
A series of echo planar imaging (EPI) volumes was obtained, entailing a 
T2*weighted gradient echo sequence using axial whole brain acquisition, with an 
interleaved slice acquisition order and with the following settings: repetition time 
(TR)=2300ms, echo time (TE)=28.0ms in Groningen and 30ms in Amsterdam and Leiden, 
and a flip angle of 90°. At UMCG 39 slices per EPI volume were acquired, with a matrix 
size of 64x64 voxels and an in-plane resolution of 3x3mm. In Amsterdam and Leiden 35 
slices per EPI volume were acquired, with a matrix size of 96x96 voxels and an in-plane 
resolution of 2.29x2.29mm. The slices had a 0mm gap and 3mm thickness. The images 
were acquired parallel to the anterior-posterior commissure plane.  
In addition, a T1-weighted anatomical MRI scan was obtained (TR=9ms, 
TE=3.5ms, matrix size 256x256, voxelsize: 1x1x1mm).  
Statistical analyses 
Genotype data 
To test if the genotype distribution was in Hardy-Weinberg equilibrium (HWE), a Chi-
square test was performed.   
Clinical and behavioral data 
To test for effects of genotype, CEM and their interactions with psychopathological status 
on clinical and behavioral data, SPSS 16.0 was used. Chi-square tests, t-tests and analysis 
of variance (ANOVA) were used where appropriate.  
For the behavioral data, a repeated-measures ANOVA was conducted with RT as 
dependent variable, emotional expression as within group factor and diagnosis, genotype 
and CEM as between group factors. 
fMRI data 
Data were analyzed with SPM5, implemented in Matlab 7.1. (The MathWorks Inc., ) 
Preprocessing included slice time correction, image realignment, registration of the T1-scan 
to the mean EPI, warping to MNI-space as defined by the SPM5 T1-template, reslicing to 
3x3x3mm voxels and spatial smoothing using an 8mm full with half maximum (FWHM) 
Gaussian kernel. Movement of the participant of >3mm or rotation of >3 degrees in any 




 For every participant, hemodynamic responses for each stimulus were modelled. 
The model included regressors for each emotional expression (angry, fearful, happy, neutral 
and sad) and for baseline trials (scrambled faces). Low frequency temporal noise was 
removed by applying a high pass filter of 128s. For each participant, contrast images were 
calculated for “angry vs. scrambled”, “fearful vs. scrambled”, “sad vs. scrambled”, “happy 
vs. scrambled” and “neutral vs. scrambled”. We chose scrambled faces as our primary 
baseline condition, because a meta-analysis has shown that amygdala activation can be 
more reliably obtained by the use of a low-level baseline condition such as a scrambled 
image compared to neutral facial stimuli as a baseline (Sergerie et al., 2008). For 
completeness, we have also analyzed our data with the neutral condition as our baseline 
condition.  
On a group level, we first performed a ROI-based approach to test for the effects 
of genotype, CEM and diagnosis on amygdala activity. The individual contrast maps were 
entered in a group level analysis in a full-factorial model, with type of emotional facial 
expression added as within-subject factor. The individual signals of the entire bilateral 
amygdala were extracted from this full-factorial model using the MARSBAR toolbox (Brett 
et al., 2002) for each contrast and data were exported to SPSS for further analysis. The 
bilateral amygdala was defined according to the anatomical automatic labeling (AAL) 
library (Maldjian et al., 2003) implemented in the Wake Forest University (WFU) pickatlas 
(http://fmri.wfubmc.edu/cms/software). A repeated-measures ANCOVA was performed on 
mean beta-values for all amygdala voxels with emotional expression and lateralization as 
within-subject variables and genotype, diagnosis and CEM as between-subject variables. 
Center was added as covariate of no interest. Main effects and interaction effects (F-tests) 
were regarded significant at p < .05. Post-hoc t-tests were all Bonferroni corrected for 
multiple comparisons.   
Second, an explorative whole-brain analysis was performed to test for additional 
brain regions where neuronal activity was related to NPY genotype per se or to an 
interaction between NPY genotype and CEM. Specifically, individual contrast maps were 
combined on a group level using ANOVA with emotional expression as within-subject 
factor and genotype and CEM as between-subject factors. MADRS-scores and BAI-scores 
were added as covariates to control for psychopathology. A threshold of p < .005 with an 
extent threshold of k>10 for the F-tests was used to explore possible genotype effects. For 
post-hoc t-tests clusters were regarded significant at a threshold of p < .05 corrected for 
multiple comparisons using family-wise error (FWE) at cluster-level.  
For a description of psychiatric group differences in brain activity due to 




2011) and for a description of main effects of CEM on brain activity we refer to Van 
Harmelen et al. (van Harmelen et al., 2012). 
Results 
Genotype data 
In this sample, the genotype distribution over all subjects did not differ from the expected 
numbers calculated according to the Hardy-Weinberg equilibrium (HWE, χ²(1)=.92,  p > 
.25.).  
There were relatively few T/T-homozygotes ([T/T:T/C:C/C] HC 3:16:14, MDD 
4:17:12, ANX 6:10:5, CAD 5:19:6). Therefore, to optimize power, we grouped the non-
risk-genotypes (T-allele carriers) and compared them to the risk-genotype (C/C-genotype).  
Clinical data 
MADRS, BAI-scores and psychiatric diagnosis were not related to genotype (all p > .17, 
table 1a). However, MADRS and BAI scores were both related to experienced CEM (all p 
< .04, Table 7.1b). Both scores were higher in the CEM group than in the non-CEM group. 
There was also an effect of CEM on diagnosis: HC had experienced less CEM than patients 
(Table 7.1b). There was an effect of genotype on experienced CEM. More non-risk-
genotype carriers described CEM than risk-genotype carriers (p = .002).  
Behavioural data 
Due to technical problems, there was one participant for whom responses were not 
registered. Group mean substitution was used to analyze behavioral data of this participant. 
Three participants always pressed the same button during baseline condition (responded to 
>89% of items) and one participant did not respond to baseline items at all. For this last 
participant, the first-level contrasts on the fMRI-data were thoroughly checked for 
abnormalities, which were not present. None of these participants were excluded. All other 
participants responded to >83% of the stimuli and had >93% correct gender judgments.   
There was a main effect of emotional expression on reaction time (RT, F(4, 98) = 
6.50, p < .001): participants responded faster to angry faces, than to the other expressions 
(data not shown). Over all emotional expressions, risk-genotype carriers responded faster 
than the non-risk-genotype carriers (F(1, 101) = 4.19, p = .04, data not shown). There were 
no main effects of diagnosis or CEM. However, there was an interaction between genotype 
and CEM (F(1, 101)=5.17, p=.03): the fastest responses to the faces were given by those 
who carried the risk-genotype and had experienced CEM (Figure 7.1). There was no 





Figure 7.1: Reaction times needed to judge the gender of the person in the photograph.  
This graph shows the combined effect of genotype and childhood emotional maltreatment on reaction 
times. This effect was independent of the emotional facial expression depicted. The error bars represent 
one standard error. 
 
Imaging data 
Effects on the amygdala 
There was no main effect of genotype on amygdala activity (F(1, 100)= 0.08, p=.79) nor an 
interaction between genotype and emotional expressions (F(3.56, 356.2)=1.28, p=.28). 
However, an interaction between genotype and CEM was present on bilateral amygdala 
activity (F(1, 100)=5.08, p=.026). Within risk-genotype carriers there was stronger 
amygdala activation for those who experienced CEM compared to those who did not, 
whereas there was no difference related to CEM within non-risk-genotype carriers (Figure 
7.2). Diagnosis and emotional expressions of the stimuli did not influence this effect.  
There was a trend for an effect of diagnosis (F(3, 100)= 2.63, p=.05), with ANX 
having less amygdala activation than HC and CAD. There was a main effect of CEM in the 
left and right amygdala across emotional expressions (F(1, 100)=5.13, p=.026). Participants 
who experienced CEM had stronger amygdala activation compared to those who did not, 
irrespective of emotional expression. These findings are consistent with the findings of the 




To exclude the possibility that the interaction effect was driven by a concurrent history of 
physical and/or sexual abuse in some of the participants (n = 24), we next re-ran the RM 
ANCOVA while excluding these individuals. In this analysis, all results remained 
qualitatively unchanged, including the interaction effect of genotype and CEM (F(1, 
76) = 5.35, p = 0.02). 
Except for the main effect of diagnosis, all the effects could be repeated in the 
larger sample in which patients using SSRIs were included (supplementary information 
Table S1 and S2).  
In addition, to explore the influence of our baseline condition, we repeated the 
analysis with the neutral face as baseline condition (instead of the scrambled face). In this 
analysis, only the main effect of CEM reached significance (F(1,101) = 26.78, p = .02).  
 There were no significant correlations between amygdala activity and RTs.  
 
Figure 7.2: Amygdala activity (for all faces relative to scrambled) in risk-genotype carriers (C/C-
genotype) and non-risk-genotype carriers (T-allele) split according to the experience of CEM. 
Bars represent the mean (average over emotional expressions and left and right) and standard errors of 
amygdala activity. Within risk-genotype carriers there was increased amygdala activation for those who 
experienced CEM compared to those who did not (t(36)=1.97, p=.02), whereas there was no difference 







Exploratory whole-brain analysis into the effects of genotype and CEM 
There were no additional significant effects related to genotype on regional brain 
activations in an analysis of HC and unmedicated patients. Explorative analyses showed a 
trend-wise interaction effect of genotype and CEM in the posterior cingulate cortex (PCC, 
F(1, 450) = 7.68, p = .006): those who experienced CEM demonstrated lower activation of 
this region than individuals who did not reported a history of CEM. The number of subjects 
included in this study was likely not large enough to detect significant whole-brain effects. 
When also including the medicated patients (total sample size n=165), a significant 
interaction of genotype and CEM in the PCC, extending to the precuneus, was observed 
(F(1, 642) = 21.59, Z = 4.46, k = 180, p < .001 uncorrected, Figure 7.3). Within participants 
who experienced CEM, Carriers of the risk-genotype had lower PCC activation compared 
to non-risk-genotype carriers (Z = 3.82, p = .047, FWE corrected on cluster-level), whereas 
there was no such effect present in those who had not experienced CEM. The difference 
between CEM and non-CEM within risk-genotype carriers did not reach significance (Z = 
3.68, p < .001 uncorrected and p = .78 FWE corrected). Including age and gender as 
covariates did not change the patterns of activation and association.  
When comparing emotional faces to neutral faces instead of the scrambled faces 






Figure 7.3: Posterior cingulate cortex activation was also dependent on genotype and emotional 
maltreatment (like amygdala). Risk-genotype carriers who had experienced CEM had lower PCC 
activation compared to non-risk-genotype carriers (Z=3.82, p=.047, FWE corrected on cluster-level), 
whereas there was no such effect present in those who had not experienced emotional maltreatment. 
The difference between CEM and non-CEM within risk-genotype carriers did not reach significance 






The aims of this study were to investigate first the influence of NPY-genotype on brain 
activity and second whether this would interact with the experience of childhood emotional 
maltreatment (CEM). To examine whether such an interaction could contribute to 
vulnerability for affective disorders, we specifically investigated whether the combination 
of NPY risk-genotype and CEM would impact on reactivity of brain areas involved in 
emotion processing. In addition, because of the possible associations between amygdala 
activity and affective psychopathology, the third aim of this study was to investigate 
whether the influence of NPY genotype and CEM on the brain are different in the presence 
of affective disorders. 
Our results showed that CEM was associated with heightened amygdala reactivity 
within risk-genotype carriers, but not in carriers of the non-risk-genotypes. This was 
accompanied by a faster motor response related to gender-discrimination in those carrying 
the risk-genotype and having experienced CEM, which was absent in non-risk-genotype 
carriers with CEM. The faster response together with the increased amygdala reactivity 
may point to hypervigilance for external emotional stimuli. Because increased amygdala 
reactivity has been found in anxiety and depression (Victor et al., 2010; Matthews et al., 
2008; Peluso et al., 2009; Townsend et al., 2010), our results might suggest a heightened 
vulnerability for these disorders carrying the risk-allele and having a history of CEM.  
Stronger amygdala activation in those carrying the risk-genotype (C/C-genotype) 
and in addition having experienced CEM (Figure 3) is probably related to lower NPY-
levels. The C-allele of the rs16147 polymorphism has been associated with a reduction of 
NPY expression (Zhou et al., 2008) and previous studies have also found increased 
amygdala activity within risk-genotype carriers (Zhou et al., 2008; Domschke et al., 2010). 
In addition, NPY-levels are not only genetically determined, but also depend on external 
factors. Animal models have shown that under conditions of stress, the expression and 
release of NPY is increased, implying successful behavioral adaptation (Thorsell et al., 
1999), but high levels of stress during childhood, like maternal separation (Husum et al., 
2002; Jimenez-Vasquez et al., 2001), have been shown to lead to reduced NPY-levels. 
Recently, a decrease in NPY-levels in the amygdala as a consequence of stress has also 
been demonstrated in humans (McGuire et al., 2011). Thus, it could be hypothesized that 
NPY-levels in those with risk-genotype and experienced CEM are lowest and that these low 
NPY-levels in the amygdala relate to increased amygdala activity.  
The combination of having experienced stressful life events and carrying the NPY 
risk-genotype has been found to increase vulnerability for affective disorders (Sommer et 
al., 2010). The final aim or our study was to investigate whether presence of affective 




and NPY-genotype or a three-way interaction including additionally CEM. Although we 
did not find an interaction with the presence of psychopathology, this gene by environment 
interaction on amygdala activation could be related to the onset of affective disorders 
through a disturbed stress response. Furthermore, the finding that the NPY-genotype by 
CEM interaction was also observed in those who already experience affective 
psychopathology, may serve as part of a mechanism by which patients are vulnerable for 
relapse, and thus ongoing course of the disorder. That is, amygdala reactivity could qualify 
as an endophenotype for the association between genetic and environmental influences and 
vulnerability for affective episodes.  
An unexpected association was found between genotype and experienced CEM: carriers of 
the non-risk-genotype reported CEM more often than risk-genotype carriers. It could be 
speculated that genotype is related to the subjective experience of CEM or the reporting of 
it. Notably, CEM was only measured by reports from the participants. Therefore, it could 
not be objectively verified if and to what degree CEM had occurred.  
The direction of the effect of diagnosis on amygdala activity was unexpected with 
less activation in the amygdala for anxiety patients compared to both HC and comorbid 
patients, while previous studies mostly reported increased amygdala activation in anxiety 
patients (for a review see Holzschneider et al., 2011). This could be related to chronically 
elevated amygdala activation or a strong reaction to scrambled faces, thus presenting a 
ceiling effect (Wright et al., 2006a). 
SSRI use did not seem to influence the effects of genotype and CEM on neural 
activity. By including medicated patients the effect of diagnosis on amygdala activity 
disappeared. It could be suggested that medication attenuates amygdala activity, which is a 
commonly replicated finding in studies investigating the effects of SSRIs on brain activity 
(Sheline et al., 2001; Fu et al., 2004; Anand et al., 2007; Ruhe et al., 2012). 
In the explorative whole-brain analysis, we observed a combined effect of NPY-
genotype and CEM on activity in the posterior cingulate cortex (PCC) extending to the 
precuneus. This effect was only seen in a larger sample including both SSRI-using and 
unmedicated patients. This finding may have been related to the effects of SSRI-use on 
PCC activation, as there is one report of decreased PCC activation during self-referential 
processing after use of an SSRI (escitalopram, Matthews et al., 2010). On the other hand, 
this finding may also have been due to increased power, because a similar trend was visible 
in the unmedicated sample only. This area showed stronger hypoactivity in response to 
human faces in participants carrying the risk-genotype and having experienced CEM 
(compared to non-risk-carriers who had experienced CEM, whereas the effect in the 
amygdala was compared to risk-carriers without experienced CEM). The PCC and 




autobiographical memory (Buckner et al., 2007; Cavanna et al., 2006)  and self-referential 
processes both emotionally and spatially (van der Meer et al., 2010; Dimaggio et al., 2009). 
Hypoactivity during processing of emotional faces can be interpreted as enhanced reactivity 
to external processes and less to self-related processing. In addition, this area has close 
connections with the amygdala (Veer et al., 2011; Zhang et al., 2012). Thus, our results 
suggest not only a gene by environment interaction in the amygdala, but also for other 
regions connected in a broader neural network related to self-relevance and attention.  
Interestingly, there were no differences related to genotype and/or CEM when 
neutral faces were used as baseline condition. Moreover, amygdala activation in response to 
neutral faces contrasted to the scrambled faces resulted in the same pattern of results as the 
emotional expressions contrasted against the scrambled face. These findings indicate that 
neutral faces elicit a comparable amygdala response as other emotions. This is in line with 
previous studies reporting amygdala reactivity to neutral stimuli (Blasi et al., 2009; Wright 
et al., 2006b). It has been suggested that the ambiguity of neutral stimuli (neither positive 
nor neutral) is potentially threatening and may elicit activation of the amygdala (Blasi et al., 
2009) as well as hypervigilance. Especially patients with posttraumatic stress disorder 
(PTSD) have been shown to have strong amygdala responses to neutral faces (Brunetti et 
al., 2010; Garrett et al., 2012). Although PTSD was an exclusion criterion, subclinical 
PTSD might be present after CEM.  
In addition, the effects were unrelated to type of emotional expression. This is 
contrary to the traditional idea of heightened amygdala activation for negative emotional 
expressions and the different social meaning of angry, fearful, sad, happy and neutral 
expressions. However, recent evidence suggests that the amygdala is not involved in 
processing of specific emotions, but has a general role in salience detection (Lindquist et 
al., 2012) and the amygdala reacts similarly to positive and negative stimuli (Sergerie et al., 
2008). Our findings also suggest that in our sample various emotional expressions have a 
comparable salience for the subjects and elicit a similar response in the amygdala and PCC.       
Although in a smaller sample, we replicated previous analyses carried out on data 
from the NESDA sample of an association between CEM and diagnosis (Hovens et al., 
2010; Spinhoven et al., 2010) and of increased activity in the amygdala related to CEM 
(van Harmelen et al., 2012). This suggests that the sample selection for this study reflects 
the larger NESDA sample. However, some limitations of this study should be mentioned. 
We could not replicate previously published findings regarding an association between 
NPY-genotype and amygdala activity, regardless of CEM (Zhou et al., 2008; Domschke et 
al., 2010). In addition, a difference between our study and previous studies is the 
distribution of the genotypes in the sample. Especially, previous studies had more T/T-




to genotype larger than in our study. Our study was limited by a small HC-group with T/T-
genotype and the lack of healthy T/T-carriers without experienced CEM. Therefore, we 
decided to combine this group with the heterozygotes, to increase power, but this precluded 
the investigation of an additive effect of genotype. As mentioned before, assessment of 
CEM was based on self-report, so that it could not be objectively verified if and to what 
degree CEM had occurred. However, it has been shown that this method more likely leads 
to an underestimation than an overestimation of childhood abuse (Brewin, 2007). 
Moreover, a recent paper has shown that the risk for depression is associated with 
childhood maltreatment, but is independent of whether maltreatment was assessed 
prospectively or retrospectively (Scott et al., 2012). A final limitation is that the cross-
sectional design of this study precludes drawing causal inferences about CEM and 
amygdala response.  
To conclude, in this study we demonstrated an interaction of NPY-genotype and 
childhood emotional maltreatment on amygdala and PCC activation during processing of 
emotional faces, in addition to a faster behavioral response. This is consistent with the 
notion that risk-genotype plus CEM results in a hypervigilant state. This interaction could 
contribute to the vulnerability for developing affective disorders and confirms the relevance 
of gene-environment interactions on neurobiological mechanisms. Replication and further 
investigation is needed, to establish the role of NPY genotype in emotion processing 
networks in more detail.  
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Table S1. Demographic and clinical characteristics of participants included in analysis including patients 
using SSRIs.  
Table 1a shows the demographic and clinical data divided by genotype. Table 1b show the same data, 
but than divided according to CEM. Patients using other psychotropic medication than SSRIs or 
infrequent use of benzodiazepines (oxazepam or diazepam, maximum of three times a week, max 20 
mg and not within 48 hours before scanning) were excluded from analysis. 
 
Table 1a
Risk-Genotype Non-Risk-Genotype test p
Cases N (%) 49 (29.7) 116 (70.3)
CEM N (%) 17 (34.7) 67 (57.8) χ²(1)=7.33 .007
Gender #females (%) 32 (65.3) 77 (66.4) χ²(1)=.02 .89
Age mean (SD) 39.24 (10.39) 37.04 (10.04) t(163)=1.27 .20
Education (in years) mean (SD) 12.73 (3.37) 12.44(3.12) t(163)=0.54 .59
Diagnosis HC/MDD/ANX/CAD 14/13/6/16 19/31/24/42 χ²(3)=4.04 .23
MADRS mean (SD) 11.33 (9.55) 12.86 (10.20) t(163)=0.90 .37
BAI mean (SD) 10.10 (9.55) 12.03 (10.12) t(162)=1.13 .26
SSRI use N (%) 11 (22.9) 36 (31.0) χ²(1)=1.09 .30
Table 1b
CEM no CEM test p
Cases N (%) 84 (50.9) 81 (49.1)
Genotype risk-genotyp/non-risk-genotype 17/67 32/49 χ²(1)=7.33 .007
Gender #females (%) 57 (67.9) 52 (64.2) χ²(1)=0.25 .62
Age mean (SD) 38.49 (9.73) 36.88 (10.59) t(163)=1.02 .31
Education (in years) mean (SD) 12.14 (3.13) 12.93 (3.22) t(163)=1.59 .12
Diagnosis HC/MDD/ANX/CAD 9/20/17/38 24/24/13/20 χ²(3)=13.25 .004
MADRS mean (SD) 14.52 (9.90) 10.21 (9.69) t(163)=2.88 .005
BAI mean (SD) 13.19 (9.06) 9.62 (10.59) t(162)=2.32 .02




Table S2 Effects on the amygdala in response to emotional facial expressions (angry, fearful, sad and 
happy) versus scrambled faces in a sample including patients using SSRIs (n=165). Patients using 
other psychotropic medication than SSRIs or infrequent use of benzodiazepines (oxazepam or 
diazepam, maximum of three times a week, max 20 mg and not within 48 hours before scanning) were 
excluded from analysis. Influence of Genotype, CEM and Diagnosis as indicated by a repeated 
measures ANCOVA with center added as covariate of no interest. The lines printed in bold represent 





Valence 2.67 398.28 1.65 .18
Lateralization 1 147 3.32 .07
Valence*Lateralization 2.8 417.31 1.21 .31
Genotype 1 147 0.03 .87
Genotype*Valence 2.67 398.28 3.44 .02
Genotype*Lateralization 1 147 0.28 .60
Genotype*Valence*Lateralization 2.8 417.31 1.38 .25
Diagnosis 3 147 1.89 .13
Diagnosis*Valence 8.13 398.28 0.67 .72
Diagnosis*Lateralization 3 147 2.06 .10
Diagnosis*Valence*Lateralization 8.52 417.31 1.39 .20
Genotype*Diagnosis 3 147 1.65 .18
Genotype*Diagnosis*Valence 8.13 398.28 1.09 .37
Genotype*Diagnosis*Lateralization 3 147 0.27 .85
Genotype*Diagnosis*Valence*Lateralization 8.52 417.31 1.76 .08
CEM 1 147 7.37 .007
CEM*Valence 2.67 398.28 0.30 .80
CEM*Lateralization 1 147 1.02 .32
CEM*Valence*Lateralization 2.8 417.31 1.47 .22
Genotype*CEM 1 147 7.93 .006
Genotype*CEM*Valence 2.67 398.28 0.34 .79
Genotype*CEM*Lateralization 1 147 1.91 .17
Genotype*CEM*Valence*Lateralization 2.8 417.31 0.39 .75
CEM*Diagnosis 3 147 1.23 .30
CEM*Diagnosis*Valence 8.13 398.28 0.45 .90
CEM*Diagnosis*Lateralization 3 147 4.09 .01
CEM*Diagnosis*Valence*Lateralization 8.52 417.31 1.29 .24
Genotype*CEM*Diagnosis 3 147 1.72 .17
Genotype*CEM*Diagnosis*Valence 8.13 398.28 0.37 .94
Genotype*CEM*Diagnosis*Lateralization 3 147 2.70 .05












Major depressive disorder (MDD) is a common mental disorder that, as such, involves 
alterations in brain structure and function. The aim of this thesis was to investigate several 
unresolved issues related to the neurobiological underpinnings of MDD. We employed 
several studies using different methodologies to investigate the associations between genes, 
brain activation, brain morphology and the depression phenotype.  
In this thesis, it was shown again that there are no strong direct associations 
between candidate genes and MDD. This confirms the need for hypotheses on 
endophenotypes to investigate the genetic susceptibility for depression (see Figure 8.1). To 
help define clear neuroimaging endophenotypes, consistent patterns of abnormal brain 
activations in depression were investigated. Opposing effects for processing of negative and 
positive emotional stimuli were observed in a network of limbic and visual brain areas: 
MDD patients showed more activation for negative stimuli and less activation for positive 
stimuli in these areas compared to healthy people. In addition, patients also showed less 
activation in the left dorsolateral prefrontal cortex during processing of negative stimuli and 
more activation in the orbitofrontal cortex (OFC) during processing of positive stimuli. 
Notably, from a longitudinal fMRI study, we showed that activation in the insula was 
sensitive to change in mood states.  
Based on existing neurobiological models of depression, the amygdala, 
hippocampus and prefrontal cortex were chosen to define endophenotype for the 
neuroimaging genetic studies. From the literature, it was known that the enzymes 
disrupted-in-schizophrenia-1 (DISC1), catechol-O-mehtyltransferase (COMT) and 
neuropeptide Y (NPY) are highly expressed in these areas and therefore the genes 
corresponding for these enzymes are interesting candidate genes. Indeed, we confirmed that 
these genes are likely related to susceptibility for depression via modulation of brain 
activations in amygdala, hippocampus and areas of the prefrontal cortex. 
 





Associations between genes and MDD 
There is compelling evidence that the dopamine system is disturbed in depression 
(Schildkraut, 1965; Dunlop et al., 2007; Opmeer et al., 2010). First, the symptoms of MDD 
consist of sad mood, not experiencing pleasure, concentration problems, weight loss, 
sleeping problems, psychomotor problems, loss of energy, feelings of worthlessness and 
thoughts of death. This list of symptoms bears a very striking resemblance to the processes 
regulated by dopamine. Dopamine regulates the reward system (Lippa et al., 1973; Wise, 
1978), specifically mood (Ashby et al., 1999), motivation (Blackburn et al., 1992; Wise et 
al., 1984), attention (Nieoullon, 2002), decision making (Assadi et al., 2009), and 
psychomotor speed (Poirier et al., 1975). Secondly, dopamine release in the ventral striatum 
is also correlated with the euphoric response to amphetamines (Drevets et al., 2001). In 
addition, amphetamines are used as pharmacological drug in the treatment of narcolepsy 
and obesity (Berman et al., 2009), which underscores the role of dopamine in weight 
control and sleep regulation. Finally, dopamine levels are influenced by stress (Corrodi et 
al., 1971; Pani et al., 2000) and stress is a well known factor in the aetiology of MDD. 
Indeed, stress-induced dopamine release has been shown to be tightly coupled to 
neuroendocrine stress responses (e.g. elevated plasma corticosterone levels, Sullivan et al., 
1998).  
In chapter 2 we performed an extensive literature review on the role of genes 
involved in dopamine metabolism and signalling (enzymes, receptors and transporter) on 
vulnerability to MDD. The variable number tandem repeats (VNTRs) in the dopamine 
receptor 4 (DRD4) and dopamine transporter (DAT) genes showed the most consistent 
results in the association with MDD. However, the associations were not very strong. It has 
been suggested that depression is associated with many genes (polygenic), which all 
contribute a little to the overall vulnerability (Lau et al., 2010). Therefore, associations 
between one gene and MDD are mostly weak. This is consistent with previous studies, 
which even suggest an absence of associations between candidate genes and MDD (Bosker 
et al., 2011). 
Previous studies have come to the same conclusions regarding genes influencing 
other neuromodulator systems, for example genes influencing the serotonin system 
(Anguelova et al., 2003). However, for serotonin genes it has been shown that stronger 
associations are present when taking environmental factors into account (Caspi et al., 2003; 
Karg et al., 2011, although not consistently [Risch et al., 2009]) or when it is investigated in 
association with an endophenotype, such as amygdala activation (Munafo et al., 2008). 
Therefore, we took an endophenotype approach to investigate the genetic vulnerability to 
depression. Brain activation and morphology measured with (functional) magnetic 




a good understanding of the association between the endophenotype (brain activation) and 
phenotype (depression) is invaluable. 
Associations between brain activation (endophenotype) and MDD 
Many studies have been conducted to identify brain circuits in depression during emotional 
processing. However, findings have been inconsistent. Therefore, in chapter 3 we 
employed a meta-analysis to investigate consistencies in the literature on abnormal brain 
activation. This was to our knowledge the first meta-analysis which combined region-of-
interest (ROI) and whole-brain studies and included studies which reported no associations 
between MDD and brain activation. This may yield a more balanced representation of the 
literature than previous meta-analyses on neuroimaging data.  
During processing of negative emotional stimuli, depressed patients showed more 
activation in the right amygdala, left striatum, dorsal anterior cingulate and 
parahippocampal areas than healthy controls. In contrast, during processing of positive 
emotion these same areas showed less activation in depressed patients than in HC. Stronger 
activation for negative emotional stimuli and less activation for positive emotional stimuli 
in amygdala and striatum might underlie to the negativity bias often reported in depression 
(Harmer et al., 2009; Roiser et al., 2012), by selecting negative information and inhibiting 
positive information for further processing. A similar modulating effect of emotional 
valence was observed in the anterior cingulate cortex (ACC). The dorsal ACC has been 
associated with attention and learning from negative feedback (Shackman et al, 2011). 
Furthermore, the dorsal ACC is thought to work in concert with the amygdala to generate 
bodily responses to emotion evoking stimuli (Etkin et al., 2011). Moreover, it has been 
suggested that the dorsal ACC, as part of the default-mode network, plays an important role 
in rumination and self-associations (Pizzagalli, 2011). Hence, abnormal dorsal ACC 
functioning could contribute to a multitude of depressive symptoms, ranging from biased 
attention to negative stimuli and rumination to increased sensitivity to stress.  
Besides opposite effects for emotional valence in these areas, two areas showed 
abnormal activation only during either processing of negative or positive stimuli. The left 
DLPFC showed less activation in MDD patients than in healthy participants during 
processing of negative stimuli. This is consistent with the hypothesis of impaired affective 
state monitoring in depression (e.g. Beck, 2008; Phillips et al., 2003). The left DLPFC is 
thought to inhibit amygdala activation during voluntary emotion regulation using 
suppression, attention redirection or reappraisal strategies. Accordingly, MDD patients 





In contrast, during processing of positive stimuli, MDD patients showed more 
activation than healthy participants in the medial OFC. The OFC has been described as an 
area implicated in the production of emotional behaviour and affective states (Phillips et al., 
2003a). Specifically, it is thought that the OFC integrates external and internal sensory 
information and uses this to guide behaviour (Lindquist et al., 2012). In addition, the OFC 
has indeed been linked to associative and reward learning, which is in turn important for 
emotional learning (Rolls, 2004). 
In addition, it was investigated whether brain activations were dependent on type 
of emotional stimuli used. Interestingly, an effect of stimulus type was found in the 
pregenual ACC (BA25). The pregenual ACC showed increased activation to facial stimuli 
and decreased activation to non-facial stimuli (irrespective of emotional valence). This area 
has been proposed to play a central role in integrating cognitive and emotional processes 
(Mayberg, 1997). The presentation of facial stimuli depicting emotional states might elicit 
more integration of cognitive and emotional processes than the presentation of non-facial 
stimuli in depressed patients. These findings indicate that there is strong evidence for the 
association between our proposed endophenotype (brain activation in regions underlying 
emotion processing) and the MDD phenotype. 
It is important to know whether a certain pattern of brain activation is related to the 
depressive state or is present independent of that state. In chapter 4, we investigated 
whether abnormal brain activations in depression changed over time in relation to recovery 
or whether abnormal activation was independent of mood state. A decrease in depressive 
symptom severity was accompanied by a decrease in insula activation during processing of 
positive stimuli. The insula is an important region for emotional awareness (Craig, 2009)
 
and has been shown to be part of a network which is activated during both perceiving and 
expressing positive facial affect (Hennenlotter et al., 2005). The specificity of our effect for 
happy faces could imply that symptom improvement is more related to a different response 
to positive stimuli rather than to negative ones and may be related to more mood-congruent 
processing. It is not yet known if a decrease in insula activation precedes or follows the 
decrease in depressive symptoms.  
Consistent with previous studies (Costafreda et al., 2009b; Davidson et al., 2003; 
Chen et al., 2007; Keedwell et al., 2009), pregenual ACC activation in response to 
emotional expressions was found to distinguish patients who did not from those who did 
recover over the following two years. This increased ACC activation could possibly 
identify a subgroup with a higher resilience against a chronic course of depression 
characterized by a differential response of the emotion processing network. It has been 
shown that an early increase in positive affect after the start of treatment, rather than a 




results are in line with this finding, because the predictive value of ACC activation was 
most pronounced in response to happy faces and may reflect increased attention for mood-
incongruent (i.e., positive) stimuli preceding remission.  
In addition, prolonged depression was shown not to be a stable state but rather a 
progressive departure from normality in non-recoverers, reflected by decreased amygdala 
and increased insula activation over time in non-recoverers, which was not present in the 
other groups. These more profound abnormalities after two years may reflect poor 
prognosis (Spijker et al., 2004; Penninx et al., 2011). The patients in our sample showed 
relatively mild symptomatology during baseline, therefore this might also explain why 
there were relatively few differences in brain activation between patients and healthy 
controls in our baseline study (chapter 4 and Demenescu et al., 2011). In addition, this 
finding is also supportive for brain activation being correlated to the depressive state.  
Implications for neurobiological models of depression  
Our findings from chapters 3 and 4 can be evaluated in light of the proposed models of 
disturbances in brain circuits described in the introduction of this thesis. In short, an 
integration of the models by Mayberg (Seminowicz et al., 2004; Mayberg, 1997) and 
Phillips et al.(Phillips et al., 2003b) implies that depression is associated with an overactive 
ventral frontal brain network (including the amygdala, insula, ventral striatum and 
subgenual ACC (brodmann area [BA] 25) resulting in increased attention for and 
processing of negative stimuli. A dorsal network (including the DLPFC, dorsal ACC, 
dorsal striatum and hippocampus) is thought to be less active in depression resulting in less 
emotional control and symptoms of apathy and less executive functioning. An additional 
third ‘emotion-cognition integration’ network (including the pregenual ACC (BA 24), 
medial PFC and OFC) was thought by Mayberg to function as a link between the ventral 
and dorsal compartments. Mayberg suggested that activation of this third network is 
required for a better integration between the dorsal and ventral circuits and to lead to a 
better treatment response (Seminowicz et al., 2004; Mayberg, 1997). 
 Recently Hamilton et al. (2012) proposed an adjusted model. They suggested that 
activity in the thalamus during rest is heightened in depression and that its connections to 
the salience network (amygdala, insula and dorsal ACC) lead to increased activation of this 
network in response to negative stimuli. Hyperactivation within this salience network may 
be sustained by connections within this network. In addition, the DLPFC and dorsal 
striatum do not activate in depressed patients in response to negative stimuli, suggesting 
that signals from the salience network do not reach these areas. Hamilton et al. suggested 




which is necessary for function of nigostriatal dopamine projections in transferring 
information through the cortico-striato-thalamic circuit.   
 A notable difference between the ‘classic’ neurobiological models of depression 
and the model of Hamilton et al. is the different function and abnormalities they 
hypothesize for the dorsal ACC. Our results are in line with the suggestion of Hamilton et 
al. that the dorsal ACC is hyperactive in response to negative stimuli. This also fits with 
previous findings of a coactivation of the dorsal ACC and amygdala to generate bodily 
emotional responses (Etkin et al., 2011), and connections to the insula for interoceptive 
awareness (Craig, 2009; Medford et al., 2010). In addition, the amygdala, insula and dorsal 
ACC have been described previously in a salience network that discriminates relevant from 
irrelevant information among internal (bodily) and external stimuli in order to guide 
behaviour (Menon et al., 2010). Our results are supportive for more activation of this 
network in MDD during processing of negative stimuli, suggesting problems with filtering 
information, which might underlie the bias in attention for negative stimuli (Leppanen, 
2006). 
 In contrast to the model of Hamilton et al., we found evidence for additional brain 
areas being hyperactive in depression during negative emotional processing. These areas 
include the ventral striatum, parahippocampal gyrus (PHG) and cerebellum. The ventral 
striatum has a place in ‘classical’ models of depression in that it activates strongly in 
response to motivating cues. However, the PHG and cerebellum have not been mentioned 
often in reviews on abnormal brain activities in depression, but have also been associated 
with emotional processing (Lindquist et al., 2012). Including these areas in a model for the 
underlying neurobiology of depression could have additive value in better understanding 
this disorder.  
In agreement with the model of Mayberg we showed a relative hyperactivation of 
the pregenual ACC predicting recovery (and not to treatment response per se). Therefore 
our results confirm the important and unique role of the pregenual ACC in the neurobiology 
of depression. The pregenual ACC has close connections with the dorsal ACC and the 
ventral system (insula, amygdala, subgenual ACC) (Bush et al., 2000). Mayberg suggested 
that this area might function as a hub between the dorsal and ventral systems.   
However, our results are in odds with the previous models for a prominent role of 
the subgenual ACC in MDD (Mayberg, 1997; Drevets et al., 2008b; Hamani et al., 2011). 
One possible explanation is that the subgenual ACC has been associated more with the 
experience rather than perception of emotion, and may be targeted by explicit mood 
induction (Berna et al., 2010) or self-referential instructions (Lemogne et al., 2009). On the 
other hand, the differences may be more pronounced in resting state activity rather than 




Current models mainly focus on processing of negative emotional stimuli in 
depressed patients. However, our studies have shown that there are also great disturbances 
in brain activation during processing of positive stimuli. The areas involved during 
emotional processing and awareness show less activation in response to positive stimuli in 
MDD compared to healthy participants. Hence, this is in the opposite direction from the 
activation pattern in response to negative emotions. This is in line with the idea that MDD 
is not only characterized by more attention and awareness for negative stimuli, but also by 
less attention and awareness for positive stimuli (Leppanen, 2006).  
In addition, our results contribute to the knowledge on mood-state related changes 
in brain activation. Especially the insula appeared to be associated with alterations in mood 
states. Therefore, the insula could be suggested as a key hub in the depressive state related 
salience network.  
In summary, a refined model for the neurobiology of MDD could be proposed 
based on the findings in this thesis (Figure 8.2). A network of areas (including the 
amygdala, dorsal ACC, insula, ventral striatum, PHG and cerebellum) is involved in 
discriminating relevant from irrelevant information. In MDD, this network is more 
activated during processing of negative information and less activated during processing of 
positive information. Abnormal function of this network during perception of emotional 
information is suggested to lead to a bias in attention and further processing of both 
negative and positive stimuli: more attention for negative stimuli and less attention for 
positive stimuli. Of the areas in this network, the insula might be especially connected to 
changes in mood states. In addition, there is a proposed component including the 
dorsolateral PFC and dorsal striatum, which is less activated in response to negative stimuli. 
This component is involved in symptoms of apathy, less emotional control and less 
executive functioning. These are also key regions involved in regulation of affect. In 
response to positive stimuli, the OFC is more activated in MDD, which might make the 
integration of visceral signals and associative processes elicited by positive stimuli more 
difficult. Finally, the pregenual ACC appears to function as a hub between these the ventral 
network, dorsal network and OFC and more activation in this area is likely predictive of 






Figure 8.2. A neurobiological model for major depressive disorder (MDD).  
 
Neuroimaging genetics (genes, endophenotypes and MDD) 
As mentioned above, it is becoming more and more clear what the underlying neural 
mechanisms are in MDD. In the next part, we investigated if these abnormal activations 
could be promising endophenotypes for investigating the genetic basis of depression. We 
chose morphology and activation of the PFC, hippocampus and amygdala as our 
endophenotypes, because they have most consistently been described in the literature to 
show disturbances in MDD. A literature search was undertaken to identify genes which 
come to expression in these areas and/or have previously been associated with activation or 
structural differences in these areas.  
First, activation of the prefrontal cortex (PFC) was investigated as endophenotype 
for MDD. Catechol-O-methyltransferase (COMT) has been shown to influence PFC 
activation during tasks of emotional processing and working memory, which are both 
disturbed in MDD. In chapter 5, a replication of a recent meta-analysis (Mier et al., 2010) 
showed more inferior frontal gyrus (IFG) activation during emotional processing related to 
carrying the met-allele, whereas they had less middle frontal gyrus (MFG) activation during 
working memory. This is consistent with the idea of less efficient emotional processing by 




To our knowledge, our study was the first to investigate whether the genotype 
association with PFC activation was moderated by the presence of MDD. Only during 
emotional processing, presence of MDD moderated the association between genotype and 
PFC activation. As mentioned above, in HC there was a positive correlation between 
number of met-alleles and IFG activation, whereas in patients the genotype effect on PFC 
activation was abolished. During working memory, there was no moderating effect of 
MDD psychopathology on the association between COMT-genotype and PFC activation. 
Notably, impairments in working memory are particularly present in severely depressed 
patients (reviewed by Snyder, 2012; McDermott et al., 2009), whereas emotional 
processing is thought to be disturbed already before the onset of the first depressive episode 
(reviewed by Leppanen, 2006; Bistricky et al., 2011). This could explain why the 
psychopathological status of our relatively mildly depressed outpatient sample moderated 
the effect of genotype only during emotional processing and not during working memory. 
 
A second gene coming to expression in the PFC is the disrupted-in-schizophrenia (DISC1) 
gene. Specifically, DISC1 has been shown to be highly expressed in the dorsolateral 
prefrontal cortex (DLPFC) and hippocampus, which are both considered part of the dorsal 
system in the above mentioned neurobiological models. In chapter 6 we investigated the 
influence of DISC1 genotype on activation in these areas during tasks of executive and 
memory functioning and on regional gray matter density. Within healthy participants, 
hippocampal volume was smaller in those carrying the cys-allele, which has been 
considered the risk-allele for depression (Hashimoto et al., 2006), compared to ser/ser-
homozygotes. The hippocampal volumes of patients with MDD and/or anxiety were 
comparable to those in healthy cys-carriers i.e. relatively small, and there was no effect of 
genotype within the patient group. During executive functioning, DISC1-genotype 
influenced activation in the DLPFC and dorsal ACC, whereas in patients there was again no 
genotype effect. During memory processing, genotype also showed an influence on 
hippocampal activation, but there was no moderating effect of diagnosis on this association. 
Thus, DISC1 moderates activation and structure in paralimbic structures crucial for 
emotional encoding and in dorsal frontal structures crucial for executive functioning, 
partially dependent on psychopathology. The cys-allele influenced endophenotypes relevant 
for affective disorders, although this effect was less apparent in patients with affective 
disorders. The moderating influence of psychopathology on neuroimaging genetic 
associations might be explained by influences of psychopathological status which have 





Another key brain structure in association with MDD is the amygdala. Neuropeptide Y 
(NPY) is an anxyliotic peptide which comes highly to expression in the amygdala. Like 
COMT and DISC1, it exists in distinct isoforms, encoded by slight variations of the 
corresponding gene. In chapter 7 it was demonstrated that risk-allele carriers of the NPY 
gene influenced amygdala activation during emotional processing, but only in combination 
with a history of childhood emotional maltreatment (CEM). This was accompanied by 
faster responses to the gender decisions. Presence of psychopathology did not influence 
these associations.  
The heightened amygdala activation in people carrying the risk-genotype and 
having experienced CEM, is likely related to reduced levels of NPY. The risk-genotype has 
been associated with a reduction of NPY expression (Zhou et al., 2008) and previous 
studies have also found increased amygdala activity within risk-genotype carriers (Zhou et 
al., 2008; Domschke et al., 2010). In addition, animal models have shown that high levels 
of stress during childhood, like maternal separation (Husum et al., 2002; Jimenez-Vasquez 
et al., 2001), have been shown to lead to reduced NPY-levels. Thus, it could be 
hypothesized that NPY-levels in those with risk-genotype and experienced CEM are lowest 
and that these low NPY-levels in the amygdala relate to increased amygdala activation.  
The amygdala has been seen as a key region in the neurobiology of depression  
(Phillips et al., 2003b; Davidson et al., 2002; Hamilton et al., 2012; Drevets, 2003). The 
heightened amygdala activation in combination with the fast responses given in those 
carrying the risk-genotype and having a history of CEM might be related to a hypervigilant 
state, which may enhance susceptibility for affective disorders. 
 
In general, from the conducted neuroimaging genetic studies in this thesis, it may be 
concluded that associations between genes and endophenotypes (e.g. neuroimaging 
findings) are stronger than associations between genotype and MDD. Moreover, the studies 
included in this thesis contribute to the current field of neuroimaging genetics in that they 
demonstrate that psychopathological status is crucial to take into account. 
Psychopathological status of MDD appears to have a moderating influence on the 
neuroimaging genetic associations, especially in areas of the PFC. That is, neuroimaging 
genetic associations are different for people with and without a diagnosis of MDD.  
Neuroimaging as endophenotype  
It has been suggested that a suitable endophenotype should be present independent of 
disease status, i.e, a trait characteristic (Cannon et al., 2006). We attempted to address the 
question whether brain activation is a state or trait marker of depression in chapter 4. Our 




line with other studies, which also have shown activation patterns related to depression 
severity (van Tol et al., 2011) and changes related to use of antidepressants (Delaveau et al., 
2011). This suggests that brain activation patterns are influenced by the emotional state.  
From chapter 4, we could not conclude that brain activation in other areas was a 
trait associated with the disease, because we did not find initial baseline differences 
between patients and healthy participants in this study. However, previous studies have 
shown that abnormal brain activation patterns are present in first degree relatives without a 
history of a depressive episode (Lisiecka et al., 2012; Mannie et al., 2011; Gotlib et al., 
2010; Monk et al., 2008; McCabe et al., 2012), which is suggestive for heritability of brain 
activation. In addition, cross-sectional studies have also abnormal activations present in 
recovered depressed patients (Hooley et al., 2005; Kanske et al., 2012; Kerestes et al., 
2012; Norbury et al., 2010; Hooley et al., 2009).  
It could be proposed that the influence of genes on depression via the brain is not 
only a one-way direction (Figure 8.1), because abnormalities in the brain do not only lead 
to depression, but depression status also likely influences the brain. The hypothesis could 
be tested that there is a baseline trait characteristic of brain activation in people vulnerable 
for depression and that abnormalities in brain activation are enhanced (or changed) 
depending on disease status. This makes studying endophenotypes in a group of psychiatric 
patients in a current disease episode of particular interest, because unravelling the 
mechanisms in patients is the eventual goal. Future studies should try to further elucidate 
which differences in brain activation are trait related and which are state related.  
The studies described in chapters 5 and 6 revealed that the genotype effect on PFC 
activation was dependent on the presence of a diagnosis of MDD. Strikingly, in these 
studies, the presence of psychopathological status abolished the genotype effects seen in 
healthy participants. There are not many neuroimaging genetic studies comparing the 
effects in healthy participants and psychiatric patients, which limits the possibility to 
discuss this in relationship to the published literature. Most reports of neuroimaging studies 
in patients lack a control group (e.g. Domschke et al., 2008b; Domschke et al., 2010). A 
possible explanation for not finding an effect of genotype within patients could be effects of 
disease status which overrule the genotype effects. In addition, different environmental 
factors leading to depression might also lead to an interaction with genotype on brain 
activation.  
The results of these studies support the use neuroimaging as a promising 
endophenotype and neuroimaging genetic studies constitute a viable way for exploring 





The studies in this thesis were primarily aimed at enhancing our fundamental understanding 
of the neuropsychology of depression. However, some findings may have clinical 
implications. For example, one of the studies found a predictive effect of brain activation 
with regard to symptom improvement. The caveat should be added that this was on a group 
level, and that fMRI techniques need to be developed further to achieve a level of 
refinement that allows reliable measurement at the single subject level. The relevance of 
such predictive information can not be overstated. Only 60% of all patients reach a good 
treatment response with current treatment strategies and 20% of patients do not respond at 
all (Ressler et al., 2007). By using brain activation to differentiate between different kinds 
of patients, it might be used as a tool for personalized treatment in depression and thereby 
contribute to higher treatment response rates. We specifically showed pregenual ACC 
activation as predictor. The pregenual ACC has been described as an important hub 
between the cognitive and emotional brain networks (Mayberg, 1997) and relative 
hyperactivation in this area is tied to a better prognosis. Targeting this area with treatment 
might be a promising strategy. It has been shown that glutamate within this part of the ACC 
correlates with connectivity between the ACC and the insula (Horn et al., 2010). 
Interestingly, the insula was shown to be highly associated with depressed mood changes. 
Therefore, drugs influencing glutamate levels, like ketamine,  or deep brain stimulation of 
the pregenual ACC might be helpful in some patients.    
Furthermore, genotyping might lead to more precise conclusions about the 
underlying vulnerability markers in a certain person. With increasing knowledge about the 
effects of genes on the brain and the role of brain activation as predictor of treatment 
response, this might lead to better patient stratification for personalized medicine in treating 
depression. Neuroimaging genetic studies might specifically contribute to this in that 
endophenotypes might be used as treatment targets. Identifying more specific underlying 
causes of depression on an individual basis by genotyping and MRI-scanning might lead to 
better individualized treatment strategies and this could lead to a better prevention of 
relapse.  
Future directions  
Mayberg (1997) proposed that depression is not simply a dysfunction of a few brain areas, 
but is rather a dysfunction in the coordinated interactions between individual brain areas in 
a given network in the brain and also in the interactions between networks (networks 
encompassing the dorsal, ventral, or the integrating-hub areas). Therefore, it would be 
interesting for future studies to investigate different patterns of brain activation, rather than 




this thesis. This multivariate approach could be used to find patterns differentiating between 
depressed patients and healthy controls or between patients in a depressed state and not in a 
depressed state. Multivariate pattern classification techniques, for example support vector 
machine learning, are techniques to address these questions. The advantage of multivariate 
pattern classification is its sensitivity to spatially distributed and subtle effects which 
univariate approaches sometimes can not detect. In addition, multivariate techniques could 
be used in classifying individual subjects into distinct groups based on their brain activity 
and might therefore be useful for clinical purposes (Orru et al., 2012).  
 Regarding neuroimaging genetic studies, it would be interesting for future studies 
to shed more light on the questions whether brain activation (especially during emotional 
processing) is heritable and whether these activation patterns are a cause or consequence of 
the disease. Investigating monozygote and dizygote twins could help answering this 
question. To identify whether depression is the cause or consequence of brain activation 
patterns, more longitudinal studies are necessary following people vulnerable for 
depression before the onset of the first depressive episode till remission of a depressive 
episode. In addition, to test the hypothesis that genotype leads to brain activation and that 
this predisposes to depression, applying pathway analyses techniques would be promising.  
Finally, in addition to investigating the influence of DNA differences on the brain, 
differences in RNA deserve investigation. On the level of RNA it could be seen how much 
DNA is expressed and epigenetic influences could be investigated. Epigenetics is the study 
of heritable changes in gene expression other than changes in DNA sequence and this is 
achieved by cytosine methylation and histone modification which influences the gene 
expression (Mill et al., 2007; Toyokawa et al., 2012). Stress has been shown to influence 
the epigenome and to cause less gene expression (Lau et al., 2010; Toyokawa et al., 2012) 
and this process has been associated with vulnerability for depression (Mill et al., 2007; 
Toyokawa et al., 2012). Especially with regard to interactions between genes and early life 
events, influences of RNA differences on the brain could yield novel insights and 
contribute to more comprehensive explanations.  
Concluding remarks 
The studies described in this thesis have the potential to increase our insight into the 
neurobiology of depression and relevant genetic influences. Genetic association studies into 
susceptibility genes for depression have not led to satisfying results up to this moment. 
However, there is growing consensus on disturbances on a neurobiological level in 
depression. From currently conducted functional MRI studies it has become apparent that a 
pattern of strong activation in limbic areas and less activation in the DLPFC during 




processing of positive emotional stimuli is seen in depressed patients. This underscores the 
importance of investigating the response to positive emotional stimuli in depression. This 
neurobiological network of abnormal brain activation could be used as endophenotype in 
the search for underlying genetic vulnerability markers in depression. Indeed certain 
genotypes are associated with brain activation patterns comparable to the abnormalities in 
depression. In addition, presence of MDD moderated the influence of genotype on 
prefrontal activations. Therefore, to fully understand the association between a genotype, 
endophenotype and psychiatric disorder, it is of interest to elucidate possible moderating 
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Depressie staat in de top 3 van ziekten die de meeste ziektelast geven voor de patiënt 
volgens de Wereld Gezondheid Organisatie (World Health Organization [WHO]).  De 
diagnose depressieve stoornis kan worden gesteld wanneer langer dan twee weken 
tenminste vijf van de volgende symptomen aanwezig zijn: verdrietige stemming, geen 
plezier meer kunnen ervaren, gewichtsverandering, slaapproblemen, psychomotore 
problemen, verminderde energie, gevoelens van waardeloosheid, verminderde concentratie 
en gedachten aan de dood (DSM-IV, American Psychiatry Association). Om een depressie 
goed te kunnen behandelen, is het van belang om te begrijpen hoe deze stoornis ontstaat. 
Het ontstaan van een depressie is gerelateerd aan veel verschillende factoren, waaronder 
erfelijkheid en omgevingsinvloeden. Deze factoren hebben ook invloed op de structuur en 
het functioneren van de hersenen, onder andere op de neurotransmitter overdracht, het 
volume van specifieke hersengebieden en activiteit van de hersenen. De neurobiologie van 
een depressieve stoornis wordt echter nog steeds niet volledig begrepen. Met dit 
proefschrift is geprobeerd verder helderheid te krijgen in de onderliggende 




Box 1. Basis genetica 
Ons DNA bepaalt een groot deel van hoe wij er uit komen te zien en wat voor persoon wij zijn. 
Beide ouders geven een deel van hun DNA door aan hun kinderen. Elk stukje van het DNA bepaalt 
een deel van ons uiterlijk of persoonlijkheid. Zo’n stukje wordt een gen genoemd. We hebben een 
gen die de kleur van onze ogen bepaalt, een gen die onze haarkleur bepaalt en mogelijk zijn er ook 
genen die bepalen hoe we met stress omgaan of onze persoonlijkheid.  Er zijn ook genen die voor 
bepaalde ziekten zorgen, er is bijvoorbeeld één gen die leidt tot de ziekte van Huntington. Voor 
psychiatrische ziekten is dit iets ingewikkelder en dat wordt in dit proefschrift besproken. In de 
psychiatrie wordt vaak gesproken over genen die ons kwetsbaarder maken om een stoornis te 
krijgen, maar er zijn daarnaast dan ook nog andere factoren nodig (bijvoorbeeld stress) die bepalen 
of de stoornis zich ook werkelijk ontwikkelt. Wat het gen bepaalt aan ons uiterlijk of karakter wordt 
fenotype genoemd (bijvoorbeeld oogkleur is een fenotype). 
Een gen bestaat uit twee varianten, allelen genoemd. Elke variant geeft een ander fenotype 
(bijvoorbeeld grote handen (allel A) of kleine handen (allel B). Iedereen krijgt één allel van zijn 
moeder en één allel van zijn vader. Iedereen heeft dus twee allelen van het gen en dit kan 
verschillende combinaties geven. De combinatie van de twee allelen is het genotype. Op een gen 
kan je drie verschillende genotypen hebben, op basis van dit voorbeeld kan dat twee keer allel A 
zijn (grote handen), twee keer allel B (kleine handen) of één keer allel A en één keer allel B 
(middelgrote handen). Twee keer hetzelfde allel  wordt homozygoot  genoemd en twee 
verschillende allelen wordt heterozygoot genoemd. Op deze wijze kunnen ouders eigenschappen 





Depressie komt vaker voor bij mensen die ook een eerstegraads familielid met een 
depressieve stoornis hebben (Sullivan et al., 2000). Hieruit kan worden geconcludeerd dat 
depressie een erfelijke component heeft. Momenteel is het nog niet duidelijk welke genen 
precies voor de kwetsbaarheid voor depressie zorgen. Kennis hebben van welke genen (zie 
Box 1 voor uitleg over genen) specifiek bijdragen aan de kwetsbaarheid voor depressie kan 
belangrijk zijn voor het begrijpen en behandelen van depressie. Het kan bijdragen aan de 
ontwikkeling van een goed model over het ontstaan van depressie en het kan helpen in het 
opstellen van een specifiek behandelplan aangepast op de individuele patiënt.  
In hoofdstuk 2 van dit proefschrift hebben we in een uitgebreide literatuurstudie 
op een rij gezet wat de huidige stand van zaken is in het onderzoek naar de genetische basis 
van depressie. In dit hoofdstuk hebben we specifiek gekeken naar genen die invloed hebben 
op het dopamine systeem. Dopamine is een neurotransmitter die veel voorkomt in de 
hersenen. Er zijn duidelijke aanwijzingen dat het dopamine systeem verstoord is bij een 
depressie. Ten eerste: de symptomen bij een depressie hebben een opvallende gelijkenis 
met de processen die door dopamine worden gereguleerd. Dopamine reguleert namelijk het 
beloningssysteem in de hersenen, wat invloed heeft op de stemming, motivatie, aandacht, 
het maken van keuzes en psychomotore snelheid. Ten tweede: amfetamine (in de 
volksmond ook wel speed genoemd) is een dopamine agonist, wat betekent dat het het 
vrijkomen van dopamine in de hersenen stimuleert. Het gebruik van amfetamine leidt tot 
veranderingen in het gevoel en gedrag welke tegenovergesteld zijn aan de symptomen van 
depressie. Het is bekend dat amfetamine ervoor zorgt dat je je vrolijk gaat voelen. 
Daarnaast wordt amfetamine gebruikt als behandeling voor obesitas en narcolepsie, wat de 
rol van dopamine onderstreept bij gewicht- en slaapregulatie.  Als laatste: dopamine 
niveaus in de hersenen worden beïnvloed door stress (Corrodi et al., 1971; Pani et al., 2000) 
en stress speelt een belangrijke rol in het ontstaan van een depressie.  
Ondanks het overtuigende bewijs voor een rol van dopamine in een depressie 
blijkt dat er nog maar weinig bewijs is voor een directe relatie tussen genen die het 
dopaminesysteem beïnvloeden en depressie. Kwetsbaarheid voor depressie ontstaat 
waarschijnlijk door heel veel genen die allemaal een heel klein beetje bijdragen aan deze 
kwetsbaarheid (poly-genetisch). Daarom is het moeilijk om een verband aan te tonen tussen 
een specifiek gen en depressie.  
Daarnaast is depressie een zeer heterogene stoornis. Volgens de DSM-IV krijgt 
iemand de diagnose depressie, wanneer hij/zij vijf van negen mogelijke symptomen heeft. 
Theoretisch leidt dit er toe dat bij twee patiënten met een depressieve stoornis bijna alle 
symptomen verschillend zouden kunnen zijn. Het zou kunnen zijn dat deze twee patiënten 




patiënten met een depressieve stoornis als één groep worden beschouwd, zou het dus 
mogelijk kunnen zijn dat er geen verband wordt gevonden tussen genen en de stoornis.  
In hoofdstuk 2 wordt depressie als het fenotype beschouwd (voor uitleg zie Box 
1). Een fenotype is het resultaat van de genetische aanleg (genotype) en de invloed van de 
omgeving daarop. Een depressieve stoornis blijkt mogelijk een te breed of te heterogeen 
begrip om een goed fenotype te zijn voor onderzoek naar de relatie met een specifiek 
genotype. Een mogelijke oplossing voor dit probleem zou kunnen zijn om te gaan kijken 
naar endofenotypen. Endofenotypen zijn neurobiologische of neuropsychologische 
mechanismen onderliggend aan een ziekte en zouden directer door genotypen worden 
beïnvloed (Figuur 1). Dit is ook interessant voor de kliniek, omdat endofenotypen mogelijk 
het aangrijpingspunt voor antidepressiva kunnen zijn. In dit proefschrift is gekozen voor 
hersenactiviteit en hersenstructuur gemeten met magnetische resonantie imaging (MRI) als 
endofenotype om de genetische kwetsbaarheid van depressie te onderzoeken. Voor het 
onderzoek naar endofenotypen is een goed begrip van het verband tussen het endofenotype 
(hersenactiviteit) en het fenotype (depressieve stoornis) van groot belang.  
 
Figuur 1. het voorgestelde endofenotype model. Verbanden over de pijlen zijn meestal zwak. 
 
Beeldvorming van de hersenen 
Er is al veel onderzoek gedaan naar de hersenactiviteit van patiënten met een depressieve 
stoornis. De hersenactiviteit kan bijvoorbeeld worden gemeten met behulp van functionele 
magnetische resonantie imaging (fMRI, zie Box 2). De literatuur over abnormale 
hersenactiviteit tijdens het verwerken van emoties bij mensen met een depressieve stoornis 
heeft heel veel verschillende bevindingen opgeleverd. Het is lastig hier een consistent 







In hoofdstuk 3 is geprobeerd om op basis van eerdere studies te bepalen waar in de 
hersenen de activiteit consistent anders is in een depressieve stoornis. Dit hebben we 
gedaan door een meta-analyse uit te voeren op studies die hebben gekeken naar de 
hersenactiviteit gedurende emotieverwerking bij patiënten met een depressieve stoornis 
vergeleken met gezonde mensen. Het blijkt dat er tegenovergestelde effecten zijn van 
negatieve en positieve emoties op een netwerk van limbische hersengebieden (amygdala, 
striatum, dorsale anterieure cingulate cortex (ACC) en parahippocampale gebieden). 
Patiënten met een depressieve stoornis lieten meer activiteit zien dan gezonde personen 
tijdens het zien van negatieve emoties en minder activiteit in deze gebieden tijdens het zien 
van positieve emoties. Daarnaast was de prefrontale cortex (PFC) minder actief tijdens het 
zien van negatieve emoties en meer actief tijdens het zien van positieve emoties.  
Er wordt gedacht dat patiënten met een depressieve stoornis een verstoorde  
verwerking, reactie en geheugen hebben voor emotionele prikkels uit de omgeving (Beck, 
Box 2. Functionele MRI 
Met een magnetische resonantie imaging (MRI) scanner kunnen we naast de structuur van de 
hersenen in beeld brengen, ook de activiteit van de hersenen meten. Dit wordt functionele MRI 
(fMRI) genoemd. Voor het meten van de activiteit wordt aan de persoon in de scanner gevraagd 
een computertaak uit te voeren. Wanneer bepaalde gebieden in de hersenen zuurstof gebruiken, 
wordt nieuw zuurstofrijk bloed aangevoerd. Tijdens het maken van de taak meet de scanner de 
verhouding tussen zuurstofrijk en zuurstofarm bloed in de hersenen. Dit kunnen we meten op basis 
van magnetische eigenschappen van zuurstof. De verhouding tussen zuurstofrijk en zuurstofarm 
bloed in een hersengebied geeft indirect de mate van activiteit van dit gebied weer.  
 
Onze hersenen zijn eigenlijk altijd volledig actief. Daarom krijgen de personen in de scanner tijdens 
het maken van de taak verschillende opdrachten te doen (condities). Bijvoorbeeld: “kijken naar een 
negatieve gezichtsuitdrukking” en “kijken naar een neutrale gezichtsuitdrukking”. Wanneer 
vervolgens de hersenactiviteit tijdens het kijken naar een negatief gezicht wordt afgetrokken van de 
hersenactiviteit tijdens het kijken naar een neutraal gezicht, houden we alleen de activiteit over die 
specifiek is voor de negatieve emotie en is alle activiteit gerelateerd aan het kijken naar een gezicht 






2008; Leppanen, 2006). Patiënten hebben meer aandacht voor negatieve prikkels, 
bijvoorbeeld verdrietige gezichten, en kunnen negatieve prikkels ook minder goed negeren 
dan gezonde personen (Leppanen, 2006). Daarnaast hebben patiënten minder aandacht voor 
positieve prikkels uit de omgeving. De amygdala, striatum en dorsale ACC zijn gebieden in 
de hersenen die invloed hebben op het richten van de aandacht. Sterkere activiteit voor 
negatieve emoties en minder activiteit voor positieve emoties in deze gebieden kunnen ten 
grondslag liggen aan de verstoorde aandacht en verwerking van emotionele prikkels bij 
patiënten met een depressie. 
In hoofdstuk 4 hebben we onderzocht of abnormale hersenactiviteit bij patiënten 
met een depressieve stoornis verandert na herstel van de depressie of dat de abnormale 
activiteit na herstel nog steeds aanwezig is. Het bleek dat een afname in de ernst van de 
depressie samenging met een afname in activiteit tijdens het zien van blije gezichten van 
het hersengebied de insula. De insula is een belangrijk gebied voor emotionele 
bewustwording (Craig, 2009). De insula wordt gezien als onderdeel van een netwerk van 
hersengebieden die belangrijk is voor het waarnemen en uitdrukken van positieve 
gezichtsuitdrukkingen (Hennenlotter et al., 2005). Uit het feit dat de verandering in 
hersenactiviteit specifiek voor blije gezichten werd gezien, kan worden afgeleid dat een 
andere reactie op positieve emotionele prikkels van grotere invloed is op verbetering van 
een depressie dan een reactie op negatieve prikkels. Het is op basis van onze resultaten nog 
niet te zeggen of de afname in insula activiteit de oorzaak of het gevolg is van de afname in 
ernst van depressie.  
Daarnaast, hebben we in hoofdstuk 4 gekeken of we op basis van hersenactiviteit 
konden voorspellen wie wel en wie niet uit de depressieve periode komt. Consistent met 
eerdere literatuur, vonden wij dat activiteit van de ACC een onderscheid maakte tussen 
patiënten die in de volgende twee jaar wel en niet herstelden. Patiënten die waren hersteld 
na twee jaar hadden meer activiteit in dit gebied dan patiënten die niet herstelden. Deze 
verhoogde activiteit zou mogelijk een subgroep van patiënten kunnen identificeren die een 
verschillende reactie hebben van het emotieverwerkingsnetwerk en daardoor een grotere 





Neuroimaging en genetica 
In de laatste hoofdstukken van dit proefschrift hebben we gekeken of de genetische basis 
voor kwetsbaarheid van depressie onderzocht kan worden door het gebruik van MRI-
gegevens als endofenotype. Studies die neuroimaging en genetica combineren worden ook 
wel “neuroimaging genetic” studies genoemd. Wij hebben gekozen om te kijken naar de 
prefrontale cortex (PFC), hippocampus en de amygdala, omdat deze gebieden het meest 
consistent in de literatuur als verstoord beschreven zijn. Vervolgens is in de literatuur 
gekeken welke genen invloed hebben op de activiteit of structuur van deze gebieden.  
 
Als eerste hebben we gekeken naar de activiteit van de PFC als endofenotype voor 
depressie. Catechol-O-methyltransferase (COMT) is een enzym dat  dopamine in de 
hersenen afbreekt. Dus hoe actiever dit enzym is, hoe minder dopamine er in de hersenen 
zit. Het is aangetoond dat COMT  de activiteit van de PFC beïnvloedt tijdens het maken 
van taken gericht op emotieverwerking en werkgeheugen. Het is ook bekend dat deze beide 
processen verstoord zijn bij een depressieve stoornis. In hoofdstuk 5 hebben we laten zien 
dat dragers van een specifiek genotype op dit gen (met/met-genotype) meer activiteit laten 
zien gedurende emotieverwerking in de PFC en minder activiteit in de PFC tijdens een 
werkgeheugen taak. Dit is consistent met het idee dat mensen met dit genotype minder 
efficiënt zijn in het verwerken van emoties, maar wel heel efficiënt zijn in cognitieve 
verwerking (Stein et al., 2006).  
Dit was tevens de eerste studie die heeft onderzocht wat de invloed van de 
aanwezigheid van een depressieve stoornis de relatie tussen het genotype en het brein 
beïnvloed. Alleen tijdens het verwerken van emoties bleek de aanwezigheid van een 
depressieve stoornis de invloed van dit genotype op PFC activiteit te beïnvloeden. Bij 
gezonde personen was het met/met-genotype geassocieerd met meer PFC activiteit, maar 
bij patiënten was het verband tussen het genotype en PFC activiteit niet aanwezig. 
Gedurende de werkgeheugen taak was er geen invloed van depressie op het effect en zagen 
we bij patiënten dezelfde invloed van het genotype op PFC activiteit. Deze bevindingen 
zijn interessant, omdat beperkingen in het werkgeheugen vooral aanwezig zijn bij ernstig 
depressieve patiënten (Snyder, 2012; McDermott et al., 2009), terwijl er aanwijzingen zijn 
dat emotieverwerking al verstoord is voor de eerste depressieve periode (Leppanen, 2006; 
Bistricky et al., 2011). Dit zou kunnen verklaren waarom in onze groep van mild 
depressieve patiënten alleen een invloed van depressie was te zien op de relatie tussen 






Een ander gen dat invloed heeft op de PFC is het “disrupted-in-schizophrenia” (DISC1) 
gen. Dit gen is ontdekt, omdat een genotype op dit gen veel voorkwam bij patiënten met 
schizofrenie (vandaar de naam), maar later is gebleken dat dit gen tot een meer algemene 
kwetsbaarheid voor psychiatrische problemen leidt. In hoofdstuk 6 hebben we gekeken 
naar de invloed van het DISC1 gen op de structuur en activiteit van de PFC en de 
hippocampus. Bij gezonde personen was de hippocampus kleiner bij mensen die het Cys-
allel hadden dan in hen die dit allel niet hadden. Het is eerder gevonden dat mensen die 
drager zijn van het Cys-allel kwetsbaarder zijn voor een depressie (Hashimoto et al., 2006). 
Wij vonden ook dat de grootte van de hippocampus bij patiënten vergelijkbaar was met de 
gezonde Cys-allel dragers. Het genotype had geen invloed op de grootte van de 
hippocampus bij patiënten. Activiteit van de hippocampus tijdens een geheugentaak werd 
ook beïnvloed door dit genotype. Gedurende de werkgeheugentaak was er een invloed te 
zien van het DISC1-gen op de activiteit van de PFC bij gezonde personen. Ook hier was er 
geen effect van het gen zichtbaar in de patiënten groep.  
 
Een ander belangrijk hersengebied is de amygdala. Het wordt gedacht dat de amygdala 
invloed heeft op het ontstaan en in stand houden van een depressie.  Neuropeptide Y (NPY) 
is een stof die veel voorkomt in de amygdala. NPY heeft invloed op hoe wij op stress 
reageren: veel NPY zorgt dat je beter met stress om gaat. Het ontstaan van een depressieve 
stoornis hangt samen met stressvolle gebeurtenissen en hoe iemand daarmee omgaat. Deze 
gegevens gaven het idee dat het gen dat zorgt voor de hoeveelheid NPY misschien wel eens 
met een depressieve stoornis te maken zou kunnen hebben. In hoofdstuk 7 hebben we laten 
zien dat de activiteit in de amygdala hoger was bij personen die een genotype hadden die 
voor minder NPY in de amygdala zorgt en daarnaast emotionele verwaarlozing in de 
kindertijd hadden meegemaakt. Ook reageerden deze personen veel sneller op de foto’s met 
emotionele gezichten (Figuur 2). De verhoogde activiteit van de amygdala in combinatie 
met de verhoogde reacties op de emotionele plaatjes zou gerelateerd kunnen zijn aan een 
verhoogde waakzaamheid. Dit kan leiden tot een verhoogde kwetsbaarheid voor een 
depressie.  
 
Dit proefschrift kan bijdragen aan ons inzicht in de neurobiologie van depressie en 
relevante genetische invloeden. Directe relaties tussen specifieke genen en depressie 
hebben tot nu toe niet geleid tot aanwijzingen voor een duidelijke genetische link. Vanuit 
de recente studies is duidelijk geworden dat een depressieve stoornis wordt gekenmerkt 
door een patroon van verhoogde limbische activiteit en verlaagde prefrontale activiteit 
tijdens het verwerken van negatief emotioneel geladen stimuli. Een omgekeerd patroon is te 




netwerk kan gebruikt worden als endofenotype in het onderzoek naar de genetische 
kwetsbaarheid van depressie. In het algemeen kan op basis van de studies in dit proefschrift 
worden geconcludeerd dat relaties tussen genen en endofenotypen (bijvoorbeeld 
neuroimaging bevindingen) sterker zijn dan relaties tussen genotypen en een depressieve 
stoornis. Er zijn inderdaad genen die de hersenactiviteit beïnvloeden die vergelijkbaar zijn 
met het patroon wat bij patiënten met een depressieve stoornis is gevonden. Verder dragen 
de studies in dit proefschrift bij aan het huidige onderzoeksveld van de neuroimaging 
genetics, omdat deze als een van de eersten aantonen dat de aanwezigheid van een 












Op deze plek wil ik graag een aantal mensen bedanken zonder wie dit proefschrift er nooit 
was gekomen.  
 
Ten eerste alle onderzoeksdeelnemers. Zonder jullie was er nooit een onderzoek geweest.  
 
André en Ruud, ik weet niet of er voor mij twee betere begeleiders zouden zijn geweest 
dan jullie. Jullie hebben allebei op jullie eigen manier, jullie enthousiasme voor de 
wetenschap op mij weten over te dragen.  
Daarnaast, André, je hebt mij altijd veel vertrouwen en vrijheid gegeven in het uitvoeren 
van mijn onderzoeken, waarbij ik altijd bij je binnen kon vallen met de vragen die ik op dat 
moment had. Daarnaast wil ik jou bedanken voor alle mogelijkheden en ruimte die ik heb 
gekregen om mij zelf te ontwikkelen. Ik kijk uit naar onze samenwerking op de nieuwe 
projecten de komende jaren.  
Ruud, ik wil je bedanken voor je vertrouwen in mij en dat je altijd voor me klaar stond. Ik 
kon mijn onzekerheden bij je uiten en jij wist mij elke keer weer het vertrouwen te geven 
om verder te gaan. Daarnaast stelde jij altijd de goede vragen om mijn gedachtengang 
verder te helpen en heb jij mij veel geleerd over hoe ik een wetenschappelijk artikel moet 
schrijven. Ik hoop dat ook wij in de toekomst zullen blijven samenwerken.    
 
Marie-José vooral in de laatste fase ben jij zeer betrokken geweest bij mijn proefschrift. Jij 
hebt een aanstekelijk enthousiasme en ambitie. Jij bent heel waardevol geweest met je 
adviezen over mijn analyses en manuscripten, maar ook in het leren omgaan met 
tegenslagen. 
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